CancerPPD 2.0 - Year of Publication

Browsing Year-wise

Browse Results:

Filter by Length
Minimum Length
Maximum Length

ID	PMID	YEAR	Sequence	Name	Length	Linear/Cyclic	Chirality	Chem-MOD	C-ter MOD	N-ter MOD	Nature	Origin	Cell Line	Cancer Type	Assay	Activity	Testing Time	Tissue Affected	Patents
7722	None	2020	LKKWWKKVKGLLGGLLGKVKKVIK	Seq ID No. 17 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	NCI-H460	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7721	None	2020	LKKWWKKVKGLLGGLLGKVKKVIK	Seq ID No. 17 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	HOP-062	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7720	None	2020	LKKWWKKVKGLLGGLLGKVKSVIK	Seq ID No. 16 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	Calu-1	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7719	None	2020	LKKWWKKVKGLLGGLLGKVKSVIK	Seq ID No. 16 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	NCI-H460	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7718	None	2020	LKKWWKKVKGLLGGLLGKVKSVIK	Seq ID No. 16 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	HOP-062	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7717	None	2020	LKKWWKKVKGLLGGLLGKVTSVIK	Seq ID No. 15 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	Calu-1	Lung Cancer	Tetrazolium-based assay	Cell viability < 50% at 20 μM	2-h	Lung	US20200079827A1
7716	None	2020	LKKWWKKVKGLLGGLLGKVTSVIK	Seq ID No. 15 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	NCI-H460	Lung Cancer	Tetrazolium-based assay	Cell viability < 25% at 20 μM	2-h	Lung	US20200079827A1
7715	None	2020	LKKWWKKVKGLLGGLLGKVTSVIK	Seq ID No. 15 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	HOP-062	Lung Cancer	Tetrazolium-based assay	Cell viability ~ 50% at 20 μM	2-h	Lung	US20200079827A1
6657	33029595	2020	{[LLKKLLKK]₂kC}₂	4-arm branched peptide	36	Linear	L	thermal oxidation between the thiol group of cysteine residue in the two 2-arm branched	Free	Free	Antimicrobial	Synthetic	PC-3	Prostate Cancer	MTT assay	Cell Viability (%) ~ 49.0 ± 0.8 at 30 µg/mL	48-h	Prostate	None
6656	33029595	2020	{[LLKKLLKK]₂kC}₂	4-arm branched peptide	36	Linear	L	thermal oxidation between the thiol group of cysteine residue in the two 2-arm branched	Free	Free	Antimicrobial	Synthetic	Bcap-37	Breast Cancer	MTT assay	Cell Viability (%) ~ 51.4 ± 4.2 at 30 µg/mL	48-h	Breast	None
6654	33029595	2020	{[LLKKLLKK]₂kC}₂	4-arm branched peptide	36	Linear	L	thermal oxidation between the thiol group of cysteine residue in the two 2-arm branched	Free	Free	Antimicrobial	Synthetic	SK-HEP-1	Liver Cancer	MTT assay	Cell Viability (%) ~ 31.7 ± 5.1 at 30 µg/mL	48-h	Liver	None
6655	33029595	2020	{[LLKKLLKK]₂kC}₂	4-arm branched peptide	36	Linear	L	thermal oxidation between the thiol group of cysteine residue in the two 2-arm branched	Free	Free	Antimicrobial	Synthetic	HCT-116	Colon Cancer	MTT assay	Cell Viability (%) ~ 67.6 ± 5.8 at 30 µg/mL	48-h	Colon	None
6653	33029595	2020	[LLKKLLKK]₂kC	2-arm branched peptide	18	Linear	L	Branched amide bond in the branching point was formed by the primary amine of lysine.	Free	Free	Antimicrobial	Synthetic	PC-3	Prostate Cancer	MTT assay	Cell Viability (%) ~ 73.5 ± 2.2 at 30 µg/mL	48-h	Prostate	None
6651	33029595	2020	[LLKKLLKK]₂kC	2-arm branched peptide	18	Linear	L	Branched amide bond in the branching point was formed by the primary amine of lysine.	Free	Free	Antimicrobial	Synthetic	HCT-116	Colon Cancer	MTT assay	Cell Viability (%) ~ 78.6 ± 10.5 at 30 µg/mL	48-h	Colon	None
6652	33029595	2020	[LLKKLLKK]₂kC	2-arm branched peptide	18	Linear	L	Branched amide bond in the branching point was formed by the primary amine of lysine.	Free	Free	Antimicrobial	Synthetic	Bcap-37	Breast Cancer	MTT assay	Cell Viability (%) ~ 81.8 ± 8.8 at 30 µg/mL	48-h	Breast	None
6650	33029595	2020	[LLKKLLKK]₂kC	2-arm branched peptide	18	Linear	L	Branched amide bond in the branching point was formed by the primary amine of lysine.	Free	Free	Antimicrobial	Synthetic	SK-HEP-1	Liver Cancer	MTT assay	Cell Viability (%) ~ 85.7 ± 4.3 at 30 µg/mL	48-h	Liver	None
6649	33029595	2020	LLKKLLKKLLKKLLKK	(LLKK)4 linear peptide	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	PC-3	Prostate Cancer	MTT assay	Cell Viability (%) ~ 17.1 ± 5.0 at 30 µg/mL	48-h	Prostate	None
6648	33029595	2020	LLKKLLKKLLKKLLKK	(LLKK)4 linear peptide	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Bcap-37	Breast Cancer	MTT assay	Cell Viability (%) ~ 15.07 ± 0.5 at 30 µg/mL	48-h	Breast	None
6647	33029595	2020	LLKKLLKKLLKKLLKK	(LLKK)4 linear peptide	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	HCT-116	Colon Cancer	MTT assay	Cell Viability (%) ~ 10.73 ± 2.4 at 30 µg/mL	48-h	Colon	None
6646	33029595	2020	LLKKLLKKLLKKLLKK	(LLKK)4 linear peptide	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	SK-HEP-1	Liver Cancer	MTT assay	Cell Viability (%) ~ 14.1 ± 0.8 at 30 µg/mL	48-h	Liver	None
6645	32716104	2020	YFYPKDFTPGCT	YT12	12	Linear	L	None	Free	Free	Anticancer	Arthrospira platensis	HT-29	Colon Cancer	MTT assay	IC₅₀ = 12.5 μM	NA	Colon	None
6644	33005727	2020	Not Available	LRH7-G5	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Synthetic	HCC-1937	Breast Cancer	MTT assay	60% cell viability at 0.1 μM	48-h	Breast	None
6642	32971958	2020	VGAlAvVvWlWlWlW	Gramicidin A	15	Linear	Mix	None	NCH2CH2OH	Formylation	Antimicrobial	Aneurinibacillus migulanus	HT-29	Colon Cancer	MTT assay	IC₅₀ = 9.78 μM	48-h	Colon	None
6643	33005727	2020	Not Available	LRH7-G5	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	60% cell viability at 0.01 μM	48-h	Breast	None
6641	32121469	2020	Figure given in Scheme 1	branched tetrapeptide Schiff bases derivative 5e	Not Available	Cyclic	L	chiral N3,N5-bis[(l-phenylalaninyl-l-leucinyl) substituted aryl or heterocyclic Schiff base]pyridine	Not Available	Not Available	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ between 8.12 ± 0.14 to 17.55 ± 0.27 μM	NA	Breast	None
6640	32121469	2020	Figure given in Scheme 1	branched tetrapeptide Schiff bases derivative 5d	Not Available	Cyclic	L	chiral N3,N5-bis[(l-phenylalaninyl-l-leucinyl) substituted aryl or heterocyclic Schiff base]pyridine	Not Available	Not Available	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ between 8.12 ± 0.14 to 17.55 ± 0.27 μM	NA	Breast	None
6639	32121469	2020	Figure given in Scheme 1	branched tetrapeptide Schiff bases derivative 5c	Not Available	Cyclic	L	chiral N3,N5-bis[(l-phenylalaninyl-l-leucinyl) substituted aryl or heterocyclic Schiff base]pyridine	Not Available	Not Available	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ between 8.12 ± 0.14 to 17.55 ± 0.27 μM	NA	Breast	None
6638	32121469	2020	Figure given in Scheme 1	branched tetrapeptide Schiff bases derivative 4c	Not Available	Cyclic	L	chiral N3,N5-bis[(l-phenylalaninyl-l-leucinyl) substituted aryl or heterocyclic Schiff base]pyridine	Not Available	Not Available	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ between 8.12 ± 0.14 to 17.55 ± 0.27 μM	NA	Breast	None
6637	32121469	2020	Figure given in Scheme 1	branched tetrapeptide Schiff bases derivative 4b	Not Available	Cyclic	L	chiral N3,N5-bis[(l-phenylalaninyl-l-leucinyl) substituted aryl or heterocyclic Schiff base]pyridine	Not Available	Not Available	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ between 8.12 ± 0.14 to 17.55 ± 0.27 μM	NA	Breast	None
6636	32121469	2020	Figure given in Scheme 1	branched tetrapeptide Schiff bases derivative 4a	Not Available	Cyclic	L	chiral N3,N5-bis[(l-phenylalaninyl-l-leucinyl) substituted aryl or heterocyclic Schiff base]pyridine	Not Available	Not Available	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ between 8.12 ± 0.14 to 17.55 ± 0.27 μM	NA	Breast	None
6635	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 5c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.568 ± 1.139 μM	72-h	Liver	None
6634	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 5b	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.088 ± 0.784 μM	72-h	Liver	None
6632	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.631 ± 0.932 μM	72-h	Liver	None
6633	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 5a	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.117 ± 0.790 μM	72-h	Liver	None
6631	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 19.552 ± 1.032 μM	72-h	Breast	None
6630	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.166 ± 0.892 μM	72-h	Liver	None
6628	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.31 ± 0.595 μM	72-h	Liver	None
6629	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.188 ± 0.545 μM	72-h	Breast	None
6626	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 16.957 ± 1.161 μM	72-h	Liver	None
6627	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 4a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.304 ± 0.536 μM	72-h	Breast	None
6624	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3b	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.66 ± 0.792 μM	72-h	Liver	None
6625	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3c	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 22.864 ± 0.992 μM	72-h	Breast	None
6623	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3b	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.911 ± 0.491 μM	72-h	Breast	None
6620	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 19.318 ± 1.057 μM	72-h	Liver	None
6621	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3a	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 10.316 ± 0.546 μM	72-h	Breast	None
6622	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 3a	7	Cyclic	L	carboxylic acid derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.063 ± 0.863 μM	72-h	Liver	None
6617	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 20.697 ± 0.974 μM	72-h	Breast	None
6618	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 18.681 ± 0.988 μM	72-h	Liver	None
6619	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 24.943 ± 1.082 μM	72-h	Breast	None
6615	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 17.011 ± 0.965 μM	72-h	Liver	None
6616	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 2a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 17.513 ± 0.876 μM	72-h	Liver	None
6614	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1c	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 34.894 ± 1.273 μM	72-h	Breast	None
6612	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 10.904 ± 0.534 μM	72-h	Breast	None
6613	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1b	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.724 ± 0.474 μM	72-h	Liver	None
6610	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 15.329 ± 0.672 μM	72-h	Breast	None
6611	32164321	2020	Structure given in Scheme 1	macrocyclic pyridoheptapeptide derivative 1a	7	Cyclic	L	ester derivatives	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 6.615 ± 0.353 μM	72-h	Liver	None
6608	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 97.1 µM	72-h	Lung	None
6609	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 82.5 µM	72-h	Breast	None
6606	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 92.2 µM	72-h	Cervix	None
6607	32806659	2020	WP	cyclic dipeptide - 7b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 82.3 µM	72-h	Liver	None
6603	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 92.8 µM	72-h	Liver	None
6604	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 99.3 µM	72-h	Lung	None
6605	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 39.9 µM	72-h	Breast	None
6600	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 98.0 µM	72-h	Lung	None
6601	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 42.8 µM	72-h	Breast	None
6602	32806659	2020	WW	cyclic dipeptide - 6b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 91.4 µM	72-h	Cervix	None
6598	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 94.8 µM	72-h	Cervix	None
6599	32806659	2020	WY	cyclic dipeptide - 5b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 97.5 µM	72-h	Liver	None
6596	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 61.5 µM	72-h	Lung	None
6597	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 32.3 µM	72-h	Breast	None
6593	32806659	2020	WF	cyclic dipeptide - 4a	2	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 100 µM	72-h	Breast	None
6594	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 75.8 µM	72-h	Cervix	None
6595	32806659	2020	WF	cyclic dipeptide - 4b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 80.3 µM	72-h	Liver	None
6590	32806659	2020	WL	cyclic dipeptide - 3b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 41.4 µM	72-h	Breast	None
6591	32806659	2020	WF	cyclic dipeptide - 4a	2	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 100 µM	72-h	Cervix	None
6592	32806659	2020	WF	cyclic dipeptide - 4a	2	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 100 µM	72-h	Lung	None
6586	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 33.7 µM	72-h	Breast	None
6587	32806659	2020	WA	cyclic dipeptide - 2b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 93.1 µM	72-h	Cervix	None
6588	32806659	2020	WA	cyclic dipeptide - 2b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 45.6 µM	72-h	Breast	None
6589	32806659	2020	WL	cyclic dipeptide - 3b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 85.2 µM	72-h	Cervix	None
6583	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 95.3 µM	72-h	Cervix	None
6584	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 87.7 µM	72-h	Liver	None
6585	32806659	2020	WG	cyclic dipeptide - 1b	2	Cyclic	L	L-7dimethylallyl at Trp	Cyclized	Cyclized	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 72.4 µM	72-h	Lung	None
6582	None	2020	klaklakklaklakGGRKKRRQRRR	D(KLAKLAK)2-TAT	25	Linear	Mix	None	Amidation	Acetylation	Antimicrobial	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.3 μM	24-h	Lung	None
6580	31947688	2020	SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRDDDDDDDDDD	Lunasin	44	Linear	L	None	Free	Free	Anticancer	Soybean	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 107.5 ± 1.9 μM	72-h	Colon	None
6579	31940927	2020	GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV	Turgencin A	36	Cyclic(C8-C33,C12-C29,C17-C26)	L	None	Amidation	Free	Antimicrobial and Anticancer	Synoicum turgens	A-2058	Skin Cancer	Cell Viability assay	IC₅₀ 1.4 µM	72-h	Skin	None
6578	31940927	2020	GIKEMLCNMACAQTVCKKSGGPLCDTCQAACKALG	Turgencin B	35	Cyclic(C7-C31,C11-C27,C16-C24)	L	None	Amidation	Free	Antimicrobial and Anticancer	Synoicum turgens	A-2058	Skin Cancer	Cell Viability assay	IC₅₀ 4.1 µM	72-h	Skin	None
6577	32567085	2020	FKRILQRIKDFLR	LL-37 Analogue 18	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 29.2 µg/mL	48-h	Lung	None
6576	32567085	2020	FKRILQRIKDFLR	LL-37 Analogue 17	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 19.2 µg/mL	48-h	Lung	None
6575	32567085	2020	FKRIVQLLKKLLR	LL-37 Analogue 16	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 9.8 µg/mL	48-h	Lung	None
6574	32567085	2020	FKRIVQLLKKLLR	LL-37 Analogue 15	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.8 µg/mL	48-h	Lung	None
6573	32567085	2020	FKRIVQIIKKFLR	LL-37 Analogue 14	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.9 µg/mL	48-h	Lung	None
6572	32567085	2020	FKRIVQIIKKFLR	LL-37 Analogue 13	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 20.0 µg/mL	48-h	Lung	None
6570	32567085	2020	FKRIVQRIKDLLR	LL-37 Analogue 11	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 75 µg/mL	48-h	Lung	None
6571	32567085	2020	FKRIVQRIKDLLR	LL-37 Analogue 12	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 45.5 µg/mL	48-h	Lung	None
6569	32567085	2020	FKRIVQLIKDFLR	LL-37 Analogue 10	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 13.9 µg/mL	48-h	Lung	None
6568	32567085	2020	FKRIVQLIKDFLR	LL-37 Analogue 9	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 18.9 µg/mL	48-h	Lung	None
6567	32567085	2020	FKRIVQKIKDFLR	LL-37 Analogue 8	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 145 µg/mL	48-h	Lung	None
6566	32567085	2020	FKRIVQRIRDFLR	LL-37 Analogue 7	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.5 µg/mL	48-h	Lung	None
6565	32567085	2020	FKRIVQRIRDFLR	LL-37 Analogue 6	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 56 µg/mL	48-h	Lung	None
6564	32567085	2020	FKSARIVQRILDFLR	LL-37 Analogue 5	15	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 10.7 µg/mL	48-h	Lung	None
6563	32567085	2020	FΚRIVQRILDFLR	LL-37 Analogue 4	13	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 3.9 µg/mL	48-h	Lung	None
6562	32567085	2020	AKRIVQRIKDFLR	LL-37 Analogue 3	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 29.8 µg/mL	48-h	Lung	None
6561	32567085	2020	LKRIVQRIKDFLR	LL-37 Analogue 2	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 33.7 µg/mL	48-h	Lung	None
6560	32567085	2020	FKRIVQRIKDFLR	LL-37 Analogue 1	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic Analog of LL-37	A-549	Lung Cancer	MTT assay	IC₅₀ = 20.1 µg/mL	48-h	Lung	None
6559	33276536	2020	NFFKRIRRAWKRIWKWIYSA	ΔM4	20	Linear	L	None	Free	Free	Anticancer	Synthetic	A-375	Skin Cancer	Not Available	IC₅₀ = 9.31 μM	NA	Skin	None
6558	37300579	2020	IDWKKLLDAAKLIL	MP1-Q12K	14	Linear	L	None	Amidation	Free	Antimicrobial	Analog of Polybia MP1	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.5 μM	24-h	Lung	None
6557	37300579	2020	IDWKKLLDAAKQIL	Polybia-MP1	14	Linear	L	None	Amidation	Free	Antimicrobial	Polybia paulista	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.5 μM	24-h	Lung	None
6556	32443921	2020	FLGAILKIGHALAKTVLPMVTNAFKPKQ	Figainin 2	28	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Boana raniceps	MCF-7	Breast Cancer	MTT assay	IC₅₀= 15.3 µM	24-h	Breast	None
6555	32443921	2020	FLGAILKIGHALAKTVLPMVTNAFKPKQ	Figainin 2	28	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Boana raniceps	B16-F10	Skin Cancer	MTT assay	IC₅₀ = 12.8 µM	24-h	Skin	None
6554	32967114	2020	FIGTLIPLALGALTKLFK	Figainin 1	18	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Boana raniceps	B16-F10	Skin Cancer	MTT assay	IC₅₀ = 10.5 µM	NA	Skin	None
6553	32967114	2020	FIGTLIPLALGALTKLFK	Figainin 1	18	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Boana raniceps	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 11.1 µM	NA	Cervix	None
6552	32967114	2020	FIGTLIPLALGALTKLFK	Figainin 1	18	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Boana raniceps	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 13.7 µM	NA	Breast	None
6551	32498425	2020	IWLTALKFLGKNLGKHLAKQQLSKL	LVTX-8	25	Linear	L	None	Amidation	Acetylation	Anticancer	Lycosa vittata	H-460	Lung Cancer	CCK-8 assay	IC₅₀ = 19 μM	24-h	Lung	None
6550	32498425	2020	IWLTALKFLGKNLGKHLAKQQLSKL	LVTX-8	25	Linear	L	None	Amidation	Acetylation	Anticancer	Lycosa vittata	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 8 μM	24-h	Lung	None
6547	32562730	2020	LKCKKLVPLFSKTCPAGKNLCYKMFMVAAPHVPVKRGCIDVCPKSSLLVKYVCCNTDKCN	rCT-II	60	Cyclic(C3-C21,C14-C38,C42-C53,C54-C59)	L	None	Free	Free	Anticancer	Naja naja	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 3.66 µg/mL	24-h	Breast	None
6546	32256172	2020	KAIGLVIPEIDGKLDGGAQRV	NMANF2	21	Linear	L	None	Free	Free	Anticancer	Staphylococcus hominis strain MANF2	HT-29	Colon Cancer	MTT assay	IC₅₀ = 48.9 µg/mL	NA	Colon	None
6545	32256172	2020	KAIGLVIPEIDGKLDGGAQRV	NMANF2	21	Linear	L	None	Free	Free	Anticancer	Staphylococcus hominis strain MANF2	A-549	Lung Cancer	MTT assay	IC₅₀ = 46.6 µg/mL	NA	Lung	None
6544	34508563	2020	FLGALFKVASKLVPAAICSISKKC	Brevinin-1HL	24	Linear	L	None	Free	Free	Antimicrobial	Hylarana latouchii	NCI-H23	Lung Cancer	MTT assay	IC₅₀ = 8.52 ± 1.02 μM	24-h	Lung	None
6543	34508563	2020	FFPLIFGALSSILPKIL	Temporin-HLa	17	Linear	L	None	Amidation	Free	Antimicrobial	Hylarana latouchii	H-460	Lung Cancer	MTT assay	IC₅₀ = 1.64 ± 0.41 μM	24-h	Lung	None
6542	34508563	2020	FFPLIFGALSSILPKIL	Temporin-HLa	17	Linear	L	None	Amidation	Free	Antimicrobial	Hylarana latouchii	H-157	Lung Cancer	MTT assay	IC₅₀ = 15.18 ± 2.98 μM	24-h	Lung	None
6541	34508563	2020	FFPLIFGALSSILPKIL	Temporin-HLa	17	Linear	L	None	Amidation	Free	Antimicrobial	Hylarana latouchii	NCI-H23	Lung Cancer	MTT assay	IC₅₀ = 4.96 ± 0.94 μM	24-h	Lung	None
6540	32903706	2020	FFRKVLKLIRKIWR	HX-12C	14	Linear	L	None	Free	Free	Antimicrobial	Synthetic derivative of Temporin-Pta	KB-C2	Cervical Cancer	MTT assay	IC₅₀ = 6.06 μM	72-h	Cervix	None
6539	32903706	2020	FFRKVLKLIRKIF	HX-12B	13	Linear	L	None	Free	Free	Antimicrobial	Synthetic derivative of Temporin-Pta	KB-C2	Cervical Cancer	MTT assay	IC₅₀ = 7.61 μM	72-h	Cervix	None
6538	32903706	2020	FFRKVLKLIRKI	HX-12A	12	Linear	L	None	Free	Free	Antimicrobial	Synthetic derivative of Temporin-Pta	KB-C2	Cervical Cancer	MTT assay	IC₅₀ = 6.45 μM	72-h	Cervix	None
6537	32959810	2020	RWrGGGGGLFDIIKKIAESF	RA-3	20	Linear	Mix	None	Amidation	Free	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 44.14 μM	48-h	Breast	None
6536	32959810	2020	RWrGGGGGLFDIIKKIAESF	RA-3	20	Linear	Mix	None	Amidation	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 28.4 μM	48-h	Breast	None
6535	32959810	2020	RWrGGGGGLFDIIKKIAESF	RA-3	20	Linear	Mix	None	Amidation	Free	Anticancer	Synthetic	U87-MG	Brain Tumor	MTT assay	IC₅₀ = 32.27 μM	48-h	Brain	None
6534	33237335	2020	MSSSNCANVCQTENFPGGECKAEGATRKCFCKNC	MzDef	34	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Zea mays L.	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 29.85 µg/mL	24-h	Colon	None
6533	33237335	2020	MSSSNCANVCQTENFPGGECKAEGATRKCFCKNC	MzDef	34	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Zea mays L.	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 14.85 µg/mL	24-h	Breast	None
6532	33237335	2020	MSSSNCANVCQTENFPGGECKAEGATRKCFCKNC	MzDef	34	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Zea mays L.	HepG-2	Liver Cancer	MTT assay	IC₅₀ ~ 22 µg/mL	24-h	Liver	None
6531	32836586	2020	LKCYQHGKVVTCHRDMKFCYHNTGMPFRNLKLILQGCSSSCSETENNKCCSTDRCNK	Mambalgin-1	57	Linear	L	None	Free	Free	Anticancer	Dendroaspis polylepsis	MCF-7	Breast Cancer	MTT assay	22.43% cytotoxicity at 10 µg/mL	48-h	Breast	None
6530	32151609	2020	RRWFWRRRRWFWRR	DIM-LF11-339	14	Linear	L	None	Amidation	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 3.8 ± 0.3 μM	24-h	Skin	EP_2943215_B1
6529	32151609	2020	RRWFWRRRRWFWRR	DIM-LF11-339	14	Linear	L	None	Amidation	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ = 4.7 ± 0.3 μM	24-h	Skin	EP_2943215_B1
6528	32151609	2020	RRWFWRRRRWFWRR	DIM-LF11-339	14	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ = 4.8 ± 0.4 μM	24-h	Skin	EP_2943215_B1
6527	32151609	2020	PWRIRIRRRRIRIRWPPWRIRIRR	R-DIM-LF11-334-LF11-334	24	Linear	L	None	Amidation	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 3.6 ± 0.7 μM	24-h	Skin	EP_2943215_B1
6526	32151609	2020	PWRIRIRRRRIRIRWPPWRIRIRR	R-DIM-LF11-334-LF11-334	24	Linear	L	None	Amidation	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ < 1 ± 0.1 μM	24-h	Skin	EP_2943215_B1
6525	32151609	2020	PWRIRIRRRRIRIRWPPWRIRIRR	R-DIM-LF11-334-LF11-334	24	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ < 1 ± 0.1 μM	24-h	Skin	EP_2943215_B1
6524	32151609	2020	PWRIRIRRPRRIRIWP	R-DIM-P-LF11-334	16	Linear	L	None	Amidation	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 5.0 ± 0.1 μM	24-h	Skin	EP_2943215_B1
6523	32151609	2020	PWRIRIRRPRRIRIWP	R-DIM-P-LF11-334	16	Linear	L	None	Amidation	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ = 3.4 ± 0.4 μM	24-h	Skin	EP_2943215_B1
6522	32151609	2020	PWRIRIRRPRRIRIWP	R-DIM-P-LF11-334	16	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ = 6.6 ± 0.3 μM	24-h	Skin	EP_2943215_B1
6521	32151609	2020	FWRIRIRRPRRIRIRWF	R-DIM-P-LF11-215	17	Linear	L	None	Amidation	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 4.6 ± 0.1 μM	24-h	Skin	EP_2943215_B1
6520	32151609	2020	FWRIRIRRPRRIRIRWF	R-DIM-P-LF11-215	17	Linear	L	None	Amidation	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ < 1 ± 0.0 μM	24-h	Skin	EP_2943215_B1
6519	32151609	2020	FWRIRIRRPRRIRIRWF	R-DIM-P-LF11-215	17	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ = 2.7 ± 0.9 μM	24-h	Skin	EP_2943215_B1
6518	32151609	2020	PFWRIRIRRPFWRIRIRR	DIM-LF11-322	18	Linear	L	None	Free	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 4.6 ± 0.1 μM	24-h	Skin	EP_2943215_B1
6517	32151609	2020	PFWRIRIRRPFWRIRIRR	DIM-LF11-322	18	Linear	L	None	Free	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ < 1 ± 0.0 μM	24-h	Skin	EP_2943215_B1
6516	32151609	2020	PFWRIRIRRPFWRIRIRR	DIM-LF11-322	18	Linear	L	None	Free	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ = 6.3 ± 0.3 μM	24-h	Skin	EP_2943215_B1
6515	32151609	2020	PFWRIRIRRPRRIRIRWFP	R-DIM-P-LF11-322	19	Linear	L	None	Amidation	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 4.7 ± 0.2 μM	24-h	Skin	EP_2943215_B1
6514	32151609	2020	PFWRIRIRRPRRIRIRWFP	R-DIM-P-LF11-322	19	Linear	L	None	Amidation	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ = 2.5 ± 0.1 μM	24-h	Skin	EP_2943215_B1
6513	32151609	2020	PFWRIRIRRPRRIRIRWFP	R-DIM-P-LF11-322	19	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ = 4.2 ± 0.2 μM	24-h	Skin	EP_2943215_B1
6512	32151609	2020	FQWQRNIRKVRPRVKRINRQWQF	R-DIM-P-LF11	23	Linear	L	None	Amidation	Free	Anticancer	Synthetic	WM164	Skin Cancer	MTS assay	LC₅₀ = 20.9 ± 3.9 μM	24-h	Skin	EP_2943215_B1
6511	32151609	2020	FQWQRNIRKVRPRVKRINRQWQF	R-DIM-P-LF11	23	Linear	L	None	Amidation	Free	Anticancer	Synthetic	SBcl2	Skin Cancer	MTS assay	LC₅₀ = 10.7 ± 0.2 μM	24-h	Skin	EP_2943215_B1
6510	32151609	2020	FQWQRNIRKVRPRVKRINRQWQF	R-DIM-P-LF11	23	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-375	Skin Cancer	MTS assay	LC₅₀ = 125.0 ± 16.8 μM	24-h	Skin	EP_2943215_B1
6509	33044599	2020	MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE	Latcripin-7A	164	Linear	L	None	Free	Free	Anticancer	Lentinula edodes	MDA-MB-231	Breast Cancer	CCK-8 assay	IC₅₀ = 122 μg/mL	48-h	Breast	None
6508	33044599	2020	MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE	Latcripin-7A	164	Linear	L	None	Free	Free	Anticancer	Lentinula edodes	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 91 μg/mL	48-h	Breast	None
6505	32462055	2020	Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF	AEM-28–2	28	Linear	L	Aha= α-aminohenoic acid	Amidation	Acetylation	Anti-inflammatory and Anticancer	Synthetic	OV-2008	Ovarian Cancer	MTS assay	~40% cell viability at 10 μg/mL	24-h	Ovary	None
6506	32462055	2020	Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF	AEM-28–2	28	Linear	L	Aha= α-aminohenoic acid	Amidation	Acetylation	Anti-inflammatory and Anticancer	Synthetic	SK-OV-3	Ovarian Cancer	MTS assay	~30% cell viability at 10 μg/mL	24-h	Ovary	None
6507	32462055	2020	Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF	AEM-28–2	28	Linear	L	Aha= α-aminohenoic acid	Amidation	Acetylation	Anti-inflammatory and Anticancer	Synthetic	CaCo-2	Colon Cancer	MTS assay	~60% cell viability at 10 μg/mL	24-h	Colon	None
6503	32462055	2020	Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF	AEM-28–2	28	Linear	L	Aha= α-aminohenoic acid	Amidation	Acetylation	Anti-inflammatory and Anticancer	Synthetic	CT-26	Colorectal Cancer	MTS assay	~30% cell viability at 10 μg/mL	24-h	Colon	None
6504	32462055	2020	Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF	AEM-28–2	28	Linear	L	Aha= α-aminohenoic acid	Amidation	Acetylation	Anti-inflammatory and Anticancer	Synthetic	ID8	Colon Cancer	MTS assay	~20% cell viability at 10 μg/mL	24-h	Colon	None
6502	32462055	2020	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Linear	L	None	Amidation	Acetylation	Anti-inflammatory and Anticancer	Synthetic	CT-26	Colorectal Cancer	MTS assay	~60% cell viability at 10 μg/mL	24-h	Colon	None
6501	32462055	2020	LRKLRKRLLRDWLKAFYDKVAEKLKEAF	AEM-28	28	Linear	L	None	Free	Free	Anti-inflammatory and Anticancer	Synthetic	CaCo-2	Colon Cancer	MTS assay	~70% cell viability at 10 μg/mL	24-h	Colon	None
6500	32462055	2020	LRKLRKRLLRDWLKAFYDKVAEKLKEAF	AEM-28	28	Linear	L	None	Free	Free	Anti-inflammatory and Anticancer	Synthetic	SK-OV-3	Ovarian Cancer	MTS assay	~50% cell viability at 10 μg/mL	24-h	Ovary	None
6499	32462055	2020	LRKLRKRLLRDWLKAFYDKVAEKLKEAF	AEM-28	28	Linear	L	None	Free	Free	Anti-inflammatory and Anticancer	Synthetic	OV-2008	Ovarian Cancer	MTS assay	~60% cell viability at 10 μg/mL	24-h	Ovary	None
6498	32462055	2020	LRKLRKRLLRDWLKAFYDKVAEKLKEAF	AEM-28	28	Linear	L	None	Free	Free	Anti-inflammatory and Anticancer	Synthetic	ID8	Colon Cancer	MTS assay	~60% cell viability at 10 μg/mL	24-h	Colon	None
6497	32462055	2020	LRKLRKRLLRDWLKAFYDKVAEKLKEAF	AEM-28	28	Linear	L	None	Free	Free	Anti-inflammatory and Anticancer	Synthetic	CT-26	Colorectal Cancer	MTS assay	~20% cell viability at 10 μg/mL	24-h	Colon	None
6496	32126228	2020	GALFLGFLGAAGSTMGAWSQPKKKRKV	MPG	27	Linear	L	None	Cysteamidation	Acetylation	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 15.8 μM	24-h	Blood	None
6495	32126228	2020	ILPWKWPWWPWKK	Indolicidin-Lys	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 9.5 μM	24-h	Blood	None
6494	32126228	2020	ILPWKWPWWPWRR	Indolicidin-Arg	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 13.7 μM	24-h	Blood	None
6493	32126228	2020	FPVTWRWWRWWRG	PuroA-Lys	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 12.0 μM	24-h	Blood	None
6492	32126228	2020	FPVTWKWWKWWKG	PuroA-Arg	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 10.0 μM	24-h	Blood	None
6491	32126228	2020	GIGRWLHSARRFGRAFVGEIMNS	MagaininF5W-Arg	23	Linear	L	None	Free	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 16.8 μM	24-h	Blood	None
6490	32126228	2020	GIGKWLHSAKKFGKAFVGEIMNS	MagaininF5W-Lys	23	Linear	L	None	Free	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 16.8 μM	24-h	Blood	None
6489	32126228	2020	CVRRFPWWYPFLRRC	Tritrp DiSu	15	Cyclic(C1-15)	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 12.3 μM	24-h	Blood	None
6487	32126228	2020	VRRFPWYYPFLRR	Tritrp-W78Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 25.6 μM	24-h	Blood	None
6488	32126228	2020	VRRFPYYYPFLRR	Tritrp-W678Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≥ 65 μM	24-h	Blood	None
6486	32126228	2020	VRRFPYWYPFLRR	Tritrp-W68Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 35.4 μM	24-h	Blood	None
6485	32126228	2020	VRRFPYYWPFLRR	Tritrp-W67Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 32.2 μM	24-h	Blood	None
6484	32126228	2020	VRRFPWWYPFLRR	Tritrp-W8Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 12.0 μM	24-h	Blood	None
6483	32126228	2020	VRRFPWYWPFLRR	Tritrp-W7Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 11.4 μM	24-h	Blood	None
6482	32126228	2020	VRRFPYWWPFLRR	Tritrp-W6Y	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 19.3 μM	24-h	Blood	None
6481	32126228	2020	VRRFPAAAPFLRR	Tritrp-W678A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≥ 65 μM	24-h	Blood	None
6480	32126228	2020	VRRFPWAAPFLRR	Tritrp-W78A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≥ 65 μM	24-h	Blood	None
6479	32126228	2020	VRRFPAWAPFLRR	Tritrp-W68A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≥ 65 μM	24-h	Blood	None
6478	32126228	2020	VRRFPAAWPFLRR	Tritrp-W67A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≥ 65 μM	24-h	Blood	None
6477	32126228	2020	VRRFPWWAPFLRR	Tritrp-W8A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 22.8 μM	24-h	Blood	None
6476	32126228	2020	VRRFPWAWPFLRR	Tritrp-W7A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 48.2 μM	24-h	Blood	None
6475	32126228	2020	VRRFPAWWPFLRR	Tritrp-W6A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 36.5 μM	24-h	Blood	None
6474	32126228	2020	VRRFP(hW)(hW)(hW)PFLRR	Tritrp-W789hW	13	Linear	L	5-hydroxytryptophan	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 44.8 μM	24-h	Blood	None
6472	32126228	2020	VRRFPW(hW)WPFLRR	Tritrp-W7hW	13	Linear	L	5-hydroxytryptophan	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 15.1 μM	24-h	Blood	None
6473	32126228	2020	VRRFPWW(hW)PFLRR	Tritrp-W8hW	13	Linear	L	5-hydroxytryptophan	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 10.7 μM	24-h	Blood	None
6469	32126228	2020	VRRFPFFFPFLRR	Tritrp-W678F	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 24.6 μM	24-h	Blood	None
6470	32126228	2020	VRRFP(bTA)(bTA)(bTA)PFLRR	Tritrp-W678bTA	13	Linear	L	β-3-benzothienyl-1-Ala	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 9.6 μM	24-h	Blood	None
6471	32126228	2020	VRRFP(hW)WWPFLRR	Tritrp-W6hW	13	Linear	L	5-hydroxytryptophan	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 16.1 μM	24-h	Blood	None
6468	32126228	2020	VKKFPWWWAFLKK	Tritrp-P9A-Lys	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 15.1 μM	24-h	Blood	None
6467	32126228	2020	VRRFPWWWAFLRR	Tritrp-P9A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 6.8 μM	24-h	Blood	None
6466	32126228	2020	VKKFAWWWPFLKK	Tritrp-P5A-Lys	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 27.6 μM	24-h	Blood	None
6465	32126228	2020	VRRFAWWWPFLRR	Tritrp-P5A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 16.2 μM	24-h	Blood	None
6464	32126228	2020	VKKFAWWWAFLKK	Tritrp-P59A-Lys	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 27.6 μM	24-h	Blood	None
6463	32126228	2020	VRRFAWWWAFLRR	Tritrp-P59A	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 12.5 μM	24-h	Blood	None
6462	32126228	2020	V(Orn)(Orn)FPWWWPFL(Orn)(Orn)	Tritrp-Orn	13	Linear	L	Orn = Ornithine	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≤ 6.5 μM	24-h	Blood	None
6461	32126228	2020	V(Dab)(Dab)FPWWWPFL(Dab)(Dab)	Tritrp-Dab	13	Linear	L	Dab = 2,4-diaminobutyric acid	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≤ 6.5 μM	24-h	Blood	None
6459	32126228	2020	VKKFPWWWPFLKK	Tritrp-Lys	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 11.5 μM	24-h	Blood	None
6460	32126228	2020	V(Dap)(Dap)FPWWWPFL(Dap)(Dap)	Tritrp-Dap	13	Linear	L	Dap = 2,3-diaminopropionic acid	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ ≥ 65 μM	24-h	Blood	None
6457	32126228	2020	V(Agb)(Agb)FPWWWPFL(Agb)(Agb)	Tritrp-Agb	13	Linear	L	Agb = (S)-2-amino-4 guanidinobutyric acid	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 9.6 μM	24-h	Blood	None
6458	32126228	2020	V(hArg)(hArg)FPWWWPFL(hArg)(hArg)	Tritrp-hArg	13	Linear	L	Homo-arginine	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 13.3 μM	24-h	Blood	None
6456	32126228	2020	VRRFPWWWPFLRR	Tritrp-Arg	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	Jurkat	Blood Cancer	MTT assay	IC₅₀ = 9.4 μM	24-h	Blood	None
6455	32126228	2020	VRRFPWWWPFLRR	Tritrpticin	13	Linear	L	None	Free	Free	Antimicrobial		Jurkat	Blood Cancer	MTT assay	IC₅₀ = 18.3 μM	24-h	Blood	None
6454	32069989	2020	HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR	Colicin N	321	Linear	L	None	Free	Free	Antimicrobial	NA	NCI-H23	Lung Cancer	MTT assay	Dose dependent % cell viability resuctuction at 1-15 µM	24-h	Lung	None
6453	32069989	2020	HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR	Colicin N	321	Linear	L	None	Free	Free	Antimicrobial	NA	H-292	Lung Cancer	MTT assay	Dose dependent % cell viability resuctuction at 1-15 µM	24-h	Lung	None
6452	32069989	2020	HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR	Colicin N	321	Linear	L	None	Free	Free	Antimicrobial	NA	H-460	Lung Cancer	MTT assay	Dose dependent % cell viability resuctuction at 1-15 µM	24-h	Lung	None
6451	32582642	2020	ALWKDMLKGIGKLAGKAALGAVKTLV	Dermaseptin-PP	26	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa palliata	H-157	Lung Cancer	LDH leakage assay	80% LDH release at 10−4 M	24-h	Lung	None
6450	32582642	2020	ALWKDMLKGIGKLAGKAALGAVKTLV	Dermaseptin-PP	26	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa palliata	U-251	Brain Tumor	MTT assay	IC₅₀ = 2.47 μM	24-h	Brain	None
6449	32582642	2020	ALWKDMLKGIGKLAGKAALGAVKTLV	Dermaseptin-PP	26	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa palliata	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 4.15 μM	24-h	Prostate	None
6448	32582642	2020	ALWKDMLKGIGKLAGKAALGAVKTLV	Dermaseptin-PP	26	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa palliata	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 2.92 μM	24-h	Breast	None
6447	32582642	2020	ALWKDMLKGIGKLAGKAALGAVKTLV	Dermaseptin-PP	26	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa palliata	H-157	Lung Cancer	MTT assay	IC₅₀ = 1.55 μM	24-h	Lung	None
6446	33363118	2020	GLFAVIKKVASVIKGL	A4K14 - Citropin 1.1	16	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 14.16 µM	24-h	Breast	None
6445	33363118	2020	GLFAVIKKVASVIKGL	A4K14 - Citropin 1.1	16	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 14.8 µM	24-h	Brain	None
6443	33363118	2020	GLFAVIKKVASVIKGL	A4K14 - Citropin 1.1	16	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 29.05 µM	24-h	Prostate	None
6444	33363118	2020	GLFAVIKKVASVIKGL	A4K14 - Citropin 1.1	16	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 14.97 µM	24-h	Lung	None
6442	33363118	2020	GS₅FAVS₅KKVASVIKGL	A4K14 - Citropin 1.1 - Sp 1	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 11.26 µM	24-h	Breast	None
6440	33363118	2020	GS₅FAVS₅KKVASVIKGL	A4K14 - Citropin 1.1 - Sp 1	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 12.48 µM	24-h	Lung	None
6441	33363118	2020	GS₅FAVS₅KKVASVIKGL	A4K14 - Citropin 1.1 - Sp 1	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 11.88 µM	24-h	Brain	None
6439	33363118	2020	GS₅FAVS₅KKVASVIKGL	A4K14 - Citropin 1.1 - Sp 1	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 8.94 µM	24-h	Prostate	None
6436	33363118	2020	GLFAS₅IKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 2	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 12.55 µM	24-h	Lung	None
6437	33363118	2020	GLFAS₅IKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 2	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 14.76 µM	24-h	Brain	None
6438	33363118	2020	GLFAS₅IKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 2	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 12.65 µM	24-h	Breast	None
6435	33363118	2020	GLFAS₅IKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 2	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 10.14 µM	24-h	Prostate	None
6434	33363118	2020	GLFAVS₅KKVS₅SVIKGL	A4K14 - Citropin 1.1 - Sp 3	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 11.92 µM	24-h	Breast	None
6432	33363118	2020	GLFAVS₅KKVS₅SVIKGL	A4K14 - Citropin 1.1 - Sp 3	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 12.11 µM	24-h	Lung	None
6433	33363118	2020	GLFAVS₅KKVS₅SVIKGL	A4K14 - Citropin 1.1 - Sp 3	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 11.93 µM	24-h	Brain	None
6431	33363118	2020	GLFAVS₅KKVS₅SVIKGL	A4K14 - Citropin 1.1 - Sp 3	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 17.89 µM	24-h	Prostate	None
6430	33363118	2020	GLFAVIKKS₅ASVS₅KGL	A4K14 - Citropin 1.1 - Sp 4	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 10.49 µM	24-h	Breast	None
6428	33363118	2020	GLFAVIKKS₅ASVS₅KGL	A4K14 - Citropin 1.1 - Sp 4	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 10.51 µM	24-h	Lung	None
6429	33363118	2020	GLFAVIKKS₅ASVS₅KGL	A4K14 - Citropin 1.1 - Sp 4	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 7.277 µM	24-h	Brain	None
6427	33363118	2020	GLFAVIKKS₅ASVS₅KGL	A4K14 - Citropin 1.1 - Sp 4	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 8.9 µM	24-h	Prostate	None
6426	33363118	2020	GLFAVIKKVAS₅VIKS₅L	A4K14 - Citropin 1.1 - Sp 5	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 12.42 µM	24-h	Breast	None
6424	33363118	2020	GLFAVIKKVAS₅VIKS₅L	A4K14 - Citropin 1.1 - Sp 5	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 9.899 µM	24-h	Lung	None
6425	33363118	2020	GLFAVIKKVAS₅VIKS₅L	A4K14 - Citropin 1.1 - Sp 5	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 8.229 µM	24-h	Brain	None
6423	33363118	2020	GLFAVIKKVAS₅VIKS₅L	A4K14 - Citropin 1.1 - Sp 5	16	Cyclic	L	S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 11.9 µM	24-h	Prostate	None
6422	33363118	2020	GR₈FAVIKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 6	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 23.78 µM	24-h	Breast	None
6420	33363118	2020	GR₈FAVIKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 6	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 30.19 µM	24-h	Lung	None
6421	33363118	2020	GR₈FAVIKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 6	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 34.49 µM	24-h	Brain	None
6419	33363118	2020	GR₈FAVIKKS₅ASVIKGL	A4K14 - Citropin 1.1 - Sp 6	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 35.84 µM	24-h	Prostate	None
6418	33363118	2020	GLFAVR₈KKVASVS₅KGL	A4K14 - Citropin 1.1 - Sp 7	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 12.1 µM	24-h	Breast	None
6417	33363118	2020	GLFAVR₈KKVASVS₅KGL	A4K14 - Citropin 1.1 - Sp 7	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	U-87	Brain Tumor	CCK-8 assay	IC₅₀ = 14.72 µM	24-h	Brain	None
6416	33363118	2020	GLFAVR₈KKVASVS₅KGL	A4K14 - Citropin 1.1 - Sp 7	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 16.37 µM	24-h	Lung	None
6415	33363118	2020	GLFAVR₈KKVASVS₅KGL	A4K14 - Citropin 1.1 - Sp 7	16	Cyclic	L	R₈=(R)-2-(7-octenyl)alanine; S₅= (S)-2-(4-pentenyl)alanine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	C4-2B	Prostate Cancer	CCK-8 assay	IC₅₀ = 10.23 µM	24-h	Prostate	None
6414	32630734	2020	FIQHLIPLIPHAIQGIKDIF	Kassiniatuerin-3	20	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Kassina senegalensis	NCI-H23	Lung Cancer	MTT assay	IC₅₀ = 4.52 µM	24-h	Lung	None
6413	32630734	2020	FIQHLIPLIPHAIQGIKDIF	Kassiniatuerin-3	20	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Kassina senegalensis	H-157	Lung Cancer	MTT assay	IC₅₀ = 21.54 µM	24-h	Lung	None
6412	32630734	2020	FIQHLIPLIPHAIQGIKDIF	Kassiniatuerin-3	20	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Kassina senegalensis	H-460	Lung Cancer	MTT assay	IC₅₀ = 1.67 µM	24-h	Lung	None
6411	32630734	2020	FIQHLIPLIPHAIQGIKDIF	Kassiniatuerin-3	20	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Kassina senegalensis	H-838	Lung Cancer	MTT assay	IC₅₀ = 10.03 µM	24-h	Lung	None
6410	32630734	2020	FIQHLIPLIPHAIQGIKDIF	Kassiniatuerin-3	20	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Kassina senegalensis	LNCaP	Prostate Cancer	MTT assay	IC₅₀ = 3.79 µM	24-h	Prostate	None
6409	32630734	2020	FIQHLIPLIPHAIQGIKDIF	Kassiniatuerin-3	20	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Kassina senegalensis	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 13.20 µM	24-h	Brain	None
6408	32347293	2020	FLGALFKVASKLVPAAICSISKKC	Brevinin-1GHd	24	Linear	L	None	Free	Free	Antimicrobial	Hylarana guentheri	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 9.854 µM	24-h	Prostate	None
6407	32347293	2020	FLGALFKVASKLVPAAICSISKKC	Brevinin-1GHd	24	Linear	L	None	Free	Free	Antimicrobial	Hylarana guentheri	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 1.197 µM	24-h	Skin	None
6406	32347293	2020	FLGALFKVASKLVPAAICSISKKC	Brevinin-1GHd	24	Linear	L	None	Free	Free	Antimicrobial	Hylarana guentheri	U-251-MG	Brain Tumor	MTT assay	IC₅₀ = 7.985 µM	24-h	Brain	None
6405	32347293	2020	FLGALFKVASKLVPAAICSISKKC	Brevinin-1GHd	24	Linear	L	None	Free	Free	Antimicrobial	Hylarana guentheri	NCI-H-157	Lung Cancer	MTT assay	IC₅₀ = 2.987 µM	24-h	Lung	None
6404	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colon Cancer	MTT assay	22.8% Cell death at 100 µg/ml	24-h	Colon	None
6403	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	46.58% Cell death at 100 µg/ml	24-h	Liver	None
6402	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.06 ± 0.0014 µg/ml	24-h	Colon	None
6400	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	56.51% Cell death at 100 µg/ml	24-h	Colon	None
6401	31747558	2020	FSPAG	Longicalycinin A cyclic analogue 18	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.68 ± 0.0014 µg/ml	24-h	Liver	None
6399	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	15.55% Cell death at 100 µg/ml	24-h	Liver	None
6397	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.33 ± 0.0007 µg/ml	24-h	Liver	None
6398	31747558	2020	FSPAG	Longicalycinin A linear analogue 18	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.2 ± 0.0014 µg/ml	24-h	Colon	None
6395	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	74.53% Cell death at 100 µg/ml	24-h	Liver	None
6396	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	76.14% Cell death at 100 µg/ml	24-h	Colon	None
6394	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.2 ± 0.0007 µg/ml	24-h	Colon	None
6393	31747558	2020	FSPFA	Longicalycinin A cyclic analogue 17	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.4 ± 0.0014 µg/ml	24-h	Liver	None
6391	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	27.54% Cell death at 100 µg/ml	24-h	Liver	None
6392	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	75.68% Cell death at 100 µg/ml	24-h	Colon	None
6390	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.33 ± 0.0035 µg/ml	24-h	Colon	None
6389	31747558	2020	FSPFA	Longicalycinin A linear analogue 17	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.33 ± 0.0007 µg/ml	24-h	Liver	None
6387	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	42.33% Cell death at 100 µg/ml	24-h	Liver	None
6388	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	29.87% Cell death at 100 µg/ml	24-h	Colon	None
6386	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.4 ± 0.0028 µg/ml	24-h	Colon	None
6384	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.24% Cell death at 100 µg/ml	24-h	Colon	None
6385	31747558	2020	FTPFV	Longicalycinin A cyclic analogue 16	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 12.1 ± 0.0007 µg/ml	24-h	Liver	None
6383	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	15.76% Cell death at 100 µg/ml	24-h	Liver	None
6382	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.11 ± 0.0056 µg/ml	24-h	Colon	None
6381	31747558	2020	FTPFV	Longicalycinin A linear analogue 16	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 11.1 ± 0.0007 µg/ml	24-h	Liver	None
6379	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	52.33% Cell death at 100 µg/ml	24-h	Liver	None
6380	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	27.43% Cell death at 100 µg/ml	24-h	Colon	None
6378	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.23 ± 0.0007 µg/ml	24-h	Colon	None
6377	31747558	2020	PYGFV	Longicalycinin A cyclic analogue 15	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.33 ± 0 µg/ml	24-h	Liver	None
6375	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	70.69% Cell death at 100 µg/ml	24-h	Liver	None
6376	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	52.38% Cell death at 100 µg/ml	24-h	Colon	None
6374	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.92 ± 0.0021 µg/ml	24-h	Colon	None
6373	31747558	2020	PYFFL	Longicalycinin A cyclic analogue 14	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.46 ± 0.0028 µg/ml	24-h	Liver	None
6372	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	28.62% Cell death at 100 µg/ml	24-h	Colon	None
6371	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	55.35% Cell death at 100 µg/ml	24-h	Liver	None
6370	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.08 ± 0.0007 µg/ml	24-h	Colon	None
6369	31747558	2020	VTPFL	Longicalycinin A cyclic analogue 13	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.44 ± 0.0014 µg/ml	24-h	Liver	None
6368	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	81.11% Cell death at 100 µg/ml	24-h	Colon	None
6367	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	11.79% Cell death at 100 µg/ml	24-h	Liver	None
6366	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 17.2 ± 0.0014 µg/ml	24-h	Colon	None
6365	31747558	2020	VTPFL	Longicalycinin A linear analogue 13	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.26 ± 0.0028 µg/ml	24-h	Liver	None
6364	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	52.72% Cell death at 100 µg/ml	24-h	Colon	None
6363	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	63.84% Cell death at 100 µg/ml	24-h	Liver	None
6361	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 12.37 ± 0.0014 µg/ml	24-h	Liver	None
6362	31747558	2020	FYPFI	Longicalycinin A cyclic analogue 12	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 13.2 ± 0 µg/ml	24-h	Colon	None
6360	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	81.34% Cell death at 100 µg/ml	24-h	Colon	None
6359	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	12.06% Cell death at 100 µg/ml	24-h	Liver	None
6356	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	74.89% Cell death at 100 µg/ml	24-h	Colon	None
6357	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 11.32 ± 0.0014 µg/ml	24-h	Liver	None
6358	31747558	2020	FYPFI	Longicalycinin A linear analogue 12	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 14.2 ± 0.0014 µg/ml	24-h	Colon	None
6354	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.61 ± 0.0007 µg/ml	24-h	Colon	None
6355	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	72.06% Cell death at 100 µg/ml	24-h	Liver	None
6353	31747558	2020	TVPFA	Longicalycinin A cyclic analogue 11	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.36 ± 0 µg/ml	24-h	Liver	None
6352	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.47% Cell death at 100 µg/ml	24-h	Colon	None
6350	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.67 ± 0.0014 µg/ml	24-h	Colon	None
6351	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	70.28% Cell death at 100 µg/ml	24-h	Liver	None
6349	31747558	2020	TVPFA	Longicalycinin A linear analogue 11	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.56 ± 0.0021 µg/ml	24-h	Liver	None
6347	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	72.06% Cell death at 100 µg/ml	24-h	Liver	None
6348	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	71.27% Cell death at 100 µg/ml	24-h	Colon	None
6346	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.56 ± 0.0028 µg/ml	24-h	Colon	None
6344	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	92.09% Cell death at 100 µg/ml	24-h	Colon	None
6345	31747558	2020	FYPFA	Longicalycinin A cyclic analogue 10	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.28 ± 0 µg/ml	24-h	Liver	None
6343	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	76.72% Cell death at 100 µg/ml	24-h	Liver	None
6341	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.5 ± 0.0014 µg/ml	24-h	Liver	None
6342	31747558	2020	FYPFA	Longicalycinin A linear analogue 10	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.5 ± 0.0007 µg/ml	24-h	Colon	None
6340	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	76.25% Cell death at 100 µg/ml	24-h	Colon	None
6338	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.7 ± 0.0056 µg/ml	24-h	Colon	None
6339	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	73.98% Cell death at 100 µg/ml	24-h	Liver	None
6337	31747558	2020	FYPFV	Longicalycinin A cyclic analogue 9	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.67 ± 0 µg/ml	24-h	Liver	None
6334	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.44 ± 0.5536 µg/ml	24-h	Colon	None
6335	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	72.74% Cell death at 100 µg/ml	24-h	Liver	None
6336	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	1.59% Cell death at 100 µg/ml	24-h	Colon	None
6331	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	36.85% Cell death at 100 µg/ml	24-h	Liver	None
6332	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	29.87% Cell death at 100 µg/ml	24-h	Colon	None
6333	31747558	2020	FYPFV	Longicalycinin A linear analogue 9	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.33 ± 0.0007 µg/ml	24-h	Liver	None
6329	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.12 ± 0.0007 µg/ml	24-h	Liver	None
6330	31747558	2020	FYPVG	Longicalycinin A cyclic analogue 8	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.67 ± 0.0028 µg/ml	24-h	Colon	None
6327	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	15.35% Cell death at 100 µg/ml	24-h	Liver	None
6328	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.01% Cell death at 100 µg/ml	24-h	Colon	None
6325	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.35 ± 0.0014 µg/ml	24-h	Liver	None
6326	31747558	2020	FYPVG	Longicalycinin A linear analogue 8	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.88 ± 0.0014 µg/ml	24-h	Colon	None
6324	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	22.86% Cell death at 100 µg/ml	24-h	Colon	None
6322	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.11 ± 0.0035 µg/ml	24-h	Colon	None
6323	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	47.68% Cell death at 100 µg/ml	24-h	Liver	None
6321	31747558	2020	PYVFA	Longicalycinin A cyclic analogue 7	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.21 ± 0.0056 µg/ml	24-h	Liver	None
6319	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	82.33% Cell death at 100 µg/ml	24-h	Liver	None
6320	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	84.17% Cell death at 100 µg/ml	24-h	Colon	None
6317	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.6 ± 0.0007 µg/ml	24-h	Liver	None
6318	31747558	2020	PYVFA	Longicalycinin A linear analogue 7	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.78 ± 0.0212 µg/ml	24-h	Colon	None
6316	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	27.61% Cell death at 100 µg/ml	24-h	Colon	None
6314	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.2 ± 0.0021 µg/ml	24-h	Colon	None
6315	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	51.79% Cell death at 100 µg/ml	24-h	Liver	None
6313	31747558	2020	VYPIA	Longicalycinin A cyclic analogue 6	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 17.34 ± 0.0014 µg/ml	24-h	Liver	None
6311	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	38.64% Cell death at 100 µg/ml	24-h	Liver	None
6312	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	49.33% Cell death at 100 µg/ml	24-h	Colon	None
6309	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.98 ± 0.0014 µg/ml	24-h	Liver	None
6310	31747558	2020	VYPIA	Longicalycinin A linear analogue 6	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.31 ± 0.0063 µg/ml	24-h	Colon	None
6308	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	97.74% Cell death at 100 µg/ml	24-h	Colon	None
6307	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	41.37% Cell death at 100 µg/ml	24-h	Liver	None
6305	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.45 ± 0.0056 µg/ml	24-h	Liver	None
6306	31747558	2020	FSPFG	Longicalycinin A cyclic analogue 5	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.98 ± 0.4256 µg/ml	24-h	Colon	None
6304	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	91.52% Cell death at 100 µg/ml	24-h	Colon	None
6302	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.97 ± 0.0049 µg/ml	24-h	Colon	None
6303	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	76.72% Cell death at 100 µg/ml	24-h	Liver	None
6301	31747558	2020	FSPFG	Longicalycinin A linear analogue 5	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.99 ± 0.0014 µg/ml	24-h	Liver	None
6299	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	71.1% Cell death at 100 µg/ml	24-h	Liver	None
6300	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	52.49% Cell death at 100 µg/ml	24-h	Colon	None
6298	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.33 ± 0.0035 µg/ml	24-h	Colon	None
6297	31747558	2020	AYPFG	Longicalycinin A cyclic analogue 4	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.77 ± 0.007 µg/ml	24-h	Liver	None
6295	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	27.13% Cell death at 100 µg/ml	24-h	Liver	None
6296	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	75.91% Cell death at 100 µg/ml	24-h	Colon	None
6294	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.78 ± 0.0021 µg/ml	24-h	Colon	None
6293	31747558	2020	AYPFG	Longicalycinin A linear analogue 4	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.53 ± 0.0014 µg/ml	24-h	Liver	None
6291	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	56.72% Cell death at 100 µg/ml	24-h	Liver	None
6292	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	28.51% Cell death at 100 µg/ml	24-h	Colon	None
6290	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.28 ± 0.0063 µg/ml	24-h	Colon	None
6288	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	87.56% Cell death at 100 µg/ml	24-h	Colon	None
6289	31747558	2020	GYPFA	Longicalycinin A cyclic analogue 3	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.5 ± 0.0056 µg/ml	24-h	Liver	None
6287	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	82.33% Cell death at 100 µg/ml	24-h	Liver	None
6286	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.4 ± 0 µg/ml	24-h	Colon	None
6285	31747558	2020	GYPFA	Longicalycinin A linear analogue 3	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.77 ± 0.0007 µg/ml	24-h	Liver	None
6284	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	82.36% Cell death at 100 µg/ml	24-h	Colon	None
6283	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	13.02% Cell death at 100 µg/ml	24-h	Liver	None
6282	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.12 ± 0.0042 µg/ml	24-h	Colon	None
6280	31747558	2020	FYPFG	Longicalycinin A (Linear)	5	Linear	L	None	Free	Free	Anticancer	Synthetic	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 9.61 ± 0.0007 µg/ml	24-h	Colon	None
6281	31747558	2020	PYFFL	Longicalycinin A linear analogue 14	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.67 ± 0.0007 µg/ml	24-h	Liver	None
6279	31747558	2020	FYPFG	Longicalycinin A (Linear)	5	Linear	L	None	Free	Free	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.18 ± 0.0014 µg/ml	24-h	Liver	None
6277	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.45 ± 0.0042 µg/ml	24-h	Liver	None
6278	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.87 ± 0.0021 µg/ml	24-h	Colon	None
6276	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Dianthus superbus	EAC cell Line	Breast Cancer	MTT assay	CTC₅₀ = 6.17 µM	24-h	Breast	None
6274	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Dianthus superbus	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 13.52 µg/ml	24-h	Liver	None
6275	31747558	2020	FYPFG	Longicalycinin A	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Dianthus superbus	DLA cell line	Lung Cancer	MTT assay	CTC₅₀ = 2.62 µM	24-h	Thymus	None
6272	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	69.73% Cell death at 100 µg/ml	24-h	Liver	None
6273	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	71.5% Cell death at 100 µg/ml	24-h	Colon	None
6271	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 11.4 ± 0.0028 µg/ml	24-h	Colon	None
6269	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	88.47% Cell death at 100 µg/ml	24-h	Colon	None
6270	31747558	2020	GYPFV	Longicalycinin A Cyclic analogue 1	5	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 10.2 ± 0.007 µg/ml	24-h	Liver	None
6267	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 12.33 ± 0 µg/ml	24-h	Colon	None
6268	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	71.37% Cell death at 100 µg/ml	24-h	Liver	None
6266	31747558	2020	LYPFA	Longicalycinin A linear analogue 2	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.76 ± 0.0035 µg/ml	24-h	Liver	None
6265	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	83.02% Cell death at 100 µg/ml	24-h	Colon	None
6263	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HT-29	Colorectal Cancer	MTT assay	IC₅₀ = 10.45 ± 0.0042 µg/ml	24-h	Colon	None
6264	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	13.29% Cell death at 100 µg/ml	24-h	Liver	None
6262	31747558	2020	GYPFV	Longicalycinin A linear analogue 1	5	Linear	L	None	Free	Free	Anticancer	Synthetic Analogue of Longicalycinin A	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 9.66 ± 0.0007 µg/ml	24-h	Liver	None
6261	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8b	23	Linear	L	None	Free	3′-Aminopropyl Beta-D-Galactopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	PC-3	Prostate Cancer	CCK-8 assay	IC₅₀ = 4.9 ± 0.2 µM	24-h	Prostate	None
6259	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8b	23	Linear	L	None	Free	3′-Aminopropyl Beta-D-Galactopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	H-1437	Lung Cancer	CCK-8 assay	IC₅₀ = 5.3 ± 0.2 µM	24-h	Lung	None
6260	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8b	23	Linear	L	None	Free	3′-Aminopropyl Beta-D-Galactopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	HGC-27	Gastric Cancer	CCK-8 assay	IC₅₀ = 5.3 ± 0.2 µM	24-h	Not Available	None
6257	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8b	23	Linear	L	None	Free	3′-Aminopropyl Beta-D-Galactopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 7.0 ± 0.3 µM	24-h	Lung	None
6258	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8b	23	Linear	L	None	Free	3′-Aminopropyl Beta-D-Galactopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	H-460	Lung Cancer	CCK-8 assay	IC₅₀ = 4.9 ± 0.9 µM	24-h	Lung	None
6255	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8a	23	Linear	L	None	Free	3′-Aminopropyl-D-glucopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	PC-3	Prostate Cancer	CCK-8 assay	IC₅₀ = 6.9 ± 0.4 µM	24-h	Prostate	None
6256	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8b	23	Linear	L	None	Free	3′-Aminopropyl Beta-D-Galactopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	MDA-MB-231	Breast Cancer	CCK-8 assay	IC₅₀ = 6.0 ± 0.2 µM	24-h	Breast	None
6254	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8a	23	Linear	L	None	Free	3′-Aminopropyl-D-glucopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	HGC-27	Gastric Cancer	CCK-8 assay	IC₅₀ = 12.6 ± 0.6 µM	24-h	Not Available	None
6253	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8a	23	Linear	L	None	Free	3′-Aminopropyl-D-glucopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	H-1437	Lung Cancer	CCK-8 assay	IC₅₀ = 13.0 ± 0.2 µM	24-h	Lung	None
6252	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8a	23	Linear	L	None	Free	3′-Aminopropyl-D-glucopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	H-460	Lung Cancer	CCK-8 assay	IC₅₀ = 8.5 ± 0.4 µM	24-h	Lung	None
6250	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8a	23	Linear	L	None	Free	3′-Aminopropyl-D-glucopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	MDA-MB-231	Breast Cancer	CCK-8 assay	IC₅₀ = 10.1 ± 0.2 µM	24-h	Breast	None
6251	31276399	2019	RGWFRAMRSIARFIARERLRGHL	R-Lycosin I derivative 8a	23	Linear	L	None	Free	3′-Aminopropyl-D-glucopyranoside	Anticancer	Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 9.6 ± 0.3 µM	24-h	Lung	None
6249	31089358	2019	Not Available	ICD-85	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Active fractions from Gloydius halys and Hemiscorpius lepturus	MCF-7	Breast Cancer	Neutral Red Uptake assay	IC₅₀ = 21.97 ± 0.63 μg/mL	24 h	Breast	None
6246	32641940	2019	GEGSGA	C2Triazole	6	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	81.22 ± 0.30 inhibition % at 10 µM	48-h	Breast	None
6247	32641940	2019	GEGSGA	C2Triazole	6	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	HT-29	Colon Cancer	MTT assay	92.56 ± 0.28 inhibition % at 10 µM	48-h	Colon	None
6248	31089358	2019	Not Available	ICD-85	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Active fractions from Gloydius halys and Hemiscorpius lepturus	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 36.45 ± 0.38 μg/mL	24 h	Breast	None
6244	32641940	2019	GLTSK	C1Triazole	5	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	HT-29	Colon Cancer	MTT assay	92.8 ± 0.16 inhibition % at 10 µM	48-h	Colon	None
6245	32641940	2019	GEGSGA	C2Triazole	6	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	82.12 ± 0.48 inhibition % at 10 µM	48-h	Breast	None
6242	32641940	2019	GLTSK	C1Triazole	5	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	59.76 ± 10.34 inhibition % at 10 µM	48-h	Breast	None
6243	32641940	2019	GLTSK	C1Triazole	5	Linear	L	None	Free	4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	79.9 ± 0.49 inhibition % at 10 µM	48-h	Breast	None
6240	32641940	2019	GEGSGA	C2 mother	6	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MDA-MB-231	Breast Cancer	MTT assay	79.32 ± 0.23 inhibition % at 10 µM	48-h	Breast	None
6241	32641940	2019	GEGSGA	C2 mother	6	Linear	L	None	Free	Free	Anticancer	Common bean fractions	HT-29	Colon Cancer	MTT assay	92.79 ± 0.54 inhibition % at 10 µM	48-h	Colon	None
6239	32641940	2019	GEGSGA	C2 mother	6	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MCF-7	Breast Cancer	MTT assay	83.39 ± 0.84 inhibition % at 10 µM	48-h	Breast	None
6237	32641940	2019	GLTSK	C1 mother	5	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MDA-MB-231	Breast Cancer	MTT assay	78.7 ± 1.60 inhibition % at 10 µM	48-h	Breast	None
6238	32641940	2019	GLTSK	C1 mother	5	Linear	L	None	Free	Free	Anticancer	Common bean fractions	HT-29	Colon Cancer	MTT assay	93.01 ± 1.01 inhibition % at 10 µM	48-h	Colon	None
6235	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	LN229	Brain Tumor	MTT assay	IC₅₀ = 13.32 ± 1.15 mg/ml	72-h	Brain	None
6236	32641940	2019	GLTSK	C1 mother	5	Linear	L	None	Free	Free	Anticancer	Common bean fractions	MCF-7	Breast Cancer	MTT assay	50.11 ± 2.09 inhibition % at 10 µM	48-h	Breast	None
6233	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	PC-9	Lung Cancer	MTT assay	IC₅₀ = 7.921 ± 1.19 mg/ml	72-h	Lung	None
6234	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	HT-29	Colon Cancer	MTT assay	IC₅₀ = 11.55 ± 3.33 mg/ml	72-h	Colon	None
6232	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	PANC-1	Pancreatic Cancer	MTT assay	IC₅₀ = 8.224 ± 1.43 mg/ml	72-h	Pancreas	None
6229	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	A-549	Lung Cancer	MTT assay	IC₅₀ = 9.921 ± 0.82 mg/ml	72-h	Lung	None
6230	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	H-460	Lung Cancer	MTT assay	IC₅₀ = 9.083 ± 1.22 mg/ml	72-h	Lung	None
6231	29921888	2019	Not Available	Silk Fibroin peptide	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Silkworm Cocoons	SW-1990	Pancreatic Cancer	MTT assay	IC₅₀ = 8.005 ± 1.34 mg/ml	72-h	Pancreas	None
6228	30862544	2019	GGTCVIRGCVPKKLM	GM15	15	Linear	L	None	Free	Free	Antioxidant	Arthrospira platensis	KB	Oral Cancer	MTT assay	~ 35% cell viability at 25 μM	24-h	Not Available	None
6227	31161686	2019	GIXXWLHSAXXFGXXFVXXIZNS	8Dap	23	Linear	L	X = 2,3-Diaminopropionic Acid , Z = norleucine	Amidation	Free	Anticancer	Synthetic	PANC-1	Pancreatic Cancer	WST-1 assay	EC₅₀ = 61.4±0.7 μM	24-h	Pancreas	None
6226	31161686	2019	GIKXWLHSAXXFGXKFVXXIZNS	6Dap	23	Linear	L	X = 2,3-Diaminopropionic Acid , Z = norleucine	Amidation	Free	Anticancer	Synthetic	PANC-1	Pancreatic Cancer	WST-1 assay	EC₅₀ = 55.0±1.8 μM	24-h	Pancreas	None
6225	31161686	2019	GIKXWLHSAXKFGXKFVKXIZNS	4Dap	23	Linear	L	X = 2,3-Diaminopropionic Acid , Z = norleucine	Amidation	Free	Anticancer	Synthetic	PANC-1	Pancreatic Cancer	WST-1 assay	EC₅₀ = 35.7±0.7 μM	24-h	Pancreas	None
6224	31161686	2019	GIKXWLHSAKKFGXKFVKKIZNS	2Dap	23	Linear	L	X = 2,3-Diaminopropionic Acid , Z = norleucine	Amidation	Free	Anticancer	Synthetic	PANC-1	Pancreatic Cancer	WST-1 assay	EC₅₀ = 14.7±0.6 μM	24-h	Pancreas	None
6223	31161686	2019	GIKKWLHSAKKFGKKFVKKIZNS	0Dap	23	Linear	L	Z = norleucine	Amidation	Free	Anticancer	Synthetic	PANC-1	Pancreatic Cancer	WST-1 assay	EC₅₀ = 9.1±0.3 μM	24-h	Pancreas	None
6222	31233771	2019	LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN	Nubein6.8	60	Linear	L	None	Free	Free	Anticancer	Naja nubiae	PANC-1	Pancreatic Cancer	MTT assay	slight toxicity above 3.7 μM	24-h	Pancreas	None
6221	31233771	2019	LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN	Nubein6.8	60	Linear	L	None	Free	Free	Anticancer	Naja nubiae	A-2780	Ovarian Cancer	MTT assay	EC₅₀ = 1.249 ± 0.06 μM	24-h	Ovary	None
6220	31233771	2019	LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN	Nubein6.8	60	Linear	L	None	Free	Free	Anticancer	Naja nubiae	A-375	Skin Cancer	MTT assay	EC₅₀ = 0.54 ± 0.04 μM	24-h	Skin	None
6219	30614230	2019	RDTQ	oligopeptide 3	4	Linear	L	None	Free	Free	Anticancer	Sarcophyton glaucum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 5.6 mmol/L	26 h	Cervix	None
6218	30614230	2019	AERQ	oligopeptide 2	4	Linear	L	None	Free	Free	Anticancer	Sarcophyton glaucum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 4.9 mmol/L	25 h	Cervix	None
6217	30614230	2019	AGAPGG	oligopeptide 1	6	Linear	L	None	Free	Free	Anticancer	Sarcophyton glaucum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 8.6 mmol/L	24 h	Cervix	None
6216	30461197	2019	ALWKTMLKKLGTVALHAGKAALGAVADTISQ	Dermaseptin-PS1	31	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagei	U251-MG	Brain Tumor	LDH leakage assay	20% LDH release at 10⁻⁴ M	24-h	Brain	None
6215	30461197	2019	ALWKTMLKKLGTVALHAGKAALGAVADTISQ	Dermaseptin-PS1	31	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagei	U251-MG	Brain Tumor	MTT assay	5.419 μmol/L	24-h	Brain	None
6214	30851450	2019	SPRVRRRYGRPFGGRPFVGGQFGGRPGCVCIRSPCPCANYG	Ss-arasin	41	Linear	L	None	Free	Free	Antimicrobial	Scylla serrata	HT-29	Colon Cancer	MTT assay	IC₅₀ = 2.9 µM	24-h	Colon	None
6213	30851450	2019	SPRVRRRYGRPFGGRPFVGGQFGGRPGCVCIRSPCPCANYG	Ss-arasin	41	Linear	L	None	Free	Free	Antimicrobial	Scylla serrata	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 3.06 µM	24-h	Cervix	None
6212	31234333	2019	GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC	LFB	33	Linear	L	None	Free	Free	Antimicrobial	Limnonectes fujianensi	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 2.02 µM	24-h	Colon	None
6211	31234333	2019	GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC	LFB	33	Linear	L	None	Free	Free	Antimicrobial	Limnonectes fujianensi	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 2.32 µM	24-h	Brain	None
6210	31234333	2019	GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC	LFB	33	Linear	L	None	Free	Free	Antimicrobial	Limnonectes fujianensi	MDA-MB-435S	Breast Cancer	MTT assay	IC₅₀ = 18.99 µM	24-h	Breast	None
6209	31234333	2019	GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC	LFB	33	Linear	L	None	Free	Free	Antimicrobial	Limnonectes fujianensi	H-460	Lung Cancer	MTT assay	IC₅₀ = 3.47 µM	24-h	Lung	None
6208	None	2019	CHYRVKPKIKRFEKYKGRMW	LPSBD-2	20	Linear	L	None	Free	Free	Anticancer	Synthetic	THP-1	Leukemia Cancer	Not Available	Not Available	24-h	Blood	None
6207	None	2019	CQYSVNPKIKRFELYFKGRMW	LPSBD-0	21	Linear	L	None	Free	Free	Anticancer	Synthetic	THP-1	Leukemia Cancer	Not Available	Not Available	24-h	Blood	None
6206	None	2019	IWSFLIKAATKLLPSLFGGGKKDS	SMP24	24	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	KG-1a	Leukemia Cancer	LDH leakage assay	Fig 2	NA	Blood	None
6205	None	2019	IWSFLIKAATKLLPSLFGGGKKDS	SMP24	24	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	CCRF-CEM	Leukemia Cancer	LDH leakage assay	Fig 2	NA	Blood	None
6204	None	2019	IWSFLIKAATKLLPSLFGGGKKDS	SMP24	24	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	KG-1a	Leukemia Cancer	CellTiter-Glo assay	LC₅₀ = 16 ± 1.3 µg/mL	24-h	Blood	None
6203	None	2019	IWSFLIKAATKLLPSLFGGGKKDS	SMP24	24	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	CCRF-CEM	Leukemia Cancer	CellTiter-Glo assay	LC₅₀ = 16 ± 0.9 µg/mL	24-h	Blood	None
6202	None	2019	GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS	SMP43	43	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	KG-1a	Leukemia Cancer	LDH leakage assay	Fig 2	NA	Blood	None
6201	None	2019	GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS	SMP43	43	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	CCRF-CEM	Leukemia Cancer	LDH leakage assay	Fig 2	NA	Blood	None
6200	None	2019	GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS	SMP43	43	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	KG-1a	Leukemia Cancer	CellTiter-Glo assay	LC₅₀ = 16 ± 0.7 µg/mL	24-h	Blood	None
6199	None	2019	GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS	SMP43	43	Linear	L	None	Free	Free	Antimicrobial	Scorpio maurus palmatus	CCRF-CEM	Leukemia Cancer	CellTiter-Glo assay	LC₅₀ = 13 ± 1.5 µg/mL	24-h	Blood	None
6198	31252047	2019	SRSSRAGLQFPVGRIHRLLRK	Fi-Histin_1-21	21	Linear	L	None	Amidation	Acetylation	Antimicrobial	Fenneropenaeus indicus	Hep-2	Liver Cancer	XTT assay	IC₅₀ = 31.274 ± 24.531 μM	24-h	Liver	None
6197	31252047	2019	SRSSRAGLQFPVGRIHRLLRK	Fi-Histin_1-21	21	Linear	L	None	Amidation	Acetylation	Antimicrobial	Fenneropenaeus indicus	NCI-H-460	Lung Cancer	XTT assay	IC₅₀ = 22.670 ± 13.939 μM	24-h	Lung	None
6196	30377840	2019	MTVVLLLIVLPLLGGVHSSGIL	TC22	22	Linear	L	None	Free	Free	Anticancer	Tribolium castaneum	MCF-7	Breast Cancer	MTT assay	Fig 4a	24-h	Breast	None
6195	30377840	2019	MTVVLLLIVLPLLGGVHSSGIL	TC22	22	Linear	L	None	Free	Free	Anticancer	Tribolium castaneum	HeLa	Cervical Cancer	MTT assay	Fig 4a	24-h	Cervix	None
6194	30449002	2019	IWLTALKFLGKNLGKLAKQQLAKL	LyeTx-I-b	24	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	SH-SY5Y	Brain Tumor	MTT/Resazurin dye assay	IC₅₀ = 93.80 ± 2.17 µM	48-h	Brain	None
6193	30449002	2019	IWLTALKFLGKNLGKLAKQQLAKL	LyeTx-I-b	24	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	U-373-MG	Brain Tumor	MTT/Resazurin dye assay	IC₅₀ = 20.94 ± 5.18 µM	48-h	Brain	None
6192	30449002	2019	IWLTALKFLGKNLGKLAKQQLAKL	LyeTx-I-b	24	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	U-87-MG	Brain Tumor	MTT/Resazurin dye assay	IC₅₀ = 29.20 ± 7.96 µM	48-h	Brain	None
6191	31683101	2019	(Beta-A)H	Carnosine	2	Linear	L	None	Free	Free	Anti-inflammatory and Antitumor	Muscular and Nervous tissues of vertebrates	MGH-U1 (EJ)	Bladder Cancer	MTT assay	IC₅₀ = 50 mM	24-h	Bladder	None
6190	30717309	2019	FIHHIIGGLFSAGKAIHRLIRRRRR	TP4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	U-251	Brain Tumor	MTS/PMS assay	LD₅₀ = 20 μg/mL	24-h	Brain	None
6189	30717309	2019	FIHHIIGGLFSAGKAIHRLIRRRRR	TP4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	U87-MG	Brain Tumor	MTS/PMS assay	LD₅₀ = 20 μg/mL	24-h	Brain	None
6187	31633400	2019	FALGAVTKLLPSLLCMITRKC	HN-1	21	Linear	L	None	Free	Free	Host Defense	Amolops hainanensis	PC-3	Prostate Cancer	MTT assay	Not Available	12-h	Prostate	None
6188	31633400	2019	FALGAVTKLLPSLLCMITRKC	HN-1	21	Linear	L	None	Free	Free	Host Defense	Amolops hainanensis	4T1	Breast Cancer	MTT assay	Not Available	12-h	Breast	None
6186	31633400	2019	FALGAVTKLLPSLLCMITRKC	HN-1	21	Linear	L	None	Free	Free	Host Defense	Amolops hainanensis	MDA-MB-453	Breast Cancer	MTT assay	Not Available	12-h	Breast	None
6185	31633400	2019	FALGAVTKLLPSLLCMITRKC	HN-1	21	Linear	L	None	Free	Free	Host Defense	Amolops hainanensis	SGC-7901	Stomach Cancer	MTT assay	Not Available	12-h	Stomach	None
6184	31633400	2019	FALGAVTKLLPSLLCMITRKC	HN-1	21	Linear	L	None	Free	Free	Host Defense	Amolops hainanensis	A-549	Lung Cancer	MTT assay	Not Available	12-h	Lung	None
6183	31633400	2019	FALGAVTKLLPSLLCMITRKC	HN-1	21	Linear	L	None	Free	Free	Host Defense	Amolops hainanensis	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 6.9 μM	12-h	Breast	None
6181	31226350	2019	GRFKRFRKKFKKLFKKLSPVIPLLHL	BMAP-27	27	Linear	L	None	Amidation	Free	Antimicrobial	Cathelicidin	MDA-MB-361	Breast Cancer	MTT assay	IC₅₀ = 4.2 μM	48-h	Breast	None
6182	31226350	2019	GRFKRFRKKFKKLFKKLSPVIPLLHL	BMAP-27	27	Linear	L	None	Amidation	Free	Antimicrobial	Cathelicidin	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.3 μM	48-h	Lung	None
6178	31909181	2019	FLFKLIKKKIKKLIKKFK	AP1-Z9	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	MCF-7	Breast Cancer	MTT assay	Graph Figure 2A	24-h	Breast	None
6179	31909181	2019	FLFKLIKKKIKKLIKKFK	AP1-Z9	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	A-375	Skin Cancer	MTT assay	Graph Figure 2B	24-h	Skin	None
6180	31909181	2019	FLFKLIKKKIKKLIKKFK	AP1-Z9	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	U-87	Brain Tumor	MTT assay	Graph Figure 2C	24-h	Brain	None
6176	31909181	2019	FLFKLIKKAIKKLIKAFK	AP1-Z7	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	A-375	Skin Cancer	MTT assay	Graph Figure 2B	24-h	Skin	None
6177	31909181	2019	FLFKLIKKAIKKLIKAFK	AP1-Z7	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	U-87	Brain Tumor	MTT assay	Graph Figure 2C	24-h	Brain	None
6173	31909181	2019	FLFSLIKHAISKLISAFK	AP1-Z3b	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	A-375	Skin Cancer	MTT assay	Graph Figure 2B	24-h	Skin	None
6174	31909181	2019	FLFSLIKHAISKLISAFK	AP1-Z3b	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	U-87	Brain Tumor	MTT assay	Graph Figure 2C	24-h	Brain	None
6175	31909181	2019	FLFKLIKKAIKKLIKAFK	AP1-Z7	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	MCF-7	Breast Cancer	MTT assay	Graph Figure 2A	24-h	Breast	None
6170	31909181	2019	FLFSLIKHAIKGLISAFK	AP1-Z3a	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	A-375	Skin Cancer	MTT assay	Graph Figure 2B	24-h	Skin	None
6171	31909181	2019	FLFSLIKHAIKGLISAFK	AP1-Z3a	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	U-87	Brain Tumor	MTT assay	Graph Figure 2C	24-h	Brain	None
6172	31909181	2019	FLFSLIKHAISKLISAFK	AP1-Z3b	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	MCF-7	Breast Cancer	MTT assay	Graph Figure 2A	24-h	Breast	None
6168	31909181	2019	FLFKLIKHAIKGLIKAFK	AP1-Z5b	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	U-87	Brain Tumor	MTT assay	IC₅₀ = 3.115 μM	24-h	Brain	None
6169	31909181	2019	FLFSLIKHAIKGLISAFK	AP1-Z3a	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	MCF-7	Breast Cancer	MTT assay	Graph Figure 2A	24-h	Breast	None
6165	31909181	2019	FLFKLIPKAIKGLIKAFK	AP1-Z5a	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	U-87	Brain Tumor	MTT assay	Graph Figure 2C	24-h	Brain	None
6166	31909181	2019	FLFKLIKHAIKGLIKAFK	AP1-Z5b	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 1.037 μM	24-h	Breast	None
6167	31909181	2019	FLFKLIKHAIKGLIKAFK	AP1-Z5b	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	A-375	Skin Cancer	MTT assay	IC₅₀ = 2.607 μM	24-h	Skin	None
6163	31909181	2019	FLFKLIPKAIKGLIKAFK	AP1-Z5a	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	MCF-7	Breast Cancer	MTT assay	Graph Figure 2A	24-h	Breast	None
6164	31909181	2019	FLFKLIPKAIKGLIKAFK	AP1-Z5a	18	Linear	L	None	Amidation	Amidation	Antimicrobial	Mutant of APR-Z1	A-375	Skin Cancer	MTT assay	Graph Figure 2B	24-h	Skin	None
6161	31909181	2019	FLFSLIPHAISGLISAFK	AP1-Z1	18	Linear	L	None	Amidation	Amidation	Antimicrobial	AcrAP1 from the venom of the Arabian scorpion	A-375	Skin Cancer	MTT assay	IC₅₀ = 9.478 μM	24-h	Skin	None
6162	31909181	2019	FLFSLIPHAISGLISAFK	AP1-Z1	18	Linear	L	None	Amidation	Amidation	Antimicrobial	AcrAP1 from the venom of the Arabian scorpion	U-87	Brain Tumor	MTT assay	IC₅₀ = 10.21 μM	24-h	Brain	None
6160	31909181	2019	FLFSLIPHAISGLISAFK	AP1-Z1	18	Linear	L	None	Amidation	Amidation	Antimicrobial	AcrAP1 from the venom of the Arabian scorpion	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 7.222 μM	24-h	Breast	None
6159	30885438	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	Hymenochirin - 1B	29	Linear	L	None	Amidation	Free	Host Defense Peptide	Hymenochirus boettgeri	HepG-2	Liver Cancer	MTT assay	30% cell viability at 20 μM	24-h	Liver	None
6158	30885438	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	Hymenochirin - 1B	29	Linear	L	None	Amidation	Free	Host Defense Peptide	Hymenochirus boettgeri	NCI-H-460	Lung Cancer	MTT assay	10% cell viability at 50 μM	24-h	Lung	None
6157	30885438	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	Hymenochirin - 1B	29	Linear	L	None	Amidation	Free	Host Defense Peptide	Hymenochirus boettgeri	A-549	Lung Cancer	MTT assay	40% cell viability at 10 μM	24-h	Lung	None
6156	30885438	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	Hymenochirin - 1B	29	Linear	L	None	Amidation	Free	Host Defense Peptide	Hymenochirus boettgeri	NCI-H-1299	Lung Cancer	MTT assay	20% cell viability at 10 μM	24-h	Lung	None
6155	31714739	2019	KWCFRVCYRGFCYRRCRK	[I11F-G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 5.1 ± 0.3 µM	24-h	Cervix	None
6154	31714739	2019	KWCFRVCYRGFCYRRCRK	[I11F-G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 1.9 ± 0.1 µM	24-h	Blood	None
6153	31714739	2019	KWCFRVCYRGFCYRRCRK	[I11F-G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.9 ± 0.2 µM	24-h	Skin	None
6152	31714739	2019	KWCFRVCYRGFCYRRCRK	[I11F-G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.2 ± 0.1 µM	24-h	Skin	None
6151	31714739	2019	KWCFRVCYRGFCYRRCRK	[I11F-G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.3 ± 0.1 µM	24-h	Skin	None
6150	31714739	2019	KWCFRVCYRGICYRRCRK	[G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 6.7 ± 1.1 µM	24-h	Cervix	None
6149	31714739	2019	KWCFRVCYRGICYRRCRK	[G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 1.7 ± 0.1 µM	24-h	Blood	None
6148	31714739	2019	KWCFRVCYRGICYRRCRK	[G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.2 µM	24-h	Skin	None
6147	31714739	2019	KWCFRVCYRGICYRRCRK	[G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.2 ± 0.1 µM	24-h	Skin	None
6146	31714739	2019	KWCFRVCYRGICYRRCRK	[G18K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.0 ± 0.1 µM	24-h	Skin	None
6145	31714739	2019	KWCFRVCYSGICYSRCSG	[R9S-R14S-R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 4.8 ± 0.3 µM	24-h	Blood	None
6144	31714739	2019	KWCFRVCYSGICYSRCSG	[R9S-R14S-R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 11.1 ± 0.9 µM	24-h	Skin	None
6143	31714739	2019	KWCFRVCYSGICYSRCSG	[R9S-R14S-R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 11.8 ± 0.9 µM	24-h	Skin	None
6142	31714739	2019	KWCFRVCYRGICYRRCSG	[R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 12.2 ± 0.4 µM	24-h	Cervix	None
6141	31714739	2019	KWCFRVCYRGICYRRCSG	[R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 4.5 ± 0.3 µM	24-h	Skin	None
6140	31714739	2019	KWCFRVCYRGICYRRCSG	[R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.8 ± 0.1 µM	24-h	Skin	None
6139	31714739	2019	KWCFRVCYRGICYRRCSG	[R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.2 ± 0.1 µM	24-h	Skin	None
6138	31714739	2019	KWCFRVCYRGICYRRCSG	[R17S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.8 ± 0.1 µM	24-h	Skin	None
6137	31714739	2019	KWCFRVCYRGICYSRCRG	[R14S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 7.5 ± 0.3 µM	24-h	Cervix	None
6136	31714739	2019	KWCFRVCYRGICYSRCRG	[R14S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.5 ± 0.3 µM	24-h	Skin	None
6135	31714739	2019	KWCFRVCYRGICYSRCRG	[R14S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.1 µM	24-h	Skin	None
6134	31714739	2019	KWCFRVCYRGICYSRCRG	[R14S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.3 ± 0.2 µM	24-h	Skin	None
6133	31714739	2019	KWCFRVCYRGICYSRCRG	[R14S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.7 ± 0.1 µM	24-h	Skin	None
6132	31714739	2019	KWCFRVCYSGICYRRCRG	[R9S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 5.3 ± 0.6 µM	24-h	Skin	None
6131	31714739	2019	KWCFRVCSRGSCYRRCRG	[Y8S-I11S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 13.2 ± 0.9 µM	24-h	Blood	None
6130	31714739	2019	KWCFRVCSRGSCYRRCRG	[Y8S-I11S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 28.2 ± 2.0 µM	24-h	Skin	None
6129	31714739	2019	KWCFRVCSRGSCYRRCRG	[Y8S-I11S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 27.8 ± 2.2 µM	24-h	Skin	None
6128	31714739	2019	KWCFRVCSRGSCYRRCRG	[Y8S-I11S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 17.3 ± 1.0 µM	24-h	Skin	None
6127	31714739	2019	KSCFRVCYRGICYRRCRG	[W2S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 22.5 ± 2.1 µM	24-h	Cervix	None
6126	31714739	2019	KSCFRVCYRGICYRRCRG	[W2S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.2 µM	24-h	Blood	None
6125	31714739	2019	KSCFRVCYRGICYRRCRG	[W2S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 18.9 ± 0.9 µM	24-h	Skin	None
6124	31714739	2019	KSCFRVCYRGICYRRCRG	[W2S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.9 ± 0.2 µM	24-h	Skin	None
6123	31714739	2019	KSCFRVCYRGICYRRCRG	[W2S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.0 ± 0.2 µM	24-h	Skin	None
6122	31714739	2019	KSCFRVCYRGICYRRCRG	[W2S]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.0 ± 0.1 µM	24-h	Skin	None
6121	31714739	2019	KWCFKVCYKGICYKKCKG	[R/K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 13.4 ± 1.9 µM	24-h	Cervix	None
6120	31714739	2019	KWCFKVCYKGICYKKCKG	[R/K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 2.5 ± 0.1 µM	24-h	Blood	None
6119	31714739	2019	KWCFKVCYKGICYKKCKG	[R/K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.5 ± 0.4 µM	24-h	Skin	None
6118	31714739	2019	KWCFKVCYKGICYKKCKG	[R/K]cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 4.3 ± 0.3 µM	24-h	Skin	None
6117	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 6.7 ± 0.6 µM	24-h	Cervix	None
6116	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 6.4 ± 0.6 µM	24-h	Breast	None
6115	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 2.0 ± 0.1 µM	24-h	Blood	None
6114	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.3 µM	24-h	Skin	None
6113	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.1 µM	24-h	Skin	None
6112	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.4 ± 0.1 µM	24-h	Skin	None
6111	31714739	2019	KWCFRVCYRGICYRRCRG	cT1	18	Cyclic	L	None	Cyclized	Cyclized	Host Defense Peptide	Synthetic	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.3 ± 0.1 µM	24-h	Skin	None
6110	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 13.1 ± 1.2 µM	24-h	Cervix	None
6109	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 16.0 ± 2.0 µM	24-h	Breast	None
6108	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 1.7 ± 0.1 µM	24-h	Blood	None
6107	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	MDA-MB-435S	Skin Cancer	Resazurin dye assay	CC₅₀ = 8.0 ± 0.6 µM	24-h	Skin	None
6106	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	WM164	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.5 ± 0.1 µM	24-h	Skin	None
6105	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	HT-144	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.7 ± 0.2 µM	24-h	Skin	None
6104	31714739	2019	KWCFRVCYRGICYRRCR	T1	17	Linear	L	None	Amidation	Free	Host Defense Peptide	Horseshoe Crab	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.5 ± 0.1 µM	24-h	Skin	None
6103	31426323	2019	ALWKTLLKHVGKAAGKAALNAVTDMVNQ	Dermaseptin-PS4	28	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagii	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 0.67 µM	24-h	Breast	None
6102	31426323	2019	ALWKTLLKHVGKAAGKAALNAVTDMVNQ	Dermaseptin-PS4	28	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagii	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 0.44 μM	24-h	Prostate	None
6101	31426323	2019	ALWKTLLKHVGKAAGKAALNAVTDMVNQ	Dermaseptin-PS4	28	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagii	H-157	Lung Cancer	MTT assay	IC₅₀ = 0.19 μM	24-h	Lung	None
6100	31426323	2019	ALWKTLLKHVGKAAGKAALNAVTDMVNQ	Dermaseptin-PS4	28	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagii	MDA-MB-435S	Breast Cancer	MTT assay	IC₅₀ = 0.11 μM	24-h	Breast	None
6099	31426323	2019	ALWKTLLKHVGKAAGKAALNAVTDMVNQ	Dermaseptin-PS4	28	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa sauvagii	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 57.66 nM	24-h	Brain	None
6098	30789695	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	H-0	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Hymenochirus boettgeri	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.07 ± 0.21 μM	48-h	Liver	None
6097	30789695	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	H-0	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Hymenochirus boettgeri	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 12.76 ± 0.43 μM	48-h	Colon	None
6095	30789695	2019	IKLSPS₅TKDS₅LKKVLKGAIKGAIAVAKMV	H-2	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.60 ± 0.24 μM	48-h	Liver	None
6096	30789695	2019	IKLSPETKDNLKKVLKGAIKGAIAVAKMV	H-0	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Hymenochirus boettgeri	A-549	Lung Cancer	MTT assay	IC₅₀ = 15.22 ± 0.21 μM	48-h	Lung	None
6094	30789695	2019	IKLSPS₅TKDS₅LKKVLKGAIKGAIAVAKMV	H-2	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 3.54 ± 0.72 μM	48-h	Colon	None
6093	30789695	2019	IKLSPS₅TKDS₅LKKVLKGAIKGAIAVAKMV	H-2	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 4.26 ± 0.52 μM	48-h	Lung	None
6091	30789695	2019	IKLSPETKDNLKKVLKGS₅IKGS₅IAVAKMV	H-5	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 4.16 ± 0.21 μM	48-h	Colon	None
6092	30789695	2019	IKLSPETKDNLKKVLKGS₅IKGS₅IAVAKMV	H-5	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.82 ± 0.23 μM	48-h	Liver	None
6090	30789695	2019	IKLSPETKDNLKKVLKGS₅IKGS₅IAVAKMV	H-5	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 7.35 ± 0.22 μM	48-h	Lung	None
6089	30789695	2019	IKLSPS₅TKDS₅LKKVLKGS₅IKGS₅IAVAKMV	H-10	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.50 ± 0.21 μM	48-h	Liver	None
6088	30789695	2019	IKLSPS₅TKDS₅LKKVLKGS₅IKGS₅IAVAKMV	H-10	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 3.51 ± 0.37 μM	48-h	Colon	None
6087	30789695	2019	IKLSPS₅TKDS₅LKKVLKGS₅IKGS₅IAVAKMV	H-10	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 3.59 ± 0.12 μM	48-h	Lung	None
6086	30789695	2019	IKLSKKTKKNLKKVLKGAIKGAIAVAKMV	H-14	29	Linear	L	None	Amidation	Free	Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.54 ± 0.25 μM	48-h	Liver	None
6085	30789695	2019	IKLSKKTKKNLKKVLKGAIKGAIAVAKMV	H-14	29	Linear	L	None	Amidation	Free	Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 1.841 ± 0.34 μM	48-h	Colon	None
6084	30789695	2019	IKLSKKTKKNLKKVLKGAIKGAIAVAKMV	H-14	29	Linear	L	None	Amidation	Free	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 0.98 ± 0.11 μM	48-h	Lung	None
6082	30789695	2019	IKLSKS₅TKDS₅LKKVLKGAIKGAIAVAKMV	H-15	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 2.95 ± 0.25 μM	48-h	Colon	None
6083	30789695	2019	IKLSKS₅TKDS₅LKKVLKGAIKGAIAVAKMV	H-15	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.20 ± 0.27 μM	48-h	Liver	None
6081	30789695	2019	IKLSKS₅TKDS₅LKKVLKGAIKGAIAVAKMV	H-15	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 2.26 ± 0.24 μM	48-h	Lung	None
6079	30789695	2019	IKLSPS₅TKKS₅LKKVLKGAIKGAIAVAKMV	H-16	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 2.65 ± 0.35 μM	48-h	Colon	None
6080	30789695	2019	IKLSPS₅TKKS₅LKKVLKGAIKGAIAVAKMV	H-16	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 3.14 ± 0.46 μM	48-h	Liver	None
6078	30789695	2019	IKLSPS₅TKKS₅LKKVLKGAIKGAIAVAKMV	H-16	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 1.85 ± 0.31 μM	48-h	Lung	None
6076	30789695	2019	IKLSKS₅TKKS₅LKKVLKGAIKGAIAVAKMV	H-17	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 1.49 ± 0.45 μM	48-h	Colon	None
6077	30789695	2019	IKLSKS₅TKKS₅LKKVLKGAIKGAIAVAKMV	H-17	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.64 ± 0.47 μM	48-h	Liver	None
6074	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-18	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.61 ± 0.21 μM	48-h	Liver	None
6075	30789695	2019	IKLSKS₅TKKS₅LKKVLKGAIKGAIAVAKMV	H-17	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 0.96 ± 0.33 μM	48-h	Lung	None
6072	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-18	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 0.89 ± 0.21 μM	48-h	Lung	None
6073	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-18	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 1.11 ± 0.21 μM	48-h	Colon	None
6071	30789695	2019	IKLSKETKKNLKKVLKGS₅IKGS₅IAVAKMV	H-19	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.64 ± 0.36 μM	48-h	Liver	None
6069	30789695	2019	IKLSKETKKNLKKVLKGS₅IKGS₅IAVAKMV	H-19	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 1.00 ± 0.36 μM	48-h	Lung	None
6070	30789695	2019	IKLSKETKKNLKKVLKGS₅IKGS₅IAVAKMV	H-19	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 1.78 ± 0.35 μM	48-h	Colon	None
6068	30789695	2019	IKLSPS₅TKKS₅LKKVLKGS₅IKGS₅IAVAKMV	H-20	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.93 ± 0.53 μM	48-h	Liver	None
6067	30789695	2019	IKLSPS₅TKKS₅LKKVLKGS₅IKGS₅IAVAKMV	H-20	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 2.63 ± 0.35 μM	48-h	Colon	None
6066	30789695	2019	IKLSPS₅TKKS₅LKKVLKGS₅IKGS₅IAVAKMV	H-20	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 2.10 ± 0.32 μM	48-h	Lung	None
6065	30789695	2019	IKLSKS₅TKKS₅LKKVLKGS₅IKGS₅IAVAKMV	H-21	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 1.50 ± 0.28 μM	48-h	Liver	None
6063	30789695	2019	IKLSKS₅TKKS₅LKKVLKGS₅IKGS₅IAVAKMV	H-21	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 3.26 ± 0.36 μM	48-h	Lung	None
6064	30789695	2019	IKLSKS₅TKKS₅LKKVLKGS₅IKGS₅IAVAKMV	H-21	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 3.05 ± 0.21 μM	48-h	Colon	None
6062	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-57	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.13 ± 0.07 μM	48-h	Liver	None
6061	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-57	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 1.29 ± 0.08 μM	48-h	Colon	None
6060	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-57	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 0.62 ± 0.12 μM	48-h	Lung	None
6058	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-58	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 1.29 ± 0.08 μM	48-h	Colon	None
6059	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-58	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.13 ± 0.07 μM	48-h	Liver	None
6057	30789695	2019	IKLSKKTKKNLKKVLKGS₅IKGS₅IAVAKMV	H-58	29	Cyclic	L	S₅ = (S)-N-Fmoc-2-(4′-pentenyl)alanine	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 0.62 ± 0.12 μM	48-h	Lung	None
6056	30789695	2019	IKLSKETKDNLKKVLKGAIKGAIAVAKMV	[P5K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.28 ± 0.38 μM	48-h	Liver	None
6055	30789695	2019	IKLSKETKDNLKKVLKGAIKGAIAVAKMV	[P5K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 8.09 ± 0.40 μM	48-h	Colon	None
6054	30789695	2019	IKLSKETKDNLKKVLKGAIKGAIAVAKMV	[P5K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 2.35 ± 0.31 μM	48-h	Lung	None
6053	30789695	2019	IKLSPETKKNLKKVLKGAIKGAIAVAKMV	[D9K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.96 ± 0.43 μM	48-h	Liver	None
6052	30789695	2019	IKLSPETKKNLKKVLKGAIKGAIAVAKMV	[D9K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 6.50 ± 0.32 μM	48-h	Colon	None
6051	30789695	2019	IKLSPETKKNLKKVLKGAIKGAIAVAKMV	[D9K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 1.82 ± 0.23 μM	48-h	Lung	None
6050	30789695	2019	IKLSKETKKNLKKVLKGAIKGAIAVAKMV	[P5K,D9K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.46 ± 0.32 μM	48-h	Liver	None
6049	30789695	2019	IKLSKETKKNLKKVLKGAIKGAIAVAKMV	[P5K,D9K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 4.93 ± 0.51 μM	48-h	Colon	None
6048	30789695	2019	IKLSKETKKNLKKVLKGAIKGAIAVAKMV	[P5K,D9K]Hymenochirin-1B	29	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 1.17 ± 0.23 μM	48-h	Lung	None
6047	31635388	2019	GLWSKIKKAAKTAGKAALGFVNKMV	K8, 23-DPT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	PANC-1	Pancreatic Cancer	MTT assay	IC₅₀ = 11.17 µM	24-h	Pancreas	None
6046	31635388	2019	GLWSKIKKAAKTAGKAALGFVNKMV	K8, 23-DPT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 9.97 µM	24-h	Prostate	None
6045	31635388	2019	GLWSKIKKAAKTAGKAALGFVNKMV	K8, 23-DPT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	H-157	Lung Cancer	MTT assay	IC₅₀ = 9.88 µM	24-h	Lung	None
6044	31635388	2019	GLWSKIKKAAKTAGKAALGFVNKMV	K8, 23-DPT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 18.51 µM	24-h	Brain	None
6043	31635388	2019	GLWSKIKKAAKTAGKAALGFVNKMV	K8, 23-DPT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 8.64 µM	24-h	Breast	None
6042	31635388	2019	GLWSKIKDAAKTAGKAALGFVNEMV	Dermaseptin-PT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa tarsius	PANC-1	Pancreatic Cancer	MTT assay	IC₅₀ = 28.95 µM	24-h	Pancreas	None
6041	31635388	2019	GLWSKIKDAAKTAGKAALGFVNEMV	Dermaseptin-PT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa tarsius	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 21.78 µM	24-h	Prostate	None
6040	31635388	2019	GLWSKIKDAAKTAGKAALGFVNEMV	Dermaseptin-PT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa tarsius	H-157	Lung Cancer	MTT assay	IC₅₀ = 25.51 µM	24-h	Lung	None
6039	31635388	2019	GLWSKIKDAAKTAGKAALGFVNEMV	Dermaseptin-PT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa tarsius	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 49.51 µM	24-h	Brain	None
6038	31635388	2019	GLWSKIKDAAKTAGKAALGFVNEMV	Dermaseptin-PT9	25	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa tarsius	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 7.44 µM	24-h	Breast	None
6037	30612735	2019	FLSLIPHIVSGVAALANHL	Phylloseptin-PBa3	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	H-838	Lung Cancer	MTT assay	Cell viability ~ 65% at 10^-5 M	72-h	Lung	None
6036	30612735	2019	FLSLIPHIVSGVAALANHL	Phylloseptin-PBa3	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	MDA-MB-435S	Breast Cancer	MTT assay	IC₅₀ = 208 µM	72-h	Breast	None
6035	30612735	2019	FLSLIPHIASGIASLVKNF	Phylloseptin-PBa1	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	H-838	Lung Cancer	MTT assay	Cell viability ~ 65% at 10^-5 M	72-h	Lung	None
6034	30612735	2019	FLSLIPHIASGIASLVKNF	Phylloseptin-PBa1	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	H-460	Lung Cancer	MTT assay	Cell viability < 50% at 10^-5 M	72-h	Lung	None
6033	30612735	2019	FLSLIPHIASGIASLVKNF	Phylloseptin-PBa1	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	DU-145	Prostate Cancer	MTT assay	Cell viability ~ 50% at 10^-5 M	72-h	Prostate	None
6032	30612735	2019	FLSLIPHIASGIASLVKNF	Phylloseptin-PBa1	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	U251-MG	Brain Tumor	MTT assay	Cell viability ~ 40% at 10^-5 M	72-h	Brain	None
6031	30612735	2019	FLSLIPHIASGIASLVKNF	Phylloseptin-PBa1	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	MDA-MB-435S	Breast Cancer	MTT assay	IC₅₀ = 0.50 µM	72-h	Breast	None
6030	30612735	2019	FLSLLPHIASGIASLVSKF	Phylloseptin-PBa3	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	H-838	Lung Cancer	MTT assay	Cell viability ~ 65% at 10^-5 M	72-h	Lung	None
6029	30612735	2019	FLSLLPHIASGIASLVSKF	Phylloseptin-PBa3	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	H-460	Lung Cancer	MTT assay	Cell viability ~ 60% at 10^-5 M	72-h	Lung	None
6028	30612735	2019	FLSLLPHIASGIASLVSKF	Phylloseptin-PBa2	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	U251-MG	Brain Tumor	MTT assay	Cell viability ~ 60% at 10^-5 M	72-h	Brain	None
6027	30612735	2019	FLSLLPHIASGIASLVSKF	Phylloseptin-PBa2	19	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa burmeisteri	MDA-MB-435S	Breast Cancer	MTT assay	IC₅₀ = 0.29 µM	72-h	Breast	None
6026	29043494	2018	KILRGVCKKIMRpFLRRISKDILTGKK	NK-pro	27	Linear	Mix	None	Amidated	Free	Antimicrobial	Synthetic analog of NK-2	HL-60	Leukemia Cancer	MTT assay	IC₅₀ = 26.1 μM	24-h	Blood	None
6025	29043494	2018	KILRGVCKKIMRpFLRRISKDILTGKK	NK-pro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	T-24	Bladder Cancer	MTT assay	IC₅₀ = 33.0 μM	24-h	Bladder	None
6024	29043494	2018	KILRGVCKKIMRpFLRRISKDILTGKK	NK-pro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	EJ	Bladder Cancer	MTT assay	IC₅₀ = 23.3 μM	24-h	Bladder	None
6023	29043494	2018	KILRGVCKKIMRpFLRRISKDILTGKK	NK-pro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 9.3 μM	24-h	Prostate	None
6022	29043494	2018	KILpGVCKKIMRpFLRRISKDILTGKK	NK-dpro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	HL-60	Leukemia Cancer	MTT assay	IC₅₀ = 48.4 μM	24-h	Blood	None
6021	29043494	2018	KILpGVCKKIMRpFLRRISKDILTGKK	NK-dpro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	T-24	Bladder Cancer	MTT assay	IC₅₀ = 39.6 μM	24-h	Bladder	None
6020	29043494	2018	KILpGVCKKIMRpFLRRISKDILTGKK	NK-dpro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	EJ	Bladder Cancer	MTT assay	IC₅₀ = 28.7 μM	24-h	Bladder	None
6019	29043494	2018	KILpGVCKKIMRpFLRRISKDILTGKK	NK-dpro	27	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analog of NK-2	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 9.6 μM	24-h	Prostate	None
6018	30183307	2018	RGWFRAMRSIARFIARERLREHL	R-C16	23	Linear	L	None	Amidation	Fatty acid :C16H31O	Anticancer	R-Lycosin-I	A-549	Lung Cancer	CCK-8 assay	IC₅₀ ~ 5 µM	24-h	Lung	None
6017	30563041	2018	RIRDAIAHGYIVDKV	B11	15	Linear	L	None	Free	Free	Antimicrobial	Litopenaeus vannamei hemocyanin-derived peptide	EC-109	Esophageal Cancer	MTS assay	Decreased cell viability by 13% at 50 μg/mL	24-h	Esophagus	None
6016	30563041	2018	RIRDAIAHGYIVDKV	B11	15	Linear	L	None	Free	Free	Antimicrobial	Litopenaeus vannamei hemocyanin-derived peptide	HepG-2	Liver Cancer	MTS assay	Decreased cell viability by 23% at 50 μg/mL	24-h	Liver	None
6015	30563041	2018	RIRDAIAHGYIVDKV	B11	15	Linear	L	None	Free	Free	Antimicrobial	Litopenaeus vannamei hemocyanin-derived peptide	HeLa	Cervical Cancer	MTS assay	Decreased cell viability by 20% at 50 μg/mL	24-h	Cervix	None
6013	30241374	2018	Structure in scheme 2	Compound 6b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 11.53 ± 1.70 µM	Not Available	Liver	None
6014	30241374	2018	Structure in scheme 2	Compound 6c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 12.07 ± 1.68 µM	Not Available	Liver	None
6011	30241374	2018	Structure in scheme 2	Compound 6a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 12.44 ± 1.3 µM	Not Available	Liver	None
6012	30241374	2018	Structure in scheme 2	Compound 6b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 10.87 ± 1.10 µM	Not Available	Breast	None
6009	30241374	2018	Structure in scheme 2	Compound 5c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 7.53 ± 1.33 µM	Not Available	Liver	None
6010	30241374	2018	Structure in scheme 2	Compound 6a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 11.83 ± 1.62 µM	Not Available	Breast	None
6007	30241374	2018	Structure in scheme 2	Compound 5b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 10.09 ± 2.05 µM	Not Available	Liver	None
6008	30241374	2018	Structure in scheme 2	Compound 5c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 9.41 ± 1.25 µM	Not Available	Breast	None
6005	30241374	2018	Structure in scheme 2	Compound 5a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 11.19 ± 1.95 µM	Not Available	Liver	None
6006	30241374	2018	Structure in scheme 2	Compound 5b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 11.32 ± 1.15 µM	Not Available	Breast	None
6003	30241374	2018	Structure in scheme 2	Compound 4c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 18.84 ± 1.47 µM	Not Available	Liver	None
6004	30241374	2018	Structure in scheme 2	Compound 5a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 12.67 ± 2.40 µM	Not Available	Breast	None
6001	30241374	2018	Structure in scheme 2	Compound 4b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 10.25 ± 2.20 µM	Not Available	Liver	None
6002	30241374	2018	Structure in scheme 2	Compound 4c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 29.15 ± 1.39 µM	Not Available	Breast	None
6000	30241374	2018	Structure in scheme 2	Compound 4b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 10.45 ± 1.33 µM	Not Available	Breast	None
5998	30241374	2018	Structure in scheme 2	Compound 3c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 26.64 ± 1.85 µM	Not Available	Liver	None
5999	30241374	2018	Structure in scheme 2	Compound 4a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 11.59 ± 2.70 µM	Not Available	Liver	None
5997	30241374	2018	Structure in scheme 2	Compound 3c	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 29.55 ± 2.06 µM	Not Available	Breast	None
5994	30241374	2018	Structure in scheme 2	Compound 3a	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 26.01 ± 2.35 µM	Not Available	Liver	None
5995	30241374	2018	Structure in scheme 2	Compound 3b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 25.33 ± 1.18 µM	Not Available	Breast	None
5996	30241374	2018	Structure in scheme 2	Compound 3b	5	Cyclic	L	Structure in scheme 2	Structure in scheme 2	Structure in scheme 2	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 13.54 ± 1.45 µM	Not Available	Liver	None
5992	30241374	2018	Structure in scheme 1	Compound 2b	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 15.80 ± 1.66 µM	Not Available	Liver	None
5993	30241374	2018	Structure in scheme 1	Compound 2c	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 35.52 ± 1.83 µM	Not Available	Liver	None
5990	30241374	2018	Structure in scheme 1	Compound 2a	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	HepG-2	Liver Cancer	Not Available	IC₅₀ = 20.37 ± 1.36 µM	Not Available	Liver	None
5991	30241374	2018	Structure in scheme 1	Compound 2b	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 32.58 ± 1.50 µM	Not Available	Breast	None
5989	30241374	2018	Structure in scheme 1	Compound 2a	5	Cyclic	L	Structure in scheme 1	Structure in scheme 1	Structure in scheme 1	Anticancer	Synthetic	MCF-7	Breast Cancer	Not Available	IC₅₀ = 31.64 ± 1.30 µM	Not Available	Breast	None
5988	30373232	2018	(3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine	Emericellipsin A	9	Linear	L	3-me-P = (3R)-3-methylproline; AHMOD = (2S,4S)-2-Amino-4-methyl-6-hydroxy-8-oxodecanoic acid; Aib = 2-Aminoisobutyric acid; β-alanine; N-(2-Hydroxyethyl)-1,2-propanediamine	N-(2-Hydroxyethyl)-1,2-propanediamine	2-methyldecanoic acid (2MDA)	Antimicrobial and Antitumor	Emericellopsis alkalina	HeLa	Cervical Cancer	MTT assay	EC₅₀ < 0.5 uM	24-h	Cervix	None
5987	30373232	2018	(3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine	Emericellipsin A	9	Linear	L	3-me-P = (3R)-3-methylproline; AHMOD = (2S,4S)-2-Amino-4-methyl-6-hydroxy-8-oxodecanoic acid; Aib = 2-Aminoisobutyric acid; β-alanine; N-(2-Hydroxyethyl)-1,2-propanediamine	N-(2-Hydroxyethyl)-1,2-propanediamine	2-methyldecanoic acid (2MDA)	Antimicrobial and Antitumor	Emericellopsis alkalina	HepG-2	Liver Cancer	MTT assay	EC₅₀ = 2.8 uM	24-h	Liver	None
5986	30031283	2018	NGVQPKYRWWRWWRRWW	RT2	17	Linear	L	None	Amidation	Free	Antimicrobial	Crocodylus siamensis	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 90.25 μg/mL	24-h	Colon	None
5984	29667478	2018	ytrdlvygdparpgiqgtgtf	D-FP21-PEG-PEI/pGRO-α	21	Linear	D	conjugated to polyethylenimine (PEI) and methoxy polyethylene glycol (mPEG)	Free	Free	Anti-caner, anti-proliferative, anti-tumor	Synthetic	HO-8910	Ovarian Cancer	CCK-8 assay	IC₅₀ = 21.6 μg/mL	24-h	Ovary	None
5985	30031283	2018	NGVQPKYKWWKWWKKWW	KT2	17	Linear	L	None	Amidation	Free	Antimicrobial	Crocodylus siamensis	HCT-116	Colon Cancer	MTT assay	IC₅₀ = 90.25 μg/mL	24-h	Colon	None
5982	28254375	2018	ASVVNKLTGGVAGLLK	TP	16	Linear	L	None	Free	Free	Antimicrobial	Tibetan swine	NB-4	Leukemia Cancer	MTT assay	IC₅₀ = 11.479 μM	48-h	Blood	None
5983	29667478	2018	YTRDLVYGDPARPGIQGTGTF	L-FP21-PEG-PEI/pGRO-α	21	Linear	L	conjugated to polyethylenimine (PEI) and methoxy polyethylene glycol (mPEG)	Free	Free	Anti-caner, anti-proliferative, anti-tumor	Synthetic	HO-8910	Ovarian Cancer	CCK-8 assay	IC₅₀ = 23.4 μg/mL	24-h	Ovary	None
5981	28254375	2018	ASVVNKLTGGVAGLLK	TP	16	Linear	L	None	Free	Free	Antimicrobial	Tibetan swine	MKN-45	Gastric Cancer	MTT assay	IC₅₀ = 4.686 μM	48-h	Stomach	None
5980	29628917	2018	NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN	DLP-PH	36	Linear	L	None	Free	Free	Antimicrobial	Phyllomedusa hypochondrialis	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 32.25 μg/mL	24-h	Prostate	None
5979	29628917	2018	NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN	DLP-PH	36	Linear	L	None	Free	Free	Antimicrobial	Phyllomedusa hypochondrialis	H-157	Lung Cancer	MTT assay	IC₅₀ = 15.41 μg/mL	24-h	Lung	None
5978	30481557	2018	HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK	PACAP38	38	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Clarias gariepinus	H-460	Lung Cancer	Crystal Violet assay	IC₅₀=14.97± 1.16 µM	48-h	Lung	None
5975	30483133	2018	GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI	myristoyl-CM4	36	Linear	L	None	Amidation	N-myristoylation	Antimicrobial	Bombyx mori	MCF-7	Breast cancer	MTT assay	IC₅₀ = 6 μM	24-h	Breast	None
5976	30483133	2018	GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI	myristoyl-CM4	36	Linear	L	None	Amidation	N-myristoylation	Antimicrobial	Bombyx mori	MDA-MB-231	Breast cancer	MTT assay	IC₅₀ = 4 μM	24-h	Breast	None
5977	30483133	2018	GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI	myristoyl-CM4	36	Linear	L	None	Amidation	N-myristoylation	Antimicrobial	Bombyx mori	MX-1	Breast cancer	MTT assay	IC₅₀ = 3 μM	24-h	Breast	None
5974	29757646	2018	GIPCGESCVWIPCISSAIGCSCKNKVCYRN	CyO4	30	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial,Cytotoxic	Viola odorata	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 9.8 μM	24-h	Breast	None
5973	29757646	2018	GIPCAESCVFIPCVTAILGCSCKDVCYN	Poca B	28	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial,Cytotoxic	Pombalia calceolaria	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 2.7 μM	24-h	Breast	None
5972	29757646	2018	GLPCAESCVFIPCTITAILGCSCRDRVCYD	Poca A	30	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial,Cytotoxic	Pombalia calceolaria	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 1.8 μM	24-h	Breast	None
5971	29301308	2018	FIHHIIGGLFSAGKAIHRLIRRRRR	MSP-4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	MG-63	Bone Cancer	MTT assay	Cell viability = 26.78 ± 1.75% at 10 µM	24-h	Bone	None
5970	30123940	2018	Ahx-(KAVPIAQKE)GG(KRRRRRRRRE)	SmacN7-Arg8 fused peptide P7	22	Cyclic	L	Ahx = aminohexanoic acid; Lactam Bridge between K2 and E10 and between K13 and E22	Amidation	Free	Anticancer	Synthetic	U-266	Skin Cancer	Cell Titer Blue Cell Viability assay	Cell viability < 50% at 50 μM	48-h	Skin	None
5969	30123940	2018	Ahx-(KAVPIAQKE)RRRRRRRR	SmacN7-Arg8 fused peptide P5	18	Cyclic	L	Ahx = aminohexanoic acid; Lactam Bridge between K2 and E10	Amidation	Free	Anticancer	Synthetic	U-266	Skin Cancer	Cell Titer Blue Cell Viability assay	Cell viability < 50% at 50 μM	48-h	Skin	None
5968	30123940	2018	Ahx-AVPIAQK(KRRRRRRRRRE)	SmacN7-Arg8 fused peptide P4	18	Cyclic	L	Ahx = aminohexanoic acid; Lactam Bridge between K6 and E18	Amidation	Free	Anticancer	Synthetic	U-266	Skin Cancer	Cell Titer Blue Cell Viability assay	Cell viability < 50% at 50 μM	48-h	Skin	None
5967	29875773	2018	RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa	R11-NLS-pep8	38	Linear	Mix	None	Free	Acetylation	Anticancer	NKp44 derived synthetic peptide	MDA-MD-231	Breast Cancer	PrestoBlue assay	ED50 = 5.6 μM	24-h	Breast	None
5966	29875773	2018	RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa	R11-NLS-pep8	38	Linear	Mix	None	Free	Acetylation	Anticancer	NKp44 derived synthetic peptide	HepG-2	Liver Cancer	PrestoBlue assay	ED50 = 5.9 μM	24-h	Liver	None
5965	29875773	2018	RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa	R11-NLS-pep8	38	Linear	Mix	None	Free	Acetylation	Anticancer	NKp44 derived synthetic peptide	PANC-1	Pancreatic Cancer	PrestoBlue assay	ED50 = 7.8 μM	24-h	Pancreas	None
5964	29875773	2018	RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa	R11-NLS-pep8	38	Linear	Mix	None	Free	Acetylation	Anticancer	NKp44 derived synthetic peptide	B-16	Skin Cancer	PrestoBlue assay	ED50 = 7.1 μM	24-h	Skin	None
5962	None	2018	PIPRPIF	P18-2	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	BEL-7042	Cervical Cancer	Cytotoxicity assay	IC₅₀ >100 µM	Not Available	Cervix	None
5963	29800725	2018	GIGAVLKKLTTGLKALISWIKRKRQQ	MEL-Pep	26	Linear	L	None	Amidation	Free	Anticancer	Synthetic analog of Melittin	BEL-7402/5-FU	Liver Cancer	CCK-8 assay	IC₅₀ = 4.36 μM	24-h	Liver	None
5961	None	2018	PIPRPIF	P18-2	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	A-549	Lung Cancer	Cytotoxicity assay	IC₅₀ = 79.71 µM	Not Available	Lung	None
5959	None	2018	PIPYPIF	P18-1	7	Cyclic	L	Substitution of hydroxyl group at Tyrosine with sulfonyl fluoride	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	A-549	Lung Cancer	Cytotoxicity assay	IC₅₀ = 67.53 µM	Not Available	Lung	None
5960	None	2018	PIPYPIF	P18-1	7	Cyclic	L	Substitution of hydroxyl group at Tyrosine with sulfonyl fluoride	Cyclized	Cyclized	Anticancer	Analogue of Phakellistatin 18	BEL-7042	Cervical Cancer	Cytotoxicity assay	IC₅₀ = 41.28 µM	Not Available	Cervix	None
5958	None	2018	PIPYPIF	Phakellistatin 18	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Marine Sponge Phakellia fusca	BEL-7042	Cervical Cancer	Cytotoxicity assay	IC₅₀ = 82.25 µM	Not Available	Cervix	None
5957	None	2018	PIPYPIF	Phakellistatin 18	7	Cyclic	L	None	Cyclized	Cyclized	Anticancer	Marine Sponge Phakellia fusca	A-549	Lung Cancer	Cytotoxicity assay	IC₅₀ = 72.42 µM	Not Available	Lung	None
5956	29559362	2018	ATCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC	PaDef	47	Linear	L	None	Free	Free	Antimicrobial	Persea americana var. drymifolia	K-562	Blood Cancer	MTT assay	IC₅₀ = 97.3 μg/mL	24-h	Blood	None
5955	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	PG-BE1	Lung Cancer	CCK-8 assay	IC₅₀ = 31.3 μM	24-h	Lung	None
5954	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	H-460	Lung Cancer	CCK-8 assay	IC₅₀ = 5.19 μM	24-h	Lung	None
5953	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 11.9 μM	24-h	Lung	None
5952	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	A-431	Skin Cancer	CCK-8 assay	IC₅₀ = 1.8 μM	24-h	Skin	None
5951	29054798	2018	ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK	Nisin Z	34	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Lactococcus lactis	A-375	Skin Cancer	LDH leakage assay	60% LDH release at 60 µM	24-h	Skin	None
5949	29649141	2018	YVPGP	AAP-H	5	Linear	L	None	Free	Free	Anticancer	Anthopleura anjunae	DU-145	Prostate Cancer	MTT assay	IC₅₀ = 2.298 mM	72-h	Prostate	None
5950	29054798	2018	ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK	Nisin Z	34	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Lactococcus lactis	A-375	Skin Cancer	MTT assay	IC₅₀ = 188.5 ± 8.7 µM	24-h	Skin	None
5948	29993185	2018	WCYKLPDRVSIKEKGRCN	Peptide13 Gonearrestide	18	Linear	L	None	Amidation	Free	Anticancer	Androctonus mauritanicus	U-251	Brain tumor	MTT assay	Not Available	24-h	Brain	None
5947	29993185	2018	WCYKLPDRVSIKEKGRCN	Peptide13 Gonearrestide	18	Linear	L	None	Amidation	Free	Anticancer	Androctonus mauritanicus	Dks8	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5945	29993185	2018	WCYKLPDRVSIKEKGRCN	Peptide13 Gonearrestide	18	Linear	L	None	Amidation	Free	Anticancer	Androctonus mauritanicus	DLD-1	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5946	29993185	2018	WCYKLPDRVSIKEKGRCN	Peptide13 Gonearrestide	18	Linear	L	None	Amidation	Free	Anticancer	Androctonus mauritanicus	HKe-3	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5944	29993185	2018	WCYKLPDRVSIKEKGRCN	Peptide13 Gonearrestide	18	Linear	L	None	Amidation	Free	Anticancer	Androctonus mauritanicus	HCT-116	Colon Cancer	MTT assay	IC₅₀ ~ 100 μM/L	24-h	Colon	None
5943	29993185	2018	NDADKDEMQSVYRGKANDDNSRGSKTNHRF	Peptide10 Gonearrestide	30	Linear	L	None	Free	Free	Anticancer	Androctonus mauritanicus	U-251	Brain tumor	MTT assay	Not Available	24-h	Brain	None
5942	29993185	2018	NDADKDEMQSVYRGKANDDNSRGSKTNHRF	Peptide10 Gonearrestide	30	Linear	L	None	Free	Free	Anticancer	Androctonus mauritanicus	Dks8	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5941	29993185	2018	NDADKDEMQSVYRGKANDDNSRGSKTNHRF	Peptide10 Gonearrestide	30	Linear	L	None	Free	Free	Anticancer	Androctonus mauritanicus	HKe-3	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5940	29993185	2018	NDADKDEMQSVYRGKANDDNSRGSKTNHRF	Peptide10 Gonearrestide	30	Linear	L	None	Free	Free	Anticancer	Androctonus mauritanicus	DLD-1	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5939	29993185	2018	NDADKDEMQSVYRGKANDDNSRGSKTNHRF	Peptide10 Gonearrestide	30	Linear	L	None	Free	Free	Anticancer	Androctonus mauritanicus	HCT-116	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5938	29993185	2018	KLSAIISKIRDE	Peptide6 Gonearrestide	12	Linear	L	None	Free	Free	Anticancer	Androctonus australis	U-251	Brain tumor	MTT assay	Not Available	24-h	Brain	None
5937	29993185	2018	KLSAIISKIRDE	Peptide6 Gonearrestide	12	Linear	L	None	Free	Free	Anticancer	Androctonus australis	Dks8	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5936	29993185	2018	KLSAIISKIRDE	Peptide6 Gonearrestide	12	Linear	L	None	Free	Free	Anticancer	Androctonus australis	HKe-3	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5935	29993185	2018	KLSAIISKIRDE	Peptide6 Gonearrestide	12	Linear	L	None	Free	Free	Anticancer	Androctonus australis	DLD-1	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5934	29993185	2018	KLSAIISKIRDE	Peptide6 Gonearrestide	12	Linear	L	None	Free	Free	Anticancer	Androctonus australis	HCT-116	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5933	29993185	2018	ADAPGNYPLDARGKSYYC	Peptide4 Gonearrestide	18	Linear	L	None	Free	Free	Anticancer	Androctonus australis	U-251	Brain tumor	MTT assay	Not Available	24-h	Brain	None
5932	29993185	2018	ADAPGNYPLDARGKSYYC	Peptide4 Gonearrestide	18	Linear	L	None	Free	Free	Anticancer	Androctonus australis	Dks8	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5931	29993185	2018	ADAPGNYPLDARGKSYYC	Peptide4 Gonearrestide	18	Linear	L	None	Free	Free	Anticancer	Androctonus australis	HKe-3	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5930	29993185	2018	ADAPGNYPLDARGKSYYC	Peptide4 Gonearrestide	18	Linear	L	None	Free	Free	Anticancer	Androctonus australis	DLD-1	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5929	29993185	2018	ADAPGNYPLDARGKSYYC	Peptide4 Gonearrestide	18	Linear	L	None	Free	Free	Anticancer	Androctonus australis	HCT-116	Colon Cancer	MTT assay	Not Available	24-h	Colon	None
5928	30409511	2018	FLSTIWNGIKSLL	Pantinin-3	13	Linear	L	None	Free	Free	Antimicrobial	Synthetic	DU-145	Prostate Cancer	MTS assay	IC₅₀ = 17.3 ± 1.0 µM	24-h	Prostate	None
5927	30409511	2018	FLSTIWNGIKSLL	Pantinin-3	13	Linear	L	None	Free	Free	Antimicrobial	Synthetic	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 13.5 ± 2.0 µM	24-h	Breast	None
5926	30409511	2018	IFGAIWKGISSLL	Pantinin-2	13	Linear	L	None	Free	Free	Antimicrobial	Synthetic	DU-145	Prostate Cancer	MTS assay	IC₅₀ = 16.5 ± 1.0 µM	24-h	Prostate	None
5925	30409511	2018	IFGAIWKGISSLL	Pantinin-2	13	Linear	L	None	Free	Free	Antimicrobial	Synthetic	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 12.5 ± 1.0 µM	24-h	Breast	None
5924	30409511	2018	GILGKLWEGFKSIV	Pantinin-1	14	Linear	L	None	Free	Free	Antimicrobial	Synthetic	DU-145	Prostate Cancer	MTS assay	IC₅₀ = 47.5 ± 2.0 µM	24-h	Prostate	None
5922	30318506	2018	GSETWKTIITKN	IL13Rα2 D1 peptide	12	Linear	L	None	Free	Free	Anticancer	Synthetic	U-118	Brain Cancer	MTT assay	inhibited IL13-stimulated cell adhesion	48-h	Brain	None
5923	30409511	2018	GILGKLWEGFKSIV	Pantinin-1	14	Linear	L	None	Free	Free	Antimicrobial	Synthetic	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 28.5 ± 1.0 µM	24-h	Breast	None
5921	30318506	2018	GSETWKTIITKN	IL13Rα2 D1 peptide	12	Linear	L	None	Free	Free	Anticancer	Synthetic	U-87	Brain Cancer	MTT assay	inhibited IL13-stimulated cell adhesion	48-h	Brain	None
5920	30318506	2018	GSETWKTIITKN	IL13Rα2 D1 peptide	12	Linear	L	None	Free	Free	Anticancer	Synthetic	SW-620	Colorectal Cancer	MTT assay	inhibited IL13-stimulated cell adhesion	48-h	Colon	None
5919	30318506	2018	GSETWKTIITKN	IL13Rα2 D1 peptide	12	Linear	L	None	Free	Free	Anticancer	Synthetic	KM12SM	Colorectal Cancer	MTT assay	inhibited IL13-stimulated cell adhesion	48-h	Colon	None
5918	30279210	2018	GIMDTVKNAAKNLAGQLLDKLK	R2PLx-22	22	Linear	L	None	Free	Free	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 109.30 µM	24-h	Breast	None
5917	30279210	2018	GIMDTVKNAAKNLAGQLLDKLK	R2PLx-22	22	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	U-251-MG	Brain Tumor	MTT assay	IC₅₀ = 104.10 µM	24-h	Brain	None
5916	30279210	2018	GIMDTVKNAAKNLAGQLLDKLK	R2PLx-22	22	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 283.90 µM	24-h	Prostate	None
5914	30279210	2018	GIMDTVKNAAKNLAGQLLDKLK	R2PLx-22	22	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	H-157	Lung Cancer	MTT assay	IC₅₀ = 843.40 µM	24-h	Lung	None
5915	30279210	2018	GIMDTVKNAAKNLAGQLLDKLK	R2PLx-22	22	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 872.70 µM	24-h	Skin	None
5913	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCKITAC	Ranatuerin-2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Rana palustris	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 20.19 µM	24-h	Breast	None
5912	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCKITAC	Ranatuerin-2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Rana palustris	U-251-MG	Brain Tumor	MTT assay	IC₅₀ = 16.14 µM	24-h	Brain	None
5911	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCKITAC	Ranatuerin-2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Rana palustris	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 5.79 µM	24-h	Prostate	None
5910	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCKITAC	Ranatuerin-2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Rana palustris	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 15.44 µM	24-h	Skin	None
5909	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCKITAC	Ranatuerin-2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Rana palustris	H-157	Lung Cancer	MTT assay	IC₅₀ = 5.90 µM	24-h	Lung	None
5908	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCSITAC	S-24-R2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 316.90 µM	24-h	Breast	None
5907	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCSITAC	S-24-R2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	U-251-MG	Brain Tumor	MTT assay	IC₅₀ = 278.30 µM	24-h	Brain	None
5906	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCSITAC	S-24-R2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 179.00 µM	24-h	Skin	None
5905	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCSITAC	S-24-R2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	H-157	Lung Cancer	MTT assay	IC₅₀ = 58.18 µM	24-h	Lung	None
5903	30026168	2018	FLSGIVaMLaKLF	[G7,10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ >100 µM	24-h	Lung	None
5904	30279210	2018	GIMDTVKNAAKNLAGQLLDKLKCSITAC	S-24-R2PLx	28	Linear	L	None	Free	Free	Antimicrobial	Synthetic Analogue of Ranatuerin-2PLx	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 792.60 µM	24-h	Prostate	None
5901	30026168	2018	FLSGIVaMLaKLF	[G7,10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 21.3 ± 1.13 µM	24-h	Breast	None
5902	30026168	2018	FLSGIVaMLaKLF	[G7,10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ >100 µM	24-h	Cervix	None
5899	30026168	2018	FLSaIVaMLaKLF	[G4,7,10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ >100 µM	24-h	Cervix	None
5900	30026168	2018	FLSaIVaMLaKLF	[G4,7,10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ >100 µM	24-h	Lung	None
5898	30026168	2018	FLSaIVaMLaKLF	[G4,7,10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 26.33 ± 5.8 µM	24-h	Breast	None
5896	30026168	2018	FLSaIVaMLGKLF	[G4,7a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ >100 µM	24-h	Cervix	None
5897	30026168	2018	FLSaIVaMLGKLF	[G4,7a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ = 37.3 ± 3.5 µM	24-h	Lung	None
5894	30026168	2018	FLSGIVGMLaKLF	[G10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ =24.3 ± 0.8 µM	24-h	Lung	None
5895	30026168	2018	FLSaIVaMLGKLF	[G4,7a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 29.5 ± 6.03 µM	24-h	Breast	None
5892	30026168	2018	FLSGIVGMLaKLF	[G10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 16.2 ± 2.2 µM	24-h	Breast	None
5893	30026168	2018	FLSGIVGMLaKLF	[G10a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 22.7 ± 0.86 µM	24-h	Cervix	None
5891	30026168	2018	FLSGIVaMLGKLF	[G7a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ >100 µM	24-h	Lung	None
5890	30026168	2018	FLSGIVaMLGKLF	[G7a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ >100 µM	24-h	Cervix	None
5889	30026168	2018	FLSGIVaMLGKLF	[G7a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ =22.4 ± 2.2 µM	24-h	Breast	None
5888	30026168	2018	FLSaIVGMLGKLF	[G4a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ >100 µM	24-h	Lung	None
5887	30026168	2018	FLSaIVGMLGKLF	[G4a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ >100 µM	24-h	Cervix	None
5886	30026168	2018	FLSaIVGMLGKLF	[G4a]SHa	13	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 17.9 ± 1.1 µM	24-h	Breast	None
5885	30026168	2018	FLSGIVGMLaKLFLFKQYAELW	[G10a]SHa-BCTP	22	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	NCI-H-460	Lung Cancer	MTT assay	IC₅₀ >100 µM	24-h	Lung	None
5884	30026168	2018	FLSGIVGMLaKLFLFKQYAELW	[G10a]SHa-BCTP	22	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	HeLa	Cervical Cancer	MTT assay	IC₅₀ >100 µM	24-h	Cervix	None
5883	30026168	2018	FLSGIVGMLaKLFLFKQYAELW	[G10a]SHa-BCTP	22	Linear	Mix	None	Amidation	Free	Antimicrobial	Synthetic analogue of Temporin-1SHa	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 26.85 ± 1.85 µM	24-h	Breast	None
5882	29842923	2018	IPPFIKKVLTTVF	Temporin-CPa	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	4T1	Breast Cancer	MTS assay	LC₅₀ = 80 μM	Not Available	Breast	None
5881	29842923	2018	FLPLLASLFSRLF	Temporin-1Oc	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	HeLa	Cervical Cancer	MTS assay	LC₅₀ = 50 μM	Not Available	Cervix	None
5878	29842923	2018	SILPTIVSFLSKVF	Temporin-1Ga	14	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	4T1	Breast Cancer	MTS assay	LC₅₀ = 20 μM	Not Available	Breast	None
5879	29842923	2018	FLPFLKSILGKIL	Temporin-1OLa	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	HeLa	Cervical Cancer	MTS assay	LC₅₀ = 25 μM	Not Available	Cervix	None
5880	29842923	2018	FLPLLASLFSRLF	Temporin-1Oc	13	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	4T1	Breast Cancer	MTS assay	LC₅₀ = 65 μM	Not Available	Breast	None
5876	29904274	2018	RKKRRQRRRLNLKALLAVAKKIL	tMP-C	23	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	U-251-MG	Brain tumor	MTT assay	IC₅₀ = 3.36 μM	24-h	Brain	None
5877	29904274	2018	RKKRRQRRRLNLKALLAVAKKIL	tMP-C	23	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 3.70 μM	24-h	Breast	None
5874	29904274	2018	RKKRRQRRRLNLKALLAVAKKIL	tMP-C	23	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 3.86 μM	24-h	Skin	None
5875	29904274	2018	RKKRRQRRRLNLKALLAVAKKIL	tMP-C	23	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 3.86 μM	24-h	Prostate	None
5872	29904274	2018	CLNLKALLAVAKKILC	cMP-C	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 13.66 μM	24-h	Breast	None
5873	29904274	2018	RKKRRQRRRLNLKALLAVAKKIL	tMP-C	23	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	H-157	Lung Cancer	MTT assay	IC₅₀ = 2.79 μM	24-h	Lung	None
5869	29904274	2018	CLNLKALLAVAKKILC	cMP-C	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 13.87 μM	24-h	Skin	None
5870	29904274	2018	CLNLKALLAVAKKILC	cMP-C	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 13.87 μM	24-h	Prostate	None
5871	29904274	2018	CLNLKALLAVAKKILC	cMP-C	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	U-251-MG	Brain tumor	MTT assay	IC₅₀ = 8.56 μM	24-h	Brain	None
5866	29904274	2018	LNLKALLAVAKKIL	Mastoparan-C	14	Linear	L	None	Amidation	Free	Antimicrobial	Vespa crabro	U-251-MG	Brain tumor	MTT assay	IC₅₀ = 36.65 μM	24-h	Brain	None
5867	29904274	2018	LNLKALLAVAKKIL	Mastoparan-C	14	Linear	L	None	Amidation	Free	Antimicrobial	Vespa crabro	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 25.27 μM	24-h	Breast	None
5868	29904274	2018	CLNLKALLAVAKKILC	cMP-C	16	Linear	L	None	Amidation	Free	Antimicrobial	Synthetic	H-157	Lung Cancer	MTT assay	IC₅₀ = 7.02 μM	24-h	Lung	None
5863	29904274	2018	LNLKALLAVAKKIL	Mastoparan-C	14	Linear	L	None	Amidation	Free	Antimicrobial	Vespa crabro	H-157	Lung Cancer	MTT assay	IC₅₀ = 13.57 μM	24-h	Lung	None
5864	29904274	2018	LNLKALLAVAKKIL	Mastoparan-C	14	Linear	L	None	Amidation	Free	Antimicrobial	Vespa crabro	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 27.70 μM	24-h	Skin	None
5865	29904274	2018	LNLKALLAVAKKIL	Mastoparan-C	14	Linear	L	None	Amidation	Free	Antimicrobial	Vespa crabro	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 6.29 μM	24-h	Prostate	None
5861	30087268	2018	ALWKDILKNLLKAALNEINQIVQ	L10, 11-DPS3	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of Dermaseptin-PS3	H-157	Lung Cancer	MTT assay	IC₅₀ = 0.12 μM	Not Available	Lung	None
5862	30087268	2018	ALWKDILKNLLKAALNEINQIVQ	L10, 11-DPS3	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of Dermaseptin-PS3	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 1.85 μM	Not Available	Prostate	None
5859	30087268	2018	ALWKKILKNAGKAALNKINQIVQ	K5, 17-DPS3	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of Dermaseptin-PS3	H-157	Lung Cancer	MTT assay	IC₅₀ = 18.20 μM	Not Available	Lung	None
5860	30087268	2018	ALWKKILKNAGKAALNKINQIVQ	K5, 17-DPS3	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of Dermaseptin-PS3	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 18.20 μM	Not Available	Prostate	None
5857	30087268	2018	ALWKDILKNAGKAALNEINQIVQ	Dermaseptin-PS3	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Phyllomedusa sauvagii	H-157	Lung Cancer	MTT assay	IC₅₀ = 15.67 μM	Not Available	Lung	None
5858	30087268	2018	ALWKDILKNAGKAALNEINQIVQ	Dermaseptin-PS3	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Phyllomedusa sauvagii	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 18.20 μM	Not Available	Prostate	None
5855	30258724	2018	GRKKRRQRRRGALWKSLLKNVGKA	DP-2	24	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	H-157	Lung Cancer	MTT assay	IC₅₀ = 3.21 μM	24-h	Lung	None
5856	30258724	2018	GRKKRRQRRRGALWKSLLKNVGKA	DP-2	24	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 6.75 μM	24-h	Prostate	None
5854	30258724	2018	ALWKSLLKNVGKAAGKAALNAVTDMVNQ	DRS-DU-1	28	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Callimedusa (Phyllomedusa) duellmani	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 21.6 μM	24-h	Prostate	None
5852	29191658	2018	FLPIVAKLLSGLLGRKKRRQRRR	temporin-PEb	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 3.483 μM	Not Available	Skin	None
5853	30258724	2018	ALWKSLLKNVGKAAGKAALNAVTDMVNQ	DRS-DU-1	28	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Callimedusa (Phyllomedusa) duellmani	H-157	Lung Cancer	MTT assay	IC₅₀ = 8.43 μM	24-h	Lung	None
5850	29191658	2018	FLPIVAKLLSGLLGRKKRRQRRR	temporin-PEb	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 3.087 μM	Not Available	Brain	None
5851	29191658	2018	FLPIVAKLLSGLLGRKKRRQRRR	temporin-PEb	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 3.051 μM	Not Available	Prostate	None
5847	29191658	2018	FLYIVAKLLSGLL	temporin-PEa	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 27.62 μM	Not Available	Prostate	None
5848	29191658	2018	FLYIVAKLLSGLL	temporin-PEa	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 9.864 μM	Not Available	Skin	None
5849	29191658	2018	FLPIVAKLLSGLLGRKKRRQRRR	temporin-PEb	23	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	NCI-H-157	Lung Cancer	MTT assay	IC₅₀ = 3.464 μM	Not Available	Lung	None
5846	29191658	2018	FLYIVAKLLSGLL	temporin-PEa	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 3.520 μM	Not Available	Brain	None
5845	29191658	2018	FLYIVAKLLSGLL	temporin-PEa	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic analog of Temporin-PE	NCI-H-157	Lung Cancer	MTT assay	IC₅₀ = 3.398 μM	Not Available	Lung	None
5844	29191658	2018	FLPIVAKLLSGLL	Temporin-PE	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pelophylax kl. esculentus	MDA-MB-435S	Skin Cancer	MTT assay	IC₅₀ = 33.23 μM	Not Available	Skin	None
5843	29191658	2018	FLPIVAKLLSGLL	Temporin-PE	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pelophylax kl. esculentus	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 38.56 μM	Not Available	Prostate	None
5842	29191658	2018	FLPIVAKLLSGLL	Temporin-PE	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pelophylax kl. esculentus	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 25.13 μM	Not Available	Brain	None
5841	29191658	2018	FLPIVAKLLSGLL	Temporin-PE	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pelophylax kl. esculentus	NCI-H-157	Lung Cancer	MTT assay	IC₅₀ = 34.56 μM	Not Available	Lung	None
5840	28636781	2018	GIGGALLSAGKSALKGLAKGLAEHFAN	BLP-7	27	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientali	A-375	Skin Cancer	MTT assay	Cell Viability < 20% at 10 μM	48-h	Skin	None
5839	28636781	2018	GIGGALLSAGKSALKGLAKGLAEHFAN	BLP-7	27	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientali	A-549	Lung Cancer	MTT assay	Cell Viability ~ 20% at 2.5 μM	48-h	Lung	None
5838	28636781	2018	GIGGALLSAGKSALKGLAKGLAEHFAN	BLP-7	27	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientali	PC-3	Prostate Cancer	MTT assay	Cell Viability ~ 20% at 2.5 μM	48-h	Prostate	None
5837	28636781	2018	GIGGALLSAGKSALKGLAKGLAEHFAN	BLP-7	27	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientali	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 1.81 μM	48-h	Liver	None
5836	28636781	2018	GIGGALLSAGKSALKGLAKGLAEHFAN	BLP-7	27	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientali	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.83 μM	48-h	Liver	None
5835	28636781	2018	GIGGALLSAGKSALKGLAKGLAEHFAN	BLP-7	27	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientali	SK-HEP-1	Liver Cancer	MTT assay	IC₅₀ = 0.61 μM	48-h	Liver	None
5833	28636781	2018	IIGPVLGLIGKALGGLL	Bombinin H-BO	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	A-549	Lung Cancer	MTT assay	Cell Viability ~ 20% at 5 μM	48-h	Lung	None
5834	28636781	2018	IIGPVLGLIGKALGGLL	Bombinin H-BO	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	A-375	Skin Cancer	MTT assay	Cell Viability < 20% at 5 μM	48-h	Skin	None
5831	28636781	2018	IIGPVLGLIGKALGGLL	Bombinin H-BO	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 3.87 μM	48-h	Liver	None
5832	28636781	2018	IIGPVLGLIGKALGGLL	Bombinin H-BO	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	PC-3	Prostate Cancer	MTT assay	Cell Viability ~ 40% at 2.5 μM	48-h	Prostate	None
5829	28636781	2018	IIGPVLGLIGKALGGLL	Bombinin H-BO	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	SK-HEP-1	Liver Cancer	MTT assay	IC₅₀ = 0.99 μM	48-h	Liver	None
5830	28636781	2018	IIGPVLGLIGKALGGLL	Bombinin H-BO	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.88 μM	48-h	Liver	None
5828	30622471	2018	GRFKRFRKKLKRLWHKVGPFVGPILHY	ChMAP-28	27	Linear	L	None	Free	Free	Antimicrobial	leucocytes of the goat Capra hircus	B16-F10	Skin Cancer	MTT assay	IC₅₀ = 4.82 ± 1.01 μM	48-h	Skin	None
5827	30622471	2018	GRFKRFRKKLKRLWHKVGPFVGPILHY	ChMAP-28	27	Linear	L	None	Free	Free	Antimicrobial	leucocytes of the goat Capra hircus	SK-BR-3	Breast Cancer	MTT assay	IC₅₀ = 5.63 ± 1.05 μM	48-h	Breast	None
5826	30622471	2018	GRFKRFRKKLKRLWHKVGPFVGPILHY	ChMAP-28	27	Linear	L	None	Free	Free	Antimicrobial	leucocytes of the goat Capra hircus	HEK-293T	Renal Cancer	MTT assay	IC₅₀ = 5.09 ± 0.40 μM	48-h	Renal	None
5825	30622471	2018	GRFKRFRKKLKRLWHKVGPFVGPILHY	ChMAP-28	27	Linear	L	None	Free	Free	Antimicrobial	leucocytes of the goat Capra hircus	A-431	Skin Cancer	MTT assay	IC₅₀ = 6.49 ± 0.09 μM	48-h	Skin	None
5824	30622471	2018	GRFKRFRKKLKRLWHKVGPFVGPILHY	ChMAP-29	27	Linear	L	None	Free	Free	Antimicrobial	leucocytes of the goat Capra hircus	HL-60	Leukemia Cancer	LDH leakage assay	~60% LDH Release at 2.5 μM	1-h	Blood	None
5822	29515106	2018	RKKRRQRRREFLDCFQKF	TAT-327	18	Linear	L	None	Free	Free	Anticancer	Peptide-327	SW-620	Colorectal Cancer	CCK-8 assay	EC₅₀ = 64.61 ± 1.63 μM	12-h	Colon	None
5823	30622471	2018	GRFKRFRKKLKRLWHKVGPFVGPILHY	ChMAP-28	27	Linear	L	None	Free	Free	Antimicrobial	leucocytes of the goat Capra hircus	HL-60	Leukemia Cancer	MTT assay	IC₅₀ = 3.39 ± 0.15 μM	48-h	Blood	None
5821	29515106	2018	RKKRRQRRREFLDCFQKF	TAT-327	18	Linear	L	None	Free	Free	Anticancer	Peptide-327	HT-29	Colon Cancer	CCK-8 assay	EC₅₀ = 74.08 ± 0.63 μM	12-h	Colon	None
5819	29515106	2018	RKKRRQRRREFLDCFQKF	TAT-327	18	Linear	L	None	Free	Free	Anticancer	Peptide-327	HepG-2	Liver Cancer	CCK-8 assay	EC₅₀ = 68.52 ± 2.96 μM	12-h	Liver	None
5820	29515106	2018	RKKRRQRRREFLDCFQKF	TAT-327	18	Linear	L	None	Free	Free	Anticancer	Peptide-327	Colo-320	Colon Cancer	CCK-8 assay	EC₅₀ = 68.40 ± 0.42 μM	12-h	Colon	None
5818	29515106	2018	RKKRRQRRREFLDCFQKF	TAT-327	18	Linear	L	None	Free	Free	Anticancer	Peptide-327	A-549	Lung Cancer	CCK-8 assay	EC₅₀ = 55.42 ± 0.84 μM	12-h	Lung	None
5817	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	PC-3/A24	Prostate Cancer	CCK-8 assay	EC₅₀ = 50.69 ± 1.58 μM	12-h	Prostate	None
5815	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	HT-29	Colon Cancer	CCK-8 assay	EC₅₀ = 96.00 ± 9.06 μM	12-h	Colon	None
5816	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	SW-620	Colorectal Cancer	CCK-8 assay	EC₅₀ = 102.35 ± 4.66 μM	12-h	Colon	None
5814	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	Colo-320	Colon Cancer	CCK-8 assay	EC₅₀ = 83.10 ± 1.41 μM	12-h	Colon	None
5812	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	A-549	Lung Cancer	CCK-8 assay	EC₅₀ = 119.84 ± 16.01 μM	12-h	Lung	None
5813	29515106	2018	EFLDCFQKF	Peptide-327	9	Linear	L	None	Free	Free	Anticancer	EGFR binding region for Eps8 (aa 289–362)	HepG-2	Liver Cancer	CCK-8 assay	EC₅₀ = 107.34 ± 11.87 μM	12-h	Liver	None
5811	29098406	2018	IIGPVLGLVGKALGGLL	Bombinin-H-BO1	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 8.42 μM	48-h	Liver	None
5810	29098406	2018	IIGPVLGLVGKALGGLL	Bombinin-H-BO1	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 8.08 μM	48-h	Liver	None
5809	29098406	2018	IIGPVLGLVGKALGGLL	Bombinin-H-BO1	17	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	SK-HEP-1	Liver Cancer	MTT assay	IC₅₀ = 3.61 μM	48-h	Liver	None
5808	29098406	2018	GIGSAILSAGKSIIKGLAKGLAEHF	Bombinin-BO1	25	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 3.91 μM	48-h	Liver	None
5807	29098406	2018	GIGSAILSAGKSIIKGLAKGLAEHF	Bombinin-BO1	25	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 3.75 μM	48-h	Liver	None
5806	29098406	2018	GIGSAILSAGKSIIKGLAKGLAEHF	Bombinin-BO1	25	Linear	L	None	Amidation	Free	Antimicrobial	Bombina orientalis	SK-HEP-1	Liver Cancer	MTT assay	IC₅₀ = 0.76 μM	48-h	Liver	None
5798	28872704	2017	PD	Peptide 7b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 19.1 ± 0.04 µM	48-h	Breast	None
5800	28872704	2017	PD	Peptide 7b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 21.8 ± 0.03 µM	48-h	Lung	None
5801	28872704	2017	PD	Peptide 7b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 17.9 ± 0.02 µM	48-h	Cervix	None
5794	28872704	2017	FD	Peptide 6b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 18.4 ± 0.12 µM	48-h	Breast	None
5795	28872704	2017	FD	Peptide 6b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 61.5 ± 023µM	48-h	Liver	None
5796	28872704	2017	FD	Peptide 6b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 18.6 ± 0.04 µM	48-h	Lung	None
5791	28872704	2017	FE	Peptide 5b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 18.7 ± 0.04 µM	48-h	Liver	None
5793	28872704	2017	FE	Peptide 5b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 20.6 ± 0.04 µM	48-h	Cervix	None
5788	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 28.4 ± 0.02 µM	48-h	Lung	None
5789	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 19.9 ± 0.02 µM	48-h	Cervix	None
5790	28872704	2017	FE	Peptide 5b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 19.7 ± 0.06 µM	48-h	Breast	None
5784	28872704	2017	YD	Peptide 3b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.8 ± 0.02 µM	48-h	Lung	None
5786	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 62.2 ± 0.02 µM	48-h	Breast	None
5787	28872704	2017	HD	Peptide 4b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 63.2 ± 0.03 µM	48-h	Liver	None
5781	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 17.7 ± 0.04 µM	48-h	Cervix	None
5783	28872704	2017	YD	Peptide 3b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 62.3 ± 0.02 µM	48-h	Liver	None
5778	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 12.1 ± 0.23 µM	48-h	Breast	None
5779	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 19.3 ± 0.02 µM	48-h	Liver	None
5780	28872704	2017	PE	Peptide 2b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 19.9 ± 0.03 µM	48-h	Lung	None
5773	28872704	2017	PD	Peptide 7a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 24.4 ± 0.03 µM	48-h	Cervix	None
5774	28872704	2017	WD	Peptide 1b	2	Linear	L	None	Free	4-azidobenzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 5.7 ± 0.03 µM	48-h	Breast	None
5768	28872704	2017	WD	Peptide 6a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 61.6 ± 0.18 µM	48-h	Lung	None
5771	28872704	2017	PD	Peptide 7a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 23.0 ± 0.05 µM	48-h	Liver	None
5772	28872704	2017	PD	Peptide 7a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 23.8 ± 0.03 µM	48-h	Lung	None
5764	28872704	2017	HD	Peptide 5a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 12.9 ± 0.23 µM	48-h	Lung	None
5766	28872704	2017	WD	Peptide 6a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 18.1 ± 0.01 µM	48-h	Breast	None
5767	28872704	2017	WD	Peptide 6a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 64.3 ± 0.01 µM	48-h	Liver	None
5756	28872704	2017	YD	Peptide 3a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 5.7 ± 0.04 µM	48-h	Lung	None
5758	28872704	2017	HE	Peptide 4a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 44.1 ± 0.02 µM	48-h	Breast	None
5752	28872704	2017	YE	Peptide 2a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 20.6 ± 0.03 µM	48-h	Lung	None
5754	28872704	2017	YD	Peptide 3a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 17.5 ± 0.04 µM	48-h	Breast	None
5755	28872704	2017	YD	Peptide 3a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.8 ± 0.12 µM	48-h	Liver	None
5750	28872704	2017	YE	Peptide 2a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 16.0 ± 0.13 µM	48-h	Breast	None
5751	28872704	2017	YE	Peptide 2a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 31.1 ± 0.03 µM	48-h	Liver	None
5747	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 5.7 ± 0.04 µM	48-h	Liver	None
5748	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 13.9 ± 0.03 µM	48-h	Lung	None
5749	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 21.4 ± 0.02 µM	48-h	Cervix	None
5743	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	A-549	Lung Cancer	MTT assay	15% inhibition at 500 μg/mL	48-h	Lung	None
5746	28872704	2017	FE	Peptide 1a	2	Linear	L	None	Free	4-(methylsulfonyl)benzoic acid	Antiproliferative, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 64.4 ± 0.03 µM	48-h	Breast	None
5742	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	SGC-7901	Gastric Cancer	MTT assay	20% inhibition at 500 μg/mL	48-h	Stomach	None
5740	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	HT-29	Colon Cancer	MTT assay	IC₅₀ = 99.88 μg/mL	48-h	Colon	None
5741	27218227	2017	HVLSRAPR	HR	8	Linear	L	None	Free	Free	Anticancer	Fraction identified from Tr1	HepG-2	Liver Cancer	MTT assay	22% inhibition at 500 μg/mL	48-h	Liver	None
5737	27218227	2017	Not Available	Tr3	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	HT-29	Colon Cancer	MTT assay	IC₅₀ = 112.89 μg/mL	48-h	Colon	None
5738	27218227	2017	Not Available	Tr4	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 238.86 μg/mL	48-h	Breast	None
5739	27218227	2017	Not Available	Tr4	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 176.37 μg/mL	48-h	Liver	None
5735	27218227	2017	Not Available	Tr2	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 36.42 μg/mL	48-h	Liver	None
5736	27218227	2017	Not Available	Tr2	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	SGC-7901	Gastric Cancer	MTT assay	IC₅₀ = 48.25 μg/mL	48-h	Stomach	None
5733	27218227	2017	Not Available	Tr1	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 147.03 μg/mL	48-h	Liver	None
5734	27218227	2017	Not Available	Tr2	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	MCF-7	Breast Cancer	MTT assay	IC₅₀ < 31.25 μg/mL	48-h	Breast	None
5732	27218227	2017	Not Available	Tr1	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Anticancer	Protein extraction from Spirulina platensis	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 60.12 μg/mL	48-h	Breast	None
5730	28811617	2017	IKKILSKIKKLLK	L-K6	13	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Temporin 1CEb analogue	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 31 μM	24-h	Breast	None
5731	28867631	2017	ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK	Nisin Z	34	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Lactococcus lactis	SW-480	Colon Cancer	MTT assay	79.22% cytotoxicity at 1000 μg/mL	24-h	Colon	None
5725	28093334	2017	Not Available	Bothropoidin	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Antitumor and Antiangiogenic	Bothrops pauloensis snake venom	MDA-MB-231	Breast Cancer	Cell migration assay	Inhibited cell migration by 45% at 10 μg/mL	24 h	Breast	None
5726	28249727	2017	ILGPVLGLVSDTLDDVLGIL	Maximin H5	20	Linear	L	None	Amidation	Free	Host defense peptide	Bombina maxima	T98G	Human glioblastoma	MTS assay	IC₅₀ = 125 µM	72-h	Brain	None
5723	28093334	2017	Not Available	Bothropoidin	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Antitumor and Antiangiogenic	Bothrops pauloensis snake venom	MDA-MB-231	Breast Cancer	MTT assay	30% cytotoxicity at 100 μg/mL	24 h	Breast	None
5724	28093334	2017	Not Available	Bothropoidin	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Antitumor and Antiangiogenic	Bothrops pauloensis snake venom	MDA-MB-231	Breast Cancer	Apoptosis assay	Early apoptosis at 10 μg/mL and Late apoptosis at 40 μg/mL	24 h	Breast	None
5720	29263923	2017	GGRSFFLLRRIQGCRFRNTVDD	E5	22	Linear	L	None	Free	Free	Anticancer	Synthetic	4T1	Breast Cancer	CCK-8 assay	49% cell viability at 100 μM	24-h	Breast	None
5719	28347740	2017	RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK	ABP-dHC-Cecropin A-K(24)	37	Linear	L	None	Free	Free	Host Defence Peptide	Synthetic	THP-1	Leukemia Cancer	MTT assay	IC₅₀ = 196.1 μM	24-h	Blood	None
5718	28347740	2017	RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK	ABP-dHC-Cecropin A-K(24)	37	Linear	L	None	Free	Free	Host Defence Peptide	Synthetic	U-937	Leukemia Cancer	MTT assay	IC₅₀ = 223.9 μM	24-h	Blood	None
5717	28347740	2017	RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK	ABP-dHC-Cecropin A-K(24)	37	Linear	L	None	Free	Free	Host Defence Peptide	Synthetic	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 184.9 μM	24-h	Blood	None
5716	28347740	2017	RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK	ABP-dHC-Cecropin A	37	Linear	L	None	Free	Free	Host Defence Peptide	Synthetic	THP-1	Leukemia Cancer	MTT assay	IC₅₀ = 228.5 μM	24-h	Blood	None
5715	28347740	2017	RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK	ABP-dHC-Cecropin A	37	Linear	L	None	Free	Free	Host Defence Peptide	Synthetic	U-937	Leukemia Cancer	MTT assay	IC₅₀ = 303.2 μM	24-h	Blood	None
5714	28347740	2017	RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK	ABP-dHC-Cecropin A	37	Linear	L	None	Free	Free	Host Defence Peptide	Synthetic	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 349.5 μM	24-h	Blood	None
5713	None	2017	VLLVTLTRLHQRGVIYEKWRHFSGRKYR	VLL-28	28	Linear	L	None	Free	Acetylation	Antibacterial and Anticancer	Sulfolobus islandicus	HEK-293T	Renal Cancer	MTT assay	IC₅₀ = 10 μM	72-h	Renal	None
5712	29076508	2017	KTCENLADTYKGPCFTTGSCDDHCKNKEHLRSGRCRDDFRCWCTKNC	PvD1	47	Linear	L	None	Free	Free	Antimicrobial	Phaseolus vulgaris	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 0.82 ± 0.14 µM	24-h	Breast	None
5711	29076508	2017	KTCENLADTYKGPCFTTGSCDDHCKNKEHLRSGRCRDDFRCWCTKNC	PvD1	47	Linear	L	None	Free	Free	Antimicrobial	Phaseolus vulgaris	HBMEC	Brain Cancer	MTT assay	Not Available	24-h	Brain	None
5710	28157321	2017	GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL	MccJ25-18-4	31	Linear	Mix	x = Norleucine	Free	Free	Antimicrobial	Synthetic	MDA-MB-435-MDR	Breast Cancer	MTT assay	IC₅₀ = 25.0 ± 0.5 μM	48-h	Breast	None
5709	28157321	2017	GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL	MccJ25-18-4	31	Linear	Mix	x = Norleucine	Free	Free	Antimicrobial	Synthetic	MDA-MB-435	Breast Cancer	MTT assay	IC₅₀ = 20.0 ± 0.5 μM	48-h	Breast	None
5708	28157321	2017	GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL	MccJ25-18-4	31	Linear	Mix	x = Norleucine	Free	Free	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 14.2 ± 1.5 μM	48-h	Breast	None
5707	28719744	2017	EENFLGALFKALSKLL	PTP-7S	16	Linear	L	None	Free	Free	Anticancer	PTP-7	A-549	Lung Cancer	MTT assay	65% cell viability at 10 µΜ	6-h	Lung	None
5706	28719744	2017	EENFLGALFKALSKLL	PTP-7S	16	Linear	L	None	Free	Free	Anticancer	PTP-7	HeLa	Cervical Cancer	MTT assay	55 - 60% cell viability at 75 µM	24-h	Cervix	None
5705	29280948	2017	KWKSFLKTfKSaKKTvLHTALKAISS	F9D/A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 125.0 ± 1.8 μM	24-h	Pancreas	None
5704	29280948	2017	KWKSFLKTfKSaKKTvLHTALKAISS	F9D/A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 95.6 ± 1.8 μM	24-h	Pancreas	None
5703	29280948	2017	KWKSFLKTfKSaKKTvLHTALKAISS	F9D/A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 57.9 ± 2.8 μM	24-h	Pancreas	None
5702	29280948	2017	KWKSFLKTfKSaKKTvLHTALKAISS	F9D/A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 125.0 ± 3.4 μM	24-h	Cervix	None
5701	29280948	2017	KWKSFLKTFKSaKKTvLHTALKAISS	A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 125.0 ± 5.9 μM	24-h	Pancreas	None
5700	29280948	2017	KWKSFLKTFKSaKKTvLHTALKAISS	A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 41.4 ± 1.4 μM	24-h	Pancreas	None
5699	29280948	2017	KWKSFLKTFKSaKKTvLHTALKAISS	A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 46.2 ± 3.0 μM	24-h	Pancreas	None
5698	29280948	2017	KWKSFLKTFKSaKKTvLHTALKAISS	A12D/V16D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 60.1 ± 1.2 μM	24-h	Cervix	None
5697	29280948	2017	KWKSFLKTfKSaKKTVLHTALKAISS	F9D/A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 125.0 ± 3.7 μM	24-h	Pancreas	None
5696	29280948	2017	KWKSFLKTfKSaKKTVLHTALKAISS	F9D/A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 42.4 ± 3.0 μM	24-h	Pancreas	None
5695	29280948	2017	KWKSFLKTfKSaKKTVLHTALKAISS	F9D/A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 38.8 ± 2.9 μM	24-h	Pancreas	None
5694	29280948	2017	KWKSFLKTfKSaKKTVLHTALKAISS	F9D/A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 59.8 ± 0.5 μM	24-h	Cervix	None
5693	29280948	2017	KWKSFLKTFKSaKKTVLHTALKAISS	A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 45.1 ± 1.0 μM	24-h	Pancreas	None
5692	29280948	2017	KWKSFLKTFKSaKKTVLHTALKAISS	A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 15.5 ± 1.7 μM	24-h	Pancreas	None
5691	29280948	2017	KWKSFLKTFKSaKKTVLHTALKAISS	A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 29.9 ± 4.8 μM	24-h	Pancreas	None
5690	29280948	2017	KWKSFLKTFKSaKKTVLHTALKAISS	A12D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 28.8 ± 0.8 μM	24-h	Cervix	None
5689	29280948	2017	KWKSFLKTFKsAKktVLHTALKAISS	S11D/K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 45.5 ± 5.6 μM	24-h	Pancreas	None
5688	29280948	2017	KWKSFLKTFKsAKktVLHTALKAISS	S11D/K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 54.2 ± 1.2 μM	24-h	Pancreas	None
5687	29280948	2017	KWKSFLKTFKsAKktVLHTALKAISS	S11D/K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 56.8 ± 3.3 μM	24-h	Pancreas	None
5686	29280948	2017	KWKSFLKTFKsAKktVLHTALKAISS	S11D/K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 41.1 ± 0.5 μM	24-h	Cervix	None
5685	29280948	2017	KWKSFLKTFKSAKktVLHTALKAISS	K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 24.1 ± 5.5 μM	24-h	Pancreas	None
5684	29280948	2017	KWKSFLKTFKSAKktVLHTALKAISS	K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 22.5 ± 0.5 μM	24-h	Pancreas	None
5683	29280948	2017	KWKSFLKTFKSAKktVLHTALKAISS	K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 47.1 ± 5.3 μM	24-h	Pancreas	None
5682	29280948	2017	KWKSFLKTFKSAKktVLHTALKAISS	K14D/T15D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 31.6 ± 2.1 μM	24-h	Cervix	None
5681	29280948	2017	KWKSFLKTFKsAKkTVLHTALKAISS	S11D/K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 22.4 ± 2.3 μM	24-h	Pancreas	None
5680	29280948	2017	KWKSFLKTFKsAKkTVLHTALKAISS	S11D/K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 25.5 ± 0.5 μM	24-h	Pancreas	None
5679	29280948	2017	KWKSFLKTFKsAKkTVLHTALKAISS	S11D/K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 41.3 ± 2.6 μM	24-h	Pancreas	None
5678	29280948	2017	KWKSFLKTFKsAKkTVLHTALKAISS	S11D/K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 30.6 ± 0.5 μM	24-h	Cervix	None
5677	29280948	2017	KWKSFLKTFKSAKkTVLHTALKAISS	K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 20.0 ± 0.8 μM	24-h	Pancreas	None
5676	29280948	2017	KWKSFLKTFKSAKkTVLHTALKAISS	K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 7.2 ± 5.2 μM	24-h	Pancreas	None
5675	29280948	2017	KWKSFLKTFKSAKkTVLHTALKAISS	K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 17.9 ± 2.3 μM	24-h	Pancreas	None
5674	29280948	2017	KWKSFLKTFKSAKkTVLHTALKAISS	K14D	26	Linear	Mix	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic Analogue of V13K	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 15.6 ± 4.1 μM	24-h	Cervix	None
5673	29280948	2017	KWKSFLKTFKSAKKTVLHTALKAISS	V13K	26	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	BxPC-3	Pancreatic Cancer	MTT assay	IC₅₀ = 12.5 ± 1.2 μM	24-h	Pancreas	None
5672	29280948	2017	KWKSFLKTFKSAKKTVLHTALKAISS	V13K	26	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	HPAC	Pancreatic Cancer	MTT assay	IC₅₀ = 7.6 ± 4.0 μM	24-h	Pancreas	None
5671	29280948	2017	KWKSFLKTFKSAKKTVLHTALKAISS	V13K	26	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MIA PaCa-2	Pancreatic Cancer	MTT assay	IC₅₀ = 24.8 ± 0.6 μM	24-h	Pancreas	None
5670	29280948	2017	KWKSFLKTFKSAKKTVLHTALKAISS	V13K	26	Linear	L	None	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 16 ± 0.5 μM	24-h	Cervix	None
5669	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	52	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	H-1299	Lung Cancer	MTT assay	80% cytotoxicity 10 μM concentration	24-h	Lung	None
5668	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	53	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	HeLa	Cervical Cancer	LDH leakage assay	~80% LDH release at 15 μM	12-h	Cervix	None
5667	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	52	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	HeLa	Cervical Cancer	MTT assay	20% cytotoxicity 5 μM concentration	24-h	Cervix	None
5666	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	52	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	HT-1080	Fibrosarcoma	MTT assay	20% cytotoxicity 5 μM concentration	24-h	Fibrous connective tissue	None
5665	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	52	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	HEK-293T	Renal Cancer	MTT assay	20% cytotoxicity 5 μM concentration	24-h	Renal	None
5664	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	52	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	MCF-7	Breast Cancer	LDH leakage assay	>80% LDH release at 15 μM	24-h	Breast	None
5658	28850103	2017	FLSLIPAAISAVSALANHF	Phylloseptin-PHa	19	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pithecopus hypochondrialis	NCI-H-157	Lung Cancer	MTT assay	IC₅₀ = 14.10 μM	24-h	Lung	None
5663	28422156	2017	ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL	Laterosporulin10 (LS10)	52	Linear	L	None	Free	Free	Antimicrobial	Brevibacillus sp. strain SKDU10	MCF-7	Breast Cancer	MTT assay	40% cytotoxicity at 5 μM concentration	24-h	Breast	None
5656	28850103	2017	FLSLIPKIAGGIAALAKHL	Phylloseptin-PTa	19	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Phyllomedusa tarsius	NCI-H-157	Lung Cancer	MTT assay	IC₅₀ = 6.73 μM	24-h	Lung	None
5655	36982972	2017	GCRRLCYKQRCVTYCRGR	cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.1 μM	24-h	Blood	None
5654	36982972	2017	GCRRLCYKQRCVTYCRGR	cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 15.3 ± 1.4 μM	24-h	Breast	None
5652	36982972	2017	GCRRLCYKQRCVTYCRGR	cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.9 ± 0.1 μM	24-h	Skin	None
5653	36982972	2017	GCRRLCYKQRCVTYCRGR	cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ > 64 μM	24-h	Cervix	None
5651	36982972	2017	GCRRLCYKQRCVTYCRGR	cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 39.8 ± 1.0 μM	24-h	Stomach	None
5650	36982972	2017	GCRRLCWKQRCVTYCRGR	[Y7W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 3.9 ± 0.2 μM	24-h	Blood	None
5649	36982972	2017	GCRRLCWKQRCVTYCRGR	[Y7W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ > 64 μM	24-h	Cervix	None
5648	36982972	2017	GCRRLCWKQRCVTYCRGR	[Y7W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 5.1 ± 0.3 μM	24-h	Skin	None
5646	36982972	2017	GCRRLCYKQRCVTWCRGR	[Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 2.7 ± 0.1 μM	24-h	Blood	None
5647	36982972	2017	GCRRLCWKQRCVTYCRGR	[Y7W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 23.3 ± 0.4 μM	24-h	Stomach	None
5645	36982972	2017	GCRRLCYKQRCVTWCRGR	[Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 50.4 ± 2.4 μM	24-h	Cervix	None
5644	36982972	2017	GCRRLCYKQRCVTWCRGR	[Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 4.0 ± 0.1 μM	24-h	Skin	None
5643	36982972	2017	GCRRLCYKQRCVTWCRGR	[Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 30.3 ± 1.1 μM	24-h	Stomach	None
5642	36982972	2017	GCRRLCYRQRCVTYCRGR	[K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 3.1 ± 0.1 μM	24-h	Blood	None
5640	36982972	2017	GCRRLCYRQRCVTYCRGR	[K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 5.0 ± 0.3 μM	24-h	Skin	None
5641	36982972	2017	GCRRLCYRQRCVTYCRGR	[K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 39.4 ± 2.6 μM	24-h	Cervix	None
5639	36982972	2017	GCRRLCYRQRCVTYCRGR	[K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 29.4 ± 1.1 μM	24-h	Stomach	None
5638	36982972	2017	GCRRLCWRQRCVTWCRGR	[Y7W, K8R, Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 3.9 ± 0.1 μM	24-h	Blood	None
5637	36982972	2017	GCRRLCWRQRCVTWCRGR	[Y7W, K8R, Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 15.1 ± 1.4 μM	24-h	Breast	None
5636	36982972	2017	GCRRLCWRQRCVTWCRGR	[Y7W, K8R, Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 41.0 ± 4.2 μM	24-h	Cervix	None
5634	36982972	2017	GCRRLCWRQRCVTWCRGR	[Y7W, K8R, Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 31.6 ± 1.3 μM	24-h	Stomach	None
5635	36982972	2017	GCRRLCWRQRCVTWCRGR	[Y7W, K8R, Y14W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 5.4 ± 0.3 μM	24-h	Skin	None
5633	36982972	2017	GCRALCYKQRCVTYCRGA	[R4A, R18A]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HL-60	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 34.1 ± 3.9 μM	24-h	Blood	None
5632	36982972	2017	GCRALCYKQRCVTYCRGA	[R4A, R18A]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 11.5 ± 0.6 μM	24-h	Blood	None
5631	36982972	2017	GCRALCYKQRCVTYCRGA	[R4A, R18A]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 48.4 ± 0.7 μM	24-h	Breast	None
5629	36982972	2017	GCRALCYKQRCVTYCRGA	[R4A, R18A]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 10.3 ± 1.1 μM	24-h	Skin	None
5630	36982972	2017	GCRALCYKQRCVTYCRGA	[R4A, R18A]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ > 64 μM	24-h	Cervix	None
5628	36982972	2017	GCRALCYKQRCVTYCRGA	[R4A, R18A]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ > 64 μM	24-h	Stomach	None
5627	36982972	2017	KCRRLCYRQRCVTYCRGR	[G1K, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HL-60	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 9.0 ± 1.1μM	24-h	Blood	None
5626	36982972	2017	KCRRLCYRQRCVTYCRGR	[G1K, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 2.1 ± 0.2 μM	24-h	Blood	None
5625	36982972	2017	KCRRLCYRQRCVTYCRGR	[G1K, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 6.7 ± 0.7 μM	24-h	Breast	None
5624	36982972	2017	KCRRLCYRQRCVTYCRGR	[G1K, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 44.2 ± 2.2μM	24-h	Cervix	None
5622	36982972	2017	KCRRLCYRQRCVTYCRGR	[G1K, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 19.5 ± 0.5 μM	24-h	Stomach	None
5623	36982972	2017	KCRRLCYRQRCVTYCRGR	[G1K, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 1.7 ± 0.1 μM	24-h	Skin	None
5620	36982972	2017	GURRLUYKQRUVTYURGR	[C/U]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 1.4 ± 0.2 μM	24-h	Blood	None
5621	36982972	2017	GURRLUYKQRUVTYURGR	[C/U]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HL-60	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 38.5 ± 4.8 μM	24-h	Blood	None
5617	36982972	2017	GURRLUYKQRUVTYURGR	[C/U]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 4.6 ± 0.2 μM	24-h	Skin	None
5618	36982972	2017	GURRLUYKQRUVTYURGR	[C/U]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ > 64 μM	24-h	Cervix	None
5619	36982972	2017	GURRLUYKQRUVTYURGR	[C/U]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 37.5 ± 3.3 μM	24-h	Breast	None
5616	36982972	2017	GURRLUYKQRUVTYURGR	[C/U]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 51.0 ± 4.6 μM	24-h	Stomach	None
5615	36982972	2017	GCRRWCYKQRCVTYCRGR	[L5W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 1.0 ± 0.1 μM	24-h	Blood	None
5613	36982972	2017	GCRRWCYKQRCVTYCRGR	[L5W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 4.0 ± 0.1 μM	24-h	Skin	None
5614	36982972	2017	GCRRWCYKQRCVTYCRGR	[L5W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 17.1 ± 0.7 μM	24-h	Cervix	None
5612	36982972	2017	GCRRWCYKQRCVTYCRGR	[L5W]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 18.3 ± 1.4 μM	24-h	Stomach	None
5611	36982972	2017	GCRRLCYKQRCVTYCRGpPR	[D-P L-P]cGm	20	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 3.9 ± 0.2 μM	24-h	Blood	None
5610	36982972	2017	GCRRLCYKQRCVTYCRGpPR	[D-P L-P]cGm	20	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 51.5 ± 3.9 μM	24-h	Cervix	None
5609	36982972	2017	GCRRLCYKQRCVTYCRGpPR	[D-P L-P]cGm	20	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 3.0 ± 0.1 μM	24-h	Skin	None
5608	36982972	2017	GCRRLCYKQRCVTYCRGpPR	[D-P L-P]cGm	20	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 22.5 ± 3.3 μM	24-h	Stomach	None
5606	36982972	2017	KCRRYCYRQRCVTYCRGR	[G1K, L5Y, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 1.3 ± 0.1 μM	24-h	Blood	None
5607	36982972	2017	KCRRYCYRQRCVTYCRGR	[G1K, L5Y, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HL-60	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 15.7 ±1.1μM	24-h	Blood	None
5605	36982972	2017	KCRRYCYRQRCVTYCRGR	[G1K, L5Y, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 15.2 ± 1.9 μM	24-h	Breast	None
5604	36982972	2017	KCRRYCYRQRCVTYCRGR	[G1K, L5Y, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 20.9 ± 1.4 μM	24-h	Cervix	None
5603	36982972	2017	KCRRYCYRQRCVTYCRGR	[G1K, L5Y, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.0 ± 0.1 μM	24-h	Skin	None
5601	36982972	2017	KURRYUYRQRUVTYURGR	[C/U, G1K, L5Y, K8R]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HL-60	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 33.3 ±7.4μM	24-h	Blood	None
5602	36982972	2017	KCRRYCYRQRCVTYCRGR	[G1K, L5Y, K8R]cGm	18	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 26.5 ± 2.4 μM	24-h	Stomach	None
5598	36982972	2017	KURRYUYRQRUVTYURGR	[C/U, G1K, L5Y, K8R]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	HeLa	Cervical Cancer	Resazurin dye assay	CC₅₀ = 36.2 ± 2.8 μM	24-h	Cervix	None
5599	36982972	2017	KURRYUYRQRUVTYURGR	[C/U, G1K, L5Y, K8R]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MCF-7	Breast Cancer	Resazurin dye assay	CC₅₀ = 29.0 ± 3.7 μM	24-h	Breast	None
5600	36982972	2017	KURRYUYRQRUVTYURGR	[C/U, G1K, L5Y, K8R]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	K-562	Leukemia Cancer	Resazurin dye assay	CC₅₀ = 6.4 ± 0.6 μM	24-h	Blood	None
5596	36982972	2017	KURRYUYRQRUVTYURGR	[C/U, G1K, L5Y, K8R]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	CRL-1739	Gastric Cancer	Resazurin dye assay	CC₅₀ = 46.2 ± 7.6 μM	24-h	Stomach	None
5597	36982972	2017	KURRYUYRQRUVTYURGR	[C/U, G1K, L5Y, K8R]cGm	18	Cyclic	L	U = SelenoCys	Cyclized	Cyclized	Antimicrobial	Synthetic Analogue of Gomesin	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 2.3 ± 0.2 μM	24-h	Skin	None
5594	36982972	2017	ZCRRLCYKQRCVTYCRGR	Gomesin	18	Cyclic	L	Z= pyroglutamic acid	Amidation	Free	Antimicrobial and Anticancer	Acanthoscurria gomesiana	MM96L	Skin Cancer	Resazurin dye assay	CC₅₀ = 5.5 ± 1.1 μM	24-h	Skin	None
5595	36982972	2017	ZCRRLCYKQRCVTYCRGR	Gomesin	18	Cyclic	L	Z= pyroglutamic acid	Amidation	Free	Antimicrobial and Anticancer	Acanthoscurria gomesiana	K-562	Blood Cancer	Resazurin dye assay	CC₅₀ = 5.5 ± 1.1 μM	24-h	Blood	None
5593	None	2017	CKLKNFAKGVAQSLLNKASKLSGQC	BR-C	25	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 75.44 μg/ml	24-h	Lung	None
5592	None	2017	CKLKNFAKGVAQSLLNKASKLSGQC	BR-C	25	Cyclic	L	None	Cyclized	Cyclized	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 45.72 μg/ml	24-h	Breast	None
5590	None	2017	KlKNFAKGVAQSllNKASCKlSGQC	BR-D	25	Linear	Mix	None	Free	Free	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 67.52 μg/ml	24-h	Breast	None
5591	None	2017	KlKNFAKGVAQSllNKASCKlSGQC	BR-D	25	Linear	Mix	None	Free	Free	Antimicrobial	Synthetic	A-549	Lung Cancer	MTT assay	IC₅₀ = 94.74 μg/ml	24-h	Lung	None
5589	29064402	2017	ALWKEVLKNAGKAALNEINNLV	Dermaseptin-PH	22	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pithecopus (Phyllomedusa) hypochondrialis	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 11.8 μM	Not Available	Prostate	None
5588	29064402	2017	ALWKEVLKNAGKAALNEINNLV	Dermaseptin-PH	22	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pithecopus (Phyllomedusa) hypochondrialis	MDA-MB-435S	Breast Cancer	MTT assay	IC₅₀ = 9.94 μM	Not Available	Breast	None
5587	29064402	2017	ALWKEVLKNAGKAALNEINNLV	Dermaseptin-PH	22	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pithecopus (Phyllomedusa) hypochondrialis	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 2.36 μM	Not Available	Brain	None
5586	29064402	2017	ALWKEVLKNAGKAALNEINNLV	Dermaseptin-PH	22	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pithecopus (Phyllomedusa) hypochondrialis	H-157	Lung Cancer	MTT assay	IC₅₀ = 2.01 μM	Not Available	Lung	None
5585	29064402	2017	ALWKEVLKNAGKAALNEINNLV	Dermaseptin-PH	22	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Pithecopus (Phyllomedusa) hypochondrialis	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 0.69 μM	Not Available	Breast	None
5582	29183371;21530568	2017	LKCNKLVPLF	NN-32	10	Linear	L	None	Free	Free	Anticancer	Indian spectacled cobra venom Naja naja	MDA-MB-231	Breast Cancer	Anti-proliferation assay	Survival(%) = 64% at 10 μg/ml	72-h	Breast	None
5583	29183371;21530568	2017	LKCNKLVPLF	NN-32	10	Linear	L	None	Free	Free	Anticancer	Indian spectacled cobra venom Naja naja	MCF-7	Breast Cancer	LDH leakage assay	74% LDH Release at 2 μg/ml	72-h	Breast	None
5584	29183371;21530568	2017	LKCNKLVPLF	NN-32	10	Linear	L	None	Free	Free	Anticancer	Indian spectacled cobra venom Naja naja	MDA-MB-231	Breast Cancer	LDH leakage assay	66% LDH Release at 2 μg/ml	72-h	Breast	None
5579	29183371;21530568	2017	LKCNKLVPLF	NN-32	10	Linear	L	None	Free	Free	Anticancer	Indian spectacled cobra venom Naja naja	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 2.5 μg/ml	48-h	Breast	None
5580	29183371;21530568	2017	LKCNKLVPLF	NN-32	10	Linear	L	None	Free	Free	Anticancer	Indian spectacled cobra venom Naja naja	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 6.7 μg/ml	48-h	Breast	None
5581	29183371;21530568	2017	LKCNKLVPLF	NN-32	10	Linear	L	None	Free	Free	Anticancer	Indian spectacled cobra venom Naja naja	MCF-7	Breast Cancer	Anti-proliferation assay	Survival(%) = 68% at 10 μg/ml	48-h	Breast	None
5578	28123590	2017	KCRRWLKRMKKLG	LfcinB-P13	13	Linear	L	None	Free	Free	Anticancer	Synthetic analog of LFcinB	SMMC-7721	Liver Cancer	MTT assay	IC₅₀ = 41.8 µg/ml	24-h	Liver	None
5577	28902151	2017	GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD	APETx4	42	Linear	L	None	Free	Free	Anticancer	Anthopleura elegantissima	MDA-MB-435S	Skin Cancer	CellTox Green Dye assay	Green object count < 100 /mm² at 20 μM	20-h	Skin	None
5576	28902151	2017	GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD	APETx4	42	Linear	L	None	Free	Free	Anticancer	Anthopleura elegantissima	LNCaP	Prostate Cancer	CellTox Green Dye assay	Green object count = 300 /mm² at 20 μM	20-h	Prostate	None
5575	28902151	2017	GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD	APETx4	42	Linear	L	None	Free	Free	Anticancer	Anthopleura elegantissima	SH-SY5Y	Brain Tumor	CellTox Green Dye assay	Green object count = 400 /mm² at 20 μM	20-h	Brain	None
5574	28483698	2017	FRRFFKWPRRPFKFF	FR8,11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 15 μM	24-h	Liver	None
5572	28483698	2017	FRRFFKWPRRPFKFF	FR8,11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 18.9 μM	24-h	Cervix	None
5573	28483698	2017	FRRFFKWPRRPFKFF	FR8,11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	DLD-1	Colon Cancer	MTT assay	IC₅₀ = 22 μM	24-h	Colon	None
5571	28483698	2017	FRRFFKWPRRPFKFF	FR8,11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 27 μM	24-h	Breast	None
5570	28483698	2017	FRRPFKWPRRFFKFF	FR4,8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 5 μM	24-h	Liver	None
5568	28483698	2017	FRRPFKWPRRFFKFF	FR4,8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 13.8 μM	24-h	Cervix	None
5569	28483698	2017	FRRPFKWPRRFFKFF	FR4,8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	DLD-1	Colon Cancer	MTT assay	IC₅₀ = 15.3 μM	24-h	Colon	None
5567	28483698	2017	FRRPFKWPRRFFKFF	FR4,8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 15.4 μM	24-h	Breast	None
5565	28483698	2017	FRRFFKWFRRPFKFF	FR11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	DLD-1	Colon Cancer	MTT assay	IC₅₀ = 12.9 μM	24-h	Colon	None
5566	28483698	2017	FRRFFKWFRRPFKFF	FR11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.8 μM	24-h	Liver	None
5564	28483698	2017	FRRFFKWFRRPFKFF	FR11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 11 μM	24-h	Cervix	None
5562	28483698	2017	FRRFFKWPRRFFKFF	FR8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 4.2 μM	24-h	Liver	None
5563	28483698	2017	FRRFFKWFRRPFKFF	FR11P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 7 μM	24-h	Breast	None
5561	28483698	2017	FRRFFKWPRRFFKFF	FR8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	DLD-1	Colon Cancer	MTT assay	IC₅₀ = 10.8 μM	24-h	Colon	None
5560	28483698	2017	FRRFFKWPRRFFKFF	FR8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 10.5 μM	24-h	Cervix	None
5558	28483698	2017	FRRPFKWFRRFFKFF	FR4P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.5 μM	24-h	Liver	None
5559	28483698	2017	FRRFFKWPRRFFKFF	FR8P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 6.4 μM	24-h	Breast	None
5557	28483698	2017	FRRPFKWFRRFFKFF	FR4P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	DLD-1	Colon Cancer	MTT assay	IC₅₀ = 9.4 μM	24-h	Colon	None
5555	28483698	2017	FRRPFKWFRRFFKFF	FR4P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 6.3 μM	24-h	Breast	None
5556	28483698	2017	FRRPFKWFRRFFKFF	FR4P	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Analogue of FR-15	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 7.7 μM	24-h	Cervix	None
5554	28483698	2017	FRRFFKWFRRFFKFF	FR-15	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 2.5 μM	24-h	Liver	None
5553	28483698	2017	FRRFFKWFRRFFKFF	FR-15	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	MTT assay	IC₅₀ = 6.7 μM	24-h	Colon	None
5552	28483698	2017	FRRFFKWFRRFFKFF	FR-15	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 4.9 μM	24-h	Cervix	None
5551	28483698	2017	FRRFFKWFRRFFKFF	FR-15	15	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 3.15 μM	24-h	Breast	None
5550	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	PC-3	Prostate Cancer	LDH leakage assay	100% cytotoxicity at 2.5 μM	3-h	Prostate	None
5549	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	LNCaP	Prostate Cancer	Crystal Violet assay	GI₅₀ = 2.65 ± 1.09 μM	24-h	Prostate	None
5548	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	PC-3	Prostate Cancer	Crystal Violet assay	GI₅₀ = 2.17 ± 0.48 μM	24-h	Prostate	None
5547	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	DU-145	Prostate Cancer	Crystal Violet assay	GI₅₀ = 0.71 ± 0.55 μM	24-h	Prostate	None
5546	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	A-375	Skin Cancer	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Skin	None
5545	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	SK-Mel-28	Skin Cancer	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Skin	None
5544	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	HT-144	Skin Cancer	Crystal Violet assay	GI₅₀ = 5.08 ± 0.72 μM	24-h	Skin	None
5543	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	MIA PaCa-2	Pancreatic Cancer	Crystal Violet assay	GI₅₀ = 7.91 ± 1.40 μM	24-h	Pancreas	None
5542	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	BxPC-3	Pancreatic Cancer	Crystal Violet assay	GI₅₀ = 2.31 ± 0.41 μM	24-h	Pancreas	None
5541	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	PANC-1	Pancreatic Cancer	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Pancreas	None
5540	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	MDA-MB-453	Breast Cancer	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Breast	None
5539	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	BT-474	Breast Cancer	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Breast	None
5538	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	MDA-MB-231	Breast Cancer	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Breast	None
5537	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	U-373-MG	Brain Tumor	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Brain	None
5536	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	U-138-MG	Brain Tumor	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Brain	None
5535	28797092	2017	GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV	Dermaseptin - B2	33	Linear	L	None	Amidation	Free	Antimicrobial	Phyllomedusa bicolor	U-87-MG	Brain Tumor	Crystal Violet assay	GI₅₀ > 10 μM	24-h	Brain	None
5534	27778166	2017	FKIGGFIKKLWRSLAA	IL-5	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	LDH leakage assay	35% LDH release at 32 μM	2-h	Cervix	None
5533	27778166	2017	FKIGGFIKKLWRSLAA	IL-5	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 22.0 ± 2.6 μM	4-h	Prostate	None
5532	27778166	2017	FKIGGFIKKLWRSLAA	IL-5	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 28.0 ± 4.6 μM	4-h	Cervix	None
5531	27778166	2017	FKIGGFIKKLWRSALA	IL-4	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	LDH leakage assay	28% LDH release at 32 μM	2-h	Cervix	None
5530	27778166	2017	FKIGGFIKKLWRSALA	IL-4	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 35.5 ± 3.9 μM	4-h	Prostate	None
5529	27778166	2017	FKIGGFIKKLWRSALA	IL-4	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 54.4 ± 3.0 μM	4-h	Cervix	None
5528	27778166	2017	FKIGGFIKKAWRSLLA	IL-3	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	LDH leakage assay	35% LDH release at 32 μM	2-h	Cervix	None
5527	27778166	2017	FKIGGFIKKAWRSLLA	IL-3	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 74.9 ± 13.3 μM	4-h	Prostate	None
5526	27778166	2017	FKIGGFIKKAWRSLLA	IL-3	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 93.5 ± 19.4 μM	4-h	Cervix	None
5525	27778166	2017	FKIGGFAKKLWRSLLA	IL-2	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	LDH leakage assay	30% LDH release at 32 μM	2-h	Cervix	None
5524	27778166	2017	FKIGGFAKKLWRSLLA	IL-2	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 43.6 ± 7.9 μM	4-h	Prostate	None
5523	27778166	2017	FKIGGFAKKLWRSLLA	IL-2	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 52.0 ± 5.8 μM	4-h	Cervix	None
5522	27778166	2017	FKAGGFIKKLWRSLLA	IL-1	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	LDH leakage assay	30% LDH release at 32 μM	2-h	Cervix	None
5521	27778166	2017	FKAGGFIKKLWRSLLA	IL-1	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 58.4 ± 13.7 μM	4-h	Prostate	None
5520	27778166	2017	FKAGGFIKKLWRSLLA	IL-1	16	Linear	L	None	Free	Free	Anticancer	Synthetic; Mutant form of ZXR-II	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 73.9 ± 13.6 μM	4-h	Cervix	None
5519	27778166	2017	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	HeLa	Cervical Cancer	LDH leakage assay	40% LDH release at 32 μM	2-h	Cervix	None
5518	28524273	2017	LKKLFKKILKY	B8	11	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	LDH leakage assay	~60-60% LDH release at 8 μM	24-h	Blood	None
5517	28524273	2017	LKKLFKKILKYL	B4	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	LDH leakage assay	~60-80% LDH release at 8 μM	24-h	Blood	None
5516	28524273	2017	KKLFKKILKYL	BP100	11	Linear	L	None	Amidation	Free	Antimicrobial	Icthyopthirius multifilis (Strain G5)	K-562	Leukemia Cancer	LDH leakage assay	~40-60% LDH release at 8 μM	24-h	Blood	None
5515	28524273	2017	KLKKLFKKILKY	B9	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 83.7 ± 5.3 μM	48-h	Blood	None
5514	28524273	2017	KLKKLFKKILKY	B9	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 30.6 ± 5.7 μM	48-h	Breast	None
5513	28524273	2017	KLKKLFKKILKY	B9	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 38.3 ± 2.5 μM	48-h	Breast	None
5512	28524273	2017	KLKKLFKKILKY	B9	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 60.7 ± 5.4 μM	48-h	Blood	None
5511	28524273	2017	LKKLFKKILKY	B8	11	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 8.1 ± 0.9 μM	48-h	Blood	None
5510	28524273	2017	LKKLFKKILKY	B8	11	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 10.9 ± 1.2 μM	48-h	Breast	None
5509	28524273	2017	LKKLFKKILKY	B8	11	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 7.6 ± 1.4 μM	48-h	Breast	None
5508	28524273	2017	LKKLFKKILKY	B8	11	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 7.7 ± 1.2 μM	48-h	Blood	None
5506	28524273	2017	KKLFKKILKY	B7	10	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 97.3 ± 11.4 μM	48-h	Breast	None
5504	28524273	2017	KKLFKKILKY	B7	10	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 73.7 ± 6.1 μM	48-h	Blood	None
5505	28524273	2017	KKLFKKILKY	B7	10	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 77.3 ± 5.6 μM	48-h	Breast	None
5503	28524273	2017	LKKLFKKILKYLKK	B6	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 22.7 ± 2.3 μM	48-h	Blood	None
5502	28524273	2017	LKKLFKKILKYLKK	B6	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 20.7 ± 1.6 μM	48-h	Breast	None
5501	28524273	2017	LKKLFKKILKYLKK	B6	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 18.4 ± 1.5 μM	48-h	Breast	None
5500	28524273	2017	LKKLFKKILKYLKK	B6	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 19.2 ± 2.3 μM	48-h	Blood	None
5499	28524273	2017	LKKLFKKILKYLK	B5	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 28.3 ± 2.3 μM	48-h	Blood	None
5498	28524273	2017	LKKLFKKILKYLK	B5	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 28.2 ± 2.7 μM	48-h	Breast	None
5497	28524273	2017	LKKLFKKILKYLK	B5	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 27.3 ± 2.4 μM	48-h	Breast	None
5496	28524273	2017	LKKLFKKILKYLK	B5	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 26.5 ± 1.5 μM	48-h	Blood	None
5495	28524273	2017	LKKLFKKILKYL	B4	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 7.7 ± 0.4 μM	48-h	Blood	None
5494	28524273	2017	LKKLFKKILKYL	B4	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 6.3 ± 0.4 μM	48-h	Breast	None
5493	28524273	2017	LKKLFKKILKYL	B4	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 5.9 ± 0.2 μM	48-h	Breast	None
5492	28524273	2017	LKKLFKKILKYL	B4	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 6.6 ± 0.5 μM	48-h	Blood	None
5489	28524273	2017	KKLFKKILKYLKKL	B3	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 25.3 ± 3.2 μM	48-h	Breast	None
5490	28524273	2017	KKLFKKILKYLKKL	B3	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 28.4 ± 3.1 μM	48-h	Breast	None
5488	28524273	2017	KKLFKKILKYLKKL	B3	14	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 47.4 ± 12.5 μM	48-h	Blood	None
5487	28524273	2017	KKLFKKILKYLKK	B2	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 39.6 ± 5.7 μM	48-h	Blood	None
5486	28524273	2017	KKLFKKILKYLKK	B2	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 36.1 ± 6.7 μM	48-h	Breast	None
5485	28524273	2017	KKLFKKILKYLKK	B2	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 30.8 ± 3.4 μM	48-h	Breast	None
5484	28524273	2017	KKLFKKILKYLKK	B2	13	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 33.6 ± 4.2 μM	48-h	Blood	None
5483	28524273	2017	KKLFKKILKYLK	B1	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 19.1 ± 2.1 μM	48-h	Blood	None
5482	28524273	2017	KKLFKKILKYLK	B1	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 18.2 ± 1.3 μM	48-h	Breast	None
5481	28524273	2017	KKLFKKILKYLK	B1	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 15.7 ± 1.5 μM	48-h	Breast	None
5479	28524273	2017	KKLFKKILKYL	BP100	11	Linear	L	None	Amidation	Free	Antimicrobial	Icthyopthirius multifilis (Strain G5)	K-562/ADM	Leukemia Cancer	MTT assay	IC₅₀ = 32.6 ± 3.4 μM	48-h	Blood	None
5480	28524273	2017	KKLFKKILKYLK	B1	12	Linear	L	None	Amidation	Free	Antimicrobial	Analogue of BP 100	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 17.9 ± 1.4 μM	48-h	Blood	None
5478	28524273	2017	KKLFKKILKYL	BP100	11	Linear	L	None	Amidation	Free	Antimicrobial	Icthyopthirius multifilis (Strain G5)	MCF-7/ADM	Breast Cancer	MTT assay	IC₅₀ = 25.3 ± 2.5 μM	48-h	Breast	None
5477	28524273	2017	KKLFKKILKYL	BP100	11	Linear	L	None	Amidation	Free	Antimicrobial	Icthyopthirius multifilis (Strain G5)	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 27.6 ± 3.0 μM	48-h	Breast	None
5476	28524273	2017	KKLFKKILKYL	BP100	11	Linear	L	None	Amidation	Free	Antimicrobial	Icthyopthirius multifilis (Strain G5)	K-562	Leukemia Cancer	MTT assay	IC₅₀ = 30.4 ± 2.7 μM	48-h	Blood	None
5469	26851022	2016	Beta-AH	L-Carnosine	2	Linear	L	beta-alanyl	Free	Free	Anti-inflammatory and Antitumor	Synthetic	A-2780	Ovarian Cancer	MTT assay	IC₅₀ = 165 mM	24-h	Ovary	None
5470	26851022	2016	Beta-AH	L-Carnosine	2	Linear	L	beta-alanyl	Free	Free	Anti-inflammatory and Antitumor	Synthetic	OVCAR-3	Ovarian Cancer	MTT assay	IC₅₀ = 125 mM	24-h	Ovary	None
5471	26851022	2016	Beta-AH	L-Carnosine	2	Linear	L	beta-alanyl	Free	Free	Anti-inflammatory and Antitumor	Synthetic	SK-OV-3	Ovarian Cancer	MTT assay	IC₅₀ = 485 mM	24-h	Ovary	None
5468	27470405	2016	ATCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC	PaDef	47	Linear	L	None	Free	Free	Antimicrobial	Persea americana var. drymifolia	MCF-7	Breast Cancer	Trypan blue assay	IC₅₀ = 141.62 μg/ml	48-h	Breast	None
5467	27933724	2016	HARIKpTFRRlKWKYKGKFW	CIGB-552	20	Linear	Mix	None	Free	Acetylation	Anticancer	Synthetic	MCF-7	Breast Cancer	Sulforhodamine B assay	IC₅₀ = 379.1 ± 8.6 µM	48-h	Breast	None
5466	26657293	2016	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	HBD-3	45	Linear	L	None	Free	Free	Antimicrobial	Homo sapiens	Jurkat	Blood Cancer	MTT assay	IC₅₀ ~ 15 µM	48-h	Blood	None
5465	26657293	2016	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	HBD-3	45	Linear	L	None	Free	Free	Antimicrobial	Homo sapiens	HL-60	Blood Cancer	MTT assay	IC₅₀ ~ 10 µM	48-h	Blood	None
5464	26657293	2016	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	HBD-3	45	Linear	L	None	Free	Free	Antimicrobial	Homo sapiens	PC-3	Prostate Cancer	MTT assay	IC₅₀ ~ 22 µM	48-h	Prostate	None
5463	26657293	2016	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	HBD-3	45	Linear	L	None	Free	Free	Antimicrobial	Homo sapiens	U-937	Blood Cancer	MTT assay	IC₅₀ ~ 21 µM	48-h	Blood	None
5462	26657293	2016	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	HBD-3	45	Linear	L	None	Free	Free	Antimicrobial	Homo sapiens	HeLa	Cervical Cancer	MTT assay	IC₅₀ ~ 9 µM	48-h	Cervix	None
5459	27039838	2016	XGLUKKLUGI	[TOAC1, Lys5,6] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 10 µM	24-h	Brain	None
5460	27039838	2016	XGLUKKLUGI	[TOAC1, Lys5,6] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 6 µM	24-h	Cervix	None
5461	27039838	2016	XGLZGGLUGI	[TOAC1, Api4] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, Z = 4-aminopiperidine-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 13 µM	24-h	Brain	None
5456	27039838	2016	XGLUGGLURI	[TOAC1, Arg9] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 5 µM	24-h	Cervix	None
5457	27039838	2016	UGLUKKLUGI	[Lys5,6] TG	10	Linear	L	U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 7 µM	24-h	Brain	None
5458	27039838	2016	UGLUKKLUGI	[Lys5,6] TG	10	Linear	L	U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 10 µM	24-h	Cervix	None
5454	27039838	2016	XRLUGGLUGI	[TOAC1, Arg2] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 9 µM	24-h	Cervix	None
5455	27039838	2016	XGLUGGLURI	[TOAC1, Arg9] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 8 µM	24-h	Brain	None
5451	27039838	2016	URLUGGLUGI	[Arg2] TG	10	Linear	L	U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 8 µM	24-h	Brain	None
5452	27039838	2016	URLUGGLUGI	[Arg2] TG	10	Linear	L	U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 4 µM	24-h	Cervix	None
5453	27039838	2016	XRLUGGLUGI	[TOAC1, Arg2] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 8 µM	24-h	Brain	None
5448	27039838	2016	UGLUGKLUGI	[Lys6] TG	10	Linear	L	U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 2 µM	24-h	Cervix	None
5449	27039838	2016	XGLUGKLUGI	[TOAC1, Lys6] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 1 µM	24-h	Brain	None
5450	27039838	2016	XGLUGKLUGI	[TOAC1, Lys6] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 3 µM	24-h	Cervix	None
5445	27039838	2016	XGLUGGLUGI	[TOAC1] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 1 µM	24-h	Brain	None
5446	27039838	2016	XGLUGGLUGI	[TOAC1] TG	10	Linear	L	X = 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 3 µM	24-h	Cervix	None
5447	27039838	2016	UGLUGKLUGI	[Lys6] TG	10	Linear	L	U = 2-Aminoisobutyric acid	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichogin GA	T-67	Brain Tumor	MTT assay	EC₅₀ = 4 µM	24-h	Brain	None
5443	27039838	2016	UGLUGGLUGI	Trichogin GA	10	Linear	L	U = 2-Aminoisobutyric acid (Aib)	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichoderma longibrachiatum	T-67	Brain Tumor	MTT assay	EC₅₀ = 2 µM	24-h	Brain	None
5444	27039838	2016	UGLUGGLUGI	Trichogin GA	10	Linear	L	U = 2-Aminoisobutyric acid (Aib)	Lol = leucinol	Oct = 1-octanoyl	AMP, Anticancer	Trichoderma longibrachiatum	HeLa	Cervical Cancer	MTT assay	EC₅₀ = 8 µM	24-h	Cervix	None
5442	27347099	2016	APEPRWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK	Cecropin XJ	41	Linear	L	None	Free	Free	Antimicrobial	Larvae of Bombyx mori	Huh-7	Liver Cancer	MTT assay	Cell viability = 50% at 50 µmol/l	24-h	Liver	None
5437	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ = 4.2 µM	72-h	Kidney	None
5436	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5434	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5435	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ = 6.4 µM	72-h	Skin	None
5433	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 6.7 µM	72-h	Colon	None
5432	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5430	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5431	27387357	2016	KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c)	Peptide - 11	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ = 7.3 µM	72-h	Breast	None
5424	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5425	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Kidney	None
5422	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5423	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Skin	None
5419	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Breast	None
5420	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5421	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5413	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Kidney	None
5418	27387357	2016	GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK	Peptide - 10	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid, A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5412	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5410	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5411	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Skin	None
5409	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5408	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5407	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Breast	None
5401	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Kidney	None
5406	27387357	2016	GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK	Peptide - 9	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Oic = octahydroindolecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5400	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5399	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Skin	None
5397	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5398	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5396	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5394	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5395	27387357	2016	GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK	Peptide - 8	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid; Tic = tetrahydroisoquinolinecarboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Breast	None
5388	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5389	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Kidney	None
5386	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5387	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Skin	None
5385	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5383	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Breast	None
5384	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5377	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Kidney	None
5382	27387357	2016	GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR	Peptide - 7	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5375	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Skin	None
5376	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5373	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5374	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5372	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5370	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5371	27387357	2016	GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK	Peptide - 6	20	Cyclic	L	A5c = 1-aminocyclopentane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Breast	None
5365	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ = 2.1 µM	72-h	Kidney	None
5364	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 4.4 µM	72-h	Pancreas	None
5363	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ = 1.9 µM	72-h	Skin	None
5362	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 2.6 µM	72-h	Colon	None
5361	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 6.4 µM	72-h	Colon	None
5360	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ = 2.3 µM	72-h	Ovary	None
5359	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ = 3.0 µM	72-h	Breast	None
5358	27387357	2016	GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab	Peptide - 4	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Dab = diaminobutyric acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 2.7 µM	72-h	Pancreas	None
5352	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 3.6 µM	72-h	Pancreas	None
5353	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ = 4.7 µM	72-h	Kidney	None
5350	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 6.2 µM	72-h	Colon	None
5351	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ = 3.1 µM	72-h	Skin	None
5348	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ = 5.4 µM	72-h	Ovary	None
5349	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 3.2 µM	72-h	Colon	None
5346	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 5.9 µM	72-h	Pancreas	None
5347	27387357	2016	GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn	Peptide - 3	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid, Orn = Ornithine	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ = 4.6 µM	72-h	Breast	None
5340	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 5.0 µM	72-h	Pancreas	None
5341	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ = 5.6 µM	72-h	Kidney	None
5337	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 6.6 µM	72-h	Colon	None
5338	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 6.4 µM	72-h	Colon	None
5339	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ = 6.4 µM	72-h	Skin	None
5335	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ = 7.0 µM	72-h	Breast	None
5336	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ = 6.0 µM	72-h	Ovary	None
5333	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	RL	Lymphoma Cancer	CellTiter-Glo assay	Not Available	72-h	Blood	None
5334	27387357	2016	GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR	Peptide - 2	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 2.6 µM	72-h	Pancreas	None
5330	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	PC-3	Prostate Cancer	CellTiter-Glo assay	Not Available	72-h	Prostate	None
5331	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-549	Lung Cancer	CellTiter-Glo assay	Not Available	72-h	Lung	None
5332	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	NCI-H69	Lung Cancer	CellTiter-Glo assay	Not Available	72-h	Lung	None
5328	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MiaPaCa.2	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ = 7.3 µM	72-h	Pancreas	None
5329	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	A-498	Renal Cancer	CellTiter-Glo assay	IC₅₀ = 3.0 µM	72-h	Kidney	None
5325	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	COLO-205	Colon Cancer	CellTiter-Glo assay	IC₅₀ = 5.4 µM	72-h	Colon	None
5326	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	DLD-1	Colon Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Colon	None
5327	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	UACC-62	Skin Cancer	CellTiter-Glo assay	IC₅₀ = 2.6 µM	72-h	Skin	None
5323	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	MCF-7	Breast Cancer	CellTiter-Glo assay	IC₅₀ = 6.2 µM	72-h	Breast	None
5324	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	IGROV-1	Ovarian Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Ovary	None
5322	27387357	2016	GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK	Peptide - 1	20	Cyclic	L	A6c = 1-aminocyclohexane carboxylic acid	Amidation	Acetylation	Antimicrobial and Anticancer	Synthetic	CPFAC-1	Pancreatic Cancer	CellTiter-Glo assay	IC₅₀ > 7.5 µM	72-h	Pancreas	None
5321	26831010	2016	VCMPCFTTDQQMARKCSDCCGGKGRGKCYGPQCLCR	CTX-23	36	Linear	L	None	Free	Free	Anticancer	Synthetic	U-251	Brain Tumor	MTT assay	Graph Figure 2	48-h	Brain	None
5320	26831010	2016	CGPCFTTDHNMARKCDECCGGKGRGKCFGPQCLCR	CA4	35	Linear	L	None	Free	Free	Anticancer	Synthetic	U-251	Brain Tumor	MTT assay	Graph Figure 2	48-h	Brain	None
5317	26519876	2016	SLFELGKMILQETGKNPAKSYGAYGCNCGVLGRGGPKDATDRCCYVHKCCYKKLTGCDPKKDRYSYSWKDKTIVCGENNPCLKELCECDKAVAICLRENLGTYNKKYRYHLKPFCKKADPC	BnSP-6	133	Linear	L	None	Free	Free	Antitumor	B. pauloensis	MDA-MB-231	Breast Cancer	MTT assay	45% cell cytotoxicity at 100 μg/mL	24-h	Breast	None
5311	27503651	2016	RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC	NaD1	47	pseudo cyclic	L	None	Free	Free	Antifungal and Anticancer	Nicotiana alata	U-937	Blood Cancer	PI uptake assay	46.4±8.2% cell death at 10 µM	Not Available	Blood	None
5301	27248170	2016	FIHHIIGGLFSAGKAIHRLIRRRRR	TP4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	MDA-MB-231	Breast Cancer	LDH leakage assay	LDH activity = 1.5mU/mL at 10 μg/mL	3-h	Breast	None
5300	27248170	2016	FIHHIIGGLFSAGKAIHRLIRRRRR	TP4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	MCF-7	Breast Cancer	MTS assay	IC₅₀ = 5.03 μM	6-h	Breast	None
5299	27248170	2016	FIHHIIGGLFSAGKAIHRLIRRRRR	TP4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	MDA-MB-453	Breast Cancer	MTS assay	IC₅₀ = 5.03 μM	6-h	Breast	None
5297	26952034	2016	DEDDD	XLAsp-P1	5	Linear	L	None	Free	Free	Antimicrobial	Xenopus laevis	Not Available	Breast Cancer	MTT assay	LC₅₀ < 5 μg/mL	24-h	Breast	None
5298	27248170	2016	FIHHIIGGLFSAGKAIHRLIRRRRR	TP4	25	Linear	L	None	Free	Free	Antimicrobial	Oreochromis niloticus	MDA-MB-231	Breast Cancer	MTS assay	IC₅₀ = 5.03 μM	6-h	Breast	None
5296	27129462	2016	NGVQPKYRWWRWWRRWW	RT2	17	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Crocodylus siamensis	CaSki	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 17.28 ± 0.2 µM	24-h	Cervix	None
5295	27129462	2016	NGVQPKYRWWRWWRRWW	RT2	17	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Crocodylus siamensis	HeLa	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 28.67 ± 0.4 µM	24-h	Cervix	None
5294	27129462	2016	NGVQPKYKWWKWWKKWW	KT2	17	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Crocodylus siamensis	CaSki	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 30.81 ± 0.2 µM	24-h	Cervix	None
5293	27129462	2016	NGVQPKYKWWKWWKKWW	KT2	17	Linear	L	None	Amidation	Free	Antimicrobial and Anticancer	Crocodylus siamensis	HeLa	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 53.41 ± 1.0 µM	24-h	Cervix	None
5292	27129462	2016	RGSALTHLP	RP9	9	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Crocodylus siamensis	CaSki	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 168.33 ± 1.6 µM	24-h	Cervix	None
5291	27129462	2016	RGSALTHLP	RP9	9	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Crocodylus siamensis	HeLa	Cervical Cancer	Sulforhodamine B assay	IC₅₀ = 126.24 ± 3.5 µM	24-h	Cervix	None
5290	27187467	2016	GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI	dermaseptin-PD-2	33	Linear	L	None	Free	Free	Antimicrobial	phyllomedusine leaf frogs,Pachymedusa dacnicolor	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 13.43 μM	24-h	Brain	None
5289	27187467	2016	GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI	dermaseptin-PD-2	33	Linear	L	None	Free	Free	Antimicrobial	phyllomedusine leaf frogs,Pachymedusa dacnicolor	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 3.17 μM	24-h	Prostate	None
5288	27187467	2016	GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI	dermaseptin-PD-2	33	Linear	L	None	Free	Free	Antimicrobial	phyllomedusine leaf frogs,Pachymedusa dacnicolor	H-157	Lung Cancer	MTT assay	IC₅₀ = 6.43 μM	24-h	Lung	None
5286	27503270	2016	Not Available	Bmattacin2	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Antimicrobial	silkworm Bombyx mori	HCT-116	Colorectal Cancer	MTS assay	IC₅₀ = 1.70 μM	24-h	Colon	None
5287	27187467	2016	GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ	dermaseptin-PD-1	31	Linear	L	None	Free	Free	Antimicrobial	phyllomedusine leaf frogs,Pachymedusa dacnicolor	U251-MG	Brain Tumor	MTT assay	IC₅₀ = 15.08 μM	24-h	Brain	None
5285	27503270	2016	Not Available	Bmattacin2	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Antimicrobial	silkworm Bombyx mori	A-375	Skin Cancer	MTS assay	IC₅₀ = 5.23 μM	24-h	Skin	None
5283	27207743	2016	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 14.2 ± 0.5 μM	4-h	Prostate	None
5284	27207743	2016	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	293T	Kidney Cancer	MTT assay	IC₅₀ = 6.3 ± 0.7 μM	4-h	Kidney	None
5282	27207743	2016	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 8.4 ± 1.1 μM	4-h	Liver	None
5281	27207743	2016	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 7.5 ± 1.2 μM	4-h	Liver	None
5280	27207743	2016	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	SACC-83	Salivary Cancer	MTT assay	IC₅₀ = 9.9 ± 1.7 μM	4-h	Salivary gland	None
5278	27207743	2016	FKIGGFIKKLWRSKLA	ZXR-1	16	Linear	L	None	Free	Free	Antimicrobial	Mauriporin	293T	Kidney Cancer	MTT assay	IC₅₀ = 186.7 ± 13.1 μM	4-h	Kidney	None
5279	27207743	2016	FKIGGFIKKLWRSLLA	ZXR-2	16	Linear	L	None	Free	Free	Antimicrobial	Synthetic; Mutant form of ZXR-I	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 8.1 ± 1.6 μM	4-h	Cervix	None
5277	27207743	2016	FKIGGFIKKLWRSKLA	ZXR-1	16	Linear	L	None	Free	Free	Antimicrobial	Mauriporin	PC-3	Prostate Cancer	MTT assay	IC₅₀ = 69.1 ± 1.6 μM	4-h	Prostate	None
5276	27207743	2016	FKIGGFIKKLWRSKLA	ZXR-1	16	Linear	L	None	Free	Free	Antimicrobial	Mauriporin	Huh-7	Liver Cancer	MTT assay	IC₅₀ = 77.9 ± 0.9 μM	4-h	Liver	None
5274	27207743	2016	FKIGGFIKKLWRSKLA	ZXR-1	16	Linear	L	None	Free	Free	Antimicrobial	Mauriporin	SACC-83	Salivary Cancer	MTT assay	IC₅₀ = 27.9 ± 7.7 μM	4-h	Salivary gland	None
5275	27207743	2016	FKIGGFIKKLWRSKLA	ZXR-1	16	Linear	L	None	Free	Free	Antimicrobial	Mauriporin	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 141.7 ± 12.2 μM	4-h	Liver	None
5273	27207743	2016	FKIGGFIKKLWRSKLA	ZXR-1	16	Linear	L	None	Free	Free	Antimicrobial	Mauriporin	HeLa	Cervical Cancer	MTT assay	IC₅₀ = 62.6 ± 8.4 μM	4-h	Cervix	None
7723	None	2020	LKKWWKKVKGLLGGLLGKVKKVIK	Seq ID No. 17 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	Calu-1	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7724	None	2020	RRWVRRVRRVWRRVVRVVRRWVRR	Seq ID No. 26 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	H-460	Lung Cancer	Tetrazolium-based assay	Cell viability < 50% at 20 μM	2-h	Lung	US20200079827A1
7725	None	2020	RRWVRRVRRVWRRVVRVVRRWVRR	Seq ID No. 26 from patent ID US202000079827A1	24	Linear	L	None	Free	Free	Antimicrobial and Anticancer	Synthetic	Calu-1	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7726	None	2020	RRWvRRvRRvWRRvvRvvRRWvRR	Seq ID No. 34 from patent ID US202000079827A1	24	Linear	Mix	None	Free	Free	Antimicrobial and Anticancer	Synthetic	NCI-H460	Lung Cancer	Tetrazolium-based assay	Cell viability < 25% at 20 μM	2-h	Lung	US20200079827A1
7727	None	2020	RRWvRRvRRvWRRvvRvvRRWvRR	Seq ID No. 34 from patent ID US202000079827A1	24	Linear	Mix	None	Free	Free	Antimicrobial and Anticancer	Synthetic	Calu-1	Lung Cancer	Tetrazolium-based assay	Cell viability > 50% at 20 μM	2-h	Lung	US20200079827A1
7728	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	RG1	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 7 μM	72-96 h	Brain	WO 2019/025432 A1;US011352395B2
7729	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	GMB-27	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 7.5 μM	72-96 h	Brain	WO 2019/025432 Al;US20200157150A1
7730	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	12015	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 10 μM	72-96 h	Brain	WO 2019/025432 Al
7731	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	12089	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 4 μM	72-96 h	Brain	WO 2019/025432 Al
7732	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	RG6	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 5 μM	72-96 h	Brain	WO 2019/025432 Al
7733	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	RG4	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 5 μM	72-96 h	Brain	WO 2019/025432 Al
7734	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	RG5	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 7 μM	72-96 h	Brain	WO 2019/025432 Al
7735	None	2019	AALVVILKKATEYVHS	IDP-NS10	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links L(3) and A(10)	Free	Free	Anticancer	Synthetic	12053	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 50 μM	72-96 h	Brain	WO 2019/025432 Al
7736	None	2019	RQRRNDLRSSFLTLRDH	IDP-NS02	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links D(5) and S(10)	Free	Free	Anticancer	Synthetic	NCI-H524	Lung Cancer	AlamarBlue assay	EC₅₀ ~ 5 μM	72-96 h	Lung	WO 2019/025432 Al
7737	None	2019	RQRRNDLRSSFLTLRDH	IDP-NS16	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and R(15)	Free	Free	Anticancer	Synthetic	RG1	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 15 μM	72-96 h	Brain	WO 2019/025432 Al
7738	None	2019	RQRRNDLRSSFLTLRDH	IDP-NS16	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and R(15)	Free	Free	Anticancer	Synthetic	12053	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 10 μM	72-96 h	Brain	WO 2019/025432 Al
7739	None	2019	RRNDLRSSFLTLRDHVP	IDP-Na05	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links S(8) and H(15)	Free	Free	Anticancer	Synthetic	RG1	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 10 μM	72-96 h	Brain	WO 2019/025432 Al
7740	None	2019	RQIKIWFQNRRMKWKKRQRRNDLRSSFLTLRDHVP	IDP-NLCa02	35	Linear	L	None	Free	Free	Anticancer	Synthetic	RG1	Glioblastoma	AlamarBlue assay	EC₅₀ ~ 5 μM	72-96 h	Brain	WO 2019/025432 Al
7741	None	2020	RKRRNDLRSRFLALRDQ	IDP-wtL05	17	Linear	L	None	Free	Free	Anticancer	Synthetic	RPMI	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Blood	US20200239547A1
7742	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS05	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(4) and F(11)	Free	Free	Anticancer	Synthetic	HL-60	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 5 μM	48-72 h	Blood	US20200239547A1
7743	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS05	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(4) and F(11)	Free	Free	Anticancer	Synthetic	RPMI	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 6 μM	48-72 h	Blood	US20200239547A1
7744	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS13	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and R(15)	Free	Free	Anticancer	Synthetic	MCF-7	Breast Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Breast	US20200239547A1
7745	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS13	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and R(15)	Free	Free	Anticancer	Synthetic	HL-60	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 7 μM	48-72 h	Blood	US20200239547A1
7746	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS13	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and R(15)	Free	Free	Anticancer	Synthetic	RPMI	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 9 μM	48-72 h	Blood	US20200239547A1
7747	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS13	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and R(15)	Free	Free	Anticancer	Synthetic	U266	Lymphoma Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Blood	US20200239547A1
7748	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS15	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(15) and Q(17)	Free	Free	Anticancer	Synthetic	RPMI	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 7 μM	48-72 h	Blood	US20200239547A1
7749	None	2020	RKRRNDLRSRFLALRDQ	IDP-LS15	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(15) and Q(17)	Free	Free	Anticancer	Synthetic	U266	Lymphoma Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 8 μM	48-72 h	Blood	US20200239547A1
7750	None	2020	APKVVILSKALEYLQA	IDP-LS16	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links I(6) and Y(13)	Free	Free	Anticancer	Synthetic	RPMI	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 15 μM	48-72 h	Blood	US20200239547A1
7751	None	2020	APKVVILSKALEYLQA	IDP-LS16	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links I(6) and Y(13)	Free	Free	Anticancer	Synthetic	U266	Lymphoma Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Blood	US20200239547A1
7752	None	2020	APKVVILSKALEYLQA	IDP-LS17	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links S(8) and Q(15)	Free	Free	Anticancer	Synthetic	RPMI	Leukemia Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Blood	US20200239547A1
7753	None	2020	APKVVILSKALEYLQA	IDP-LS17	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links S(8) and Q(15)	Free	Free	Anticancer	Synthetic	U266	Lymphoma Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 16 μM	48-72 h	Blood	US20200239547A1
7754	None	2020	RRRRRRRSKAPKVVILSKALEYLQA	IDP-LLCb01	25	Linear	L	None	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 5 μM	48-72 h	Lung	US20200239547A1
7755	None	2020	RRRRRRRSKAPKVVILSKALEYLQA	IDP-LLCb01	25	Linear	L	None	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 2.5 μM	48-72 h	Lung	US20200239547A1
7756	None	2020	RRRRRRRSKAPKVVILSKALEYLQA	IDP-LLCb01	25	Linear	L	None	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 5 μM	48-72 h	Lung	US20200239547A1
7757	None	2020	RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA	IDP-LLCb02	33	Linear	L	None	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 7.5 μM	48-72 h	Lung	US20200239547A1
7758	None	2020	RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA	IDP-LLCb02	33	Linear	L	None	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Lung	US20200239547A1
7759	None	2020	RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA	IDP-LLCb02	33	Linear	L	None	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 15 μM	48-72 h	Lung	US20200239547A1
7760	None	2020	SKAPKVVILSKALEYL	IDP-Lb01	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links S(1) and I(8)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 22.5 μM	48-72 h	Lung	US20200239547A1
7761	None	2020	SKAPKVVILSKALEYL	IDP-Lb01	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links S(1) and I(8)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 12.5 μM	48-72 h	Lung	US20200239547A1
7762	None	2020	SKAPKVVILSKALEYL	IDP-Lb01	16	Linear	L	-(CH₂)₂-CH=CH-(CH₂)₃; a biradical linker links S(1) and I(8)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 22.5 μM	48-72 h	Lung	US20200239547A1
7763	None	2020	SKAPKVVILSKALEYL	IDP-Lb02	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links K(2) and L(9)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 22.5 μM	48-72 h	Lung	US20200239547A1
7764	None	2020	SKAPKVVILSKALEYL	IDP-Lb02	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₂; a biradical linker links K(2) and L(9)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 7.5 μM	48-72 h	Lung	US20200239547A1
7765	None	2020	SKAPKVVILSKALEYL	IDP-Lb02	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links K(2) and L(9)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 15 μM	48-72 h	Lung	US20200239547A1
7766	None	2020	SKAPKVVILSKALEYL	IDP-Lb03	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links A(3) and S(10)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 22.5 μM	48-72 h	Lung	US20200239547A1
7767	None	2020	SKAPKVVILSKALEYL	IDP-Lb03	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links A(3) and S(10)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 5 μM	48-72 h	Lung	US20200239547A1
7768	None	2020	SKAPKVVILSKALEYL	IDP-Lb03	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links A(3) and S(10)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 15 μM	48-72 h	Lung	US20200239547A1
7769	None	2020	SKAPKVVILSKALEYL	IDP-Lb04	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links P(4) and K(11)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ > 30 μM	48-72 h	Lung	US20200239547A1
7770	None	2020	SKAPKVVILSKALEYL	IDP-Lb04	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links P(4) and K(11)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 12.5 μM	48-72 h	Lung	US20200239547A1
7771	None	2020	SKAPKVVILSKALEYL	IDP-Lb04	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links P(4) and K(11)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ > 30 μM	48-72 h	Lung	US20200239547A1
7772	None	2020	SKAPKVVILSKALEYL	IDP-Lb05	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links K(5) and A(12)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Lung	US20200239547A1
7773	None	2020	SKAPKVVILSKALEYL	IDP-Lb05	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links K(5) and A(12)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 7.5 μM	48-72 h	Lung	US20200239547A1
7774	None	2020	SKAPKVVILSKALEYL	IDP-Lb05	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links K(5) and A(12)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 12.5 μM	48-72 h	Lung	US20200239547A1
7775	None	2020	SKAPKVVILSKALEYL	IDP-Lb06	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links V(6) and L(13)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 12.5 μM	48-72 h	Lung	US20200239547A1
7776	None	2020	SKAPKVVILSKALEYL	IDP-Lb06	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links V(6) and L(13)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 7.5 μM	48-72 h	Lung	US20200239547A1
7777	None	2020	SKAPKVVILSKALEYL	IDP-Lb06	16	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links V(6) and L(13)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 12.5 μM	48-72 h	Lung	US20200239547A1
7778	None	2020	RRNDLRSRFLALRDQVP	IDP-La05	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and Q(15)	Free	Free	Anticancer	Synthetic	NCl-H187	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 22.5 μM	48-72 h	Lung	US20200239547A1
7779	None	2020	RRNDLRSRFLALRDQVP	IDP-La05	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and Q(15)	Free	Free	Anticancer	Synthetic	NCl-H82	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 15 μM	48-72 h	Lung	US20200239547A1
7780	None	2020	RRNDLRSRFLALRDQVP	IDP-La05	17	Linear	L	-(CH₂)₆-CH=CH-(CH₂)₃; a biradical linker links R(8) and Q(15)	Free	Free	Anticancer	Synthetic	NCl-H510A	Lung Cancer	MTT/Alamamar-Blue/Hexosaminidase activity test	EC₅₀ ~ 10 μM	48-72 h	Lung	US20200239547A1
7790	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	U343	Glioblastoma	MTT assay	IC₅₀ = 0.781 μM	48-h	Brain	EP3279210 B1
7791	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	U373MG	Glioblastoma	MTT assay	IC₅₀ = 0.8717 μM	48-h	Brain	EP3279210 B1
7792	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	U251	Glioblastoma	MTT assay	IC₅₀ = 0.7607 μM	48-h	Brain	EP3279210 B1
7793	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	U87-MG	Glioblastoma	MTT assay	IC₅₀ = 0.9164 μM	48-h	Brain	EP3279210 B1
7794	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	HepG-2	Liver Cancer	MTT assay	IC₅₀ = 3.064 μM	48-h	Liver	EP3279210 B1
7795	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	Hep3B	Liver Cancer	MTT assay	IC₅₀ = 0.7847 μM	48-h	Liver	EP3279210 B1
7796	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	293T	Renal Cancer	MTT assay	IC₅₀ = 1.107 μM	48-h	Renal	EP3279210 B1
7797	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 9.74 μM	48-h	Breast	EP3279210 B1
7798	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	MDA-MB-231	Breast Cancer	MTT assay	IC₅₀ = 0.8061 μM	48-h	Breast	EP3279210 B1
7799	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	HL-60	Blood Cancer	MTT assay	IC₅₀ = 1.111 μM	48-h	Blood	EP3279210 B1
7800	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	K-562	Blood Cancer	MTT assay	IC₅₀ = 1.103 μM	48-h	Blood	EP3279210 B1
7801	None	2016	NYPQRPCRGDKGPDC	5-2C	15	Linear	L	None	Amidation	Acetylation	Antimicrobial	Synthetic	Hel	Blood Cancer	MTT assay	IC₅₀ = 1.055 μM	48-h	Blood	EP3279210 B1
7802	None	2018	GKCSTRGRKCCRRKK	hBD3-3	15	Linear	L	None	Free	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	Cell Proliferation assay	Concentration dependent reduction in colony formation between 100 μM and 200 μM.	48-h	Breast	US009993519B2
7803	None	2018	GKCSTRGRKCMRRKK	hBD3-3 M1	15	Linear	L	None	Free	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	Cell Proliferation assay	Concentration dependent reduction in colony formation between 100 μM and 200 μM.	48-h	Breast	US009993519B2
7804	None	2018	GKCSTRGRKMCRRKK	hBD3-3 M2	15	Linear	L	None	Free	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	Cell Proliferation assay	Concentration dependent reduction in colony formation between 100 μM and 200 μM.	48-h	Breast	US009993519B2
7805	None	2018	GKCSTRGRKCCRRKK	hBD3-3	15	Linear	L	None	Free	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	Annexin V/ PI staining assay	Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group	8-h	Breast	US009993519B2
7806	None	2018	GKCSTRGRKCMRRKK	hBD3-3 M1	15	Linear	L	None	Free	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	Annexin V/ PI staining assay	Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group	8-h	Breast	US009993519B2
7807	None	2018	GKCSTRGRKMCRRKK	hBD3-3 M2	15	Linear	L	None	Free	Free	Anticancer	Synthetic	MDA-MB-231	Breast Cancer	Annexin V/ PI staining assay	Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group	8-h	Breast	US009993519B2
7811	None	2017	LGQQQPFPPQQPY	Alpha-gliadin peptide p31-43	13	Linear	L	None	Free	Free	Anticancer	Synthetic	A-549	Lung Cancer	MTT assay	9.4% growth inhibition at 70 μg/mL	72-h	Lung	US009669068B2
7812	None	2017	LGQQQPFPPQQPY	Alpha-gliadin peptide p31-43	13	Linear	L	None	Free	Free	Anticancer	Synthetic	NCI-H1975	Lung Cancer	MTT assay	36.3% growth inhibition at 70 μg/mL	72-h	Lung	US009669068B2
7813	None	2017	LGQQQPFPPQQPY	Alpha-gliadin peptide p31-43	13	Linear	L	None	Free	Free	Anticancer	Synthetic	PANC-1	Pancreatic Cancer	MTT assay	26.2% growth inhibition at 70 μg/mL	72-h	Pancreas	US009669068B2
7814	None	2017	LGQQQPFPPQQPY	Alpha-gliadin peptide p31-43	13	Linear	L	None	Free	Free	Anticancer	Synthetic	A-549	Lung Cancer	TUNEL assay	Mean apoptotic rate = 36% at 200 μg/mL	72-h	Lung	US009669068B2
4676	None	2016	LTFAEYWAQLaAAAAAa	ALRN-6924	17	Linear	Mix	staple between Ala4 and d-Ala11	Free	Free	Antitumor	Synthetic	TP53-WT subcutaneous mouse xenograft models	Breast Cancer	Not Available	Tumor suppression at doses 2.5 mg/kg to 5mg/kg	28 days	Breast	WO2016049359A1
7851	29580912	2018	ywNTF(AzGly)R(Me)W	TAK-448	8	Linear	Mix	aza-glycine; Me=Methylation	Amidation	Acetylation	Anticancer	Synthetic	VCaP	Prostate Cancer	Given i.h.; dosings on day 0 and 28	Had greater anti-tumor effects in VCaP xenograft model	28 days	Prostate	None
7848	None	2018	ACSAp(Dab)RYCYQKpPYH	Balixafortide	16	Cyclic ; Disulfide bridge: Cys2-Cys9	Mix	Dab = 2,4-diaminobutyric acid	Free	Free	Anticancer and Antitumor	Synthetic	Namalwa	Lymphoma	HUVEC sprouting	IC₅₀< 10 nM	Not available	Blood	None
7849	None	2018	ACSAp(Dab)RYCYQKpPYH	Balixafortide	16	Cyclic ; Disulfide bridge: Cys2-Cys9	Mix	Dab = 2,4-diaminobutyric acid	Free	Free	Anticancer and Antitumor	Synthetic	Jurkat	Blood Cancer	HUVEC sprouting	IC₅₀< 10 nM	Not available	Blood	None
7850	None	2018	ACSAp(Dab)RYCYQKpPYH	Balixafortide	16	Cyclic ; Disulfide bridge: Cys2-Cys9	Mix	Dab = 2,4-diaminobutyric acid	Free	Free	Anticancer and Antitumor	Synthetic	MDA-MB-231	Breast Cancer	HUVEC sprouting	IC₅₀< 20 nM	Not available	Breast	None
7847	30210643	2018	KEFLHPSKVDLPR	SOR-C13	13	Linear	L	None	Free	Free	Anticancer and Antitumor	Synthetic	SKOV-3	Ovarian Cancer	IP; daily; on days 1 to 12	Effectively inhibited the growth of tumor	12 days	Ovary	None